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ABSTRACT 
 
 
Epithelial ovarian cancer (EOC) represents the fifth most common cause of cancer mortality 
among women worldwide and accounts for the highest fatalities amongst gynaecological 
malignancies. The dysregulation of calcium-dependent peptidyl arginine deiminase 2 (PADI2) 
plays a key role in the tumorigenesis of several cancers; however, the role of PADI2 in the 
pathogenesis of EOC is yet to be investigated. Using RNA-seq and microarray data from 
primary serous ovarian cancers (The Cancer Genome Atlas data set) combined with survival 
data, the expression of PADI2 was assessed using each platform (n=262 and n=564). Kaplan-
Meier analysis and Log-rank tests showed an association of PADI2 mRNA expression with 
overall survival using both platforms (RNA-seq cohort p=0.008 and microarray cohort 
p=0.0112). Low expression of PADI2 was associated with improved survival. Expression studies 
were used to examine the overexpression and knockout (CRISPR/Cas9 editing) of PADI2 
expression, respectively, in the human-derived high-grade serous OVCAR-4 and mouse-
derived EOC ID8-Luc2 cell lines. In OVCAR-4 cells, PADI2 overexpression reduced proliferation 
(22%) and cellular aggregation (94%), while increasing apoptosis (34%) and autophagy (38%), 
in a Ca2+- and citrullination-dependent manner, at 72 hours. PADI2 overexpression also 
induced cisplatin cytotoxicity by 10% at 72 hours. In ID8-Luc2 cells, PADI2 overexpression 
significantly decreased cisplatin cytotoxicity by 24%, independently of exogenous Ca2+ 
supplementation or induced citrullination, at 72 hours. In addition, qRT-PCR validation of 
TCGA gene co-expression data indicated that PADI2 overexpression correlated with 
expression of a number of genes. This was confirmed in functional studies where there was a 
1.69-fold increase in ARHGEF10L and 0.75-fold decrease in FZD5 expression upon PADI2 
overexpression. In this thesis, The Cancer Genome Atlas expression studies of PADI2 showed 
that higher PADI2 confers decreased survival of EOC patients. Conversely, PADI2 
overexpression in vitro, induced apoptosis/autophagy and decreased proliferation/cellular 
aggregation possibly via deregulating FZD5 and ARHGEF10L. Collectively, this work suggests 
that PADI2 may serve as a potential therapeutic target in human EOC. Codon based selection 
analyses were used to test for evidence of positive selection in PADI2. The phylogenetic 
maximum likelihood analysis of PADI2 orthologues retrieved from 31 species indicated that 
there was no evidence of positive selection in PADI2 codons, but numerous residues were 
under evolutionary constraint.
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 INTRODUCTION 
 
Ovarian cancer (OC) is the fifth most common cancer in women worldwide and the leading 
cause of death among gynaecological malignancies (Rais et al., 2017). The overall difficulty of 
early detection and diagnosis of OC is due to the ineffective screening methods and low 
treatment efficacy that contribute to high fatality rate (Rauh-Hain et al., 2011). EOC is the 
most common type of OC, representing 95% of the cases whereas, the remaining OCs develop 
from sex cord-stromal tumours and germ cell tumours and account for the remaining 5%-10% 
(Romanidis et al., 2014). A variety of risk factors are known to influence EOC, including genetic 
factors that play a prominent role in a patient’s susceptibility to EOC. Recent advancements 
in molecular prognostic factors of EOC have enabled the assessment of suitable treatment 
strategies for EOC patients. Hence, understanding the key regulators of epigenetics and 
molecular targets can contribute to developing more effective cancer therapeutics (Sidhu and 
Capalash, 2017). The epigenetics and post-translational modifications (PTMs) of proteins, 
including acetylation, phosphorylation, methylation, glycosylation, citrullination and 
ubiquitination, were found to play key roles in pathogenesis and carcinogenesis (Bettermann 
et al., 2012; Okudela et al., 2014; Chrun et al., 2017). Peptidyl arginine deiminases (PADIs) are 
a family of calcium-dependent enzymes that catalyse the post-translational conversion of 
positively charged arginine residues into neutrally charged citrulline (Horibata et al., 2017). 
This reaction is referred to as deimination or citrullination, and can result in altered tertiary 
structures or improper substrate-binding of the target protein (Vossenaar et al., 2003). PADI-
mediated protein citrullination is also observed in normal physiological processes. However, 
aberrant citrullination can lead to different human diseases (Olsen et al., 2018). In fact, there 
is increasing evidence to suggest that the dysregulation of PADI and mediated citrullination, 
play crucial roles in cancer, neurodegenerative diseases and inflammatory diseases (Copeland 
et al., 2009; Bannister and Kouzarides, 2011; Fuhrmann et al., 2015). More recently, 
citrullinated proteins were used as potential targets for cancer diagnosis and treatment (Cook 
et al., 2018; Lin Wang et al., 2017). 
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1.2 Clinical features of EOC 
Several factors that could influence EOC may include cancer stage, histological type, early 
recognition, patient treatment, age and comorbidities (Bristow et al., 2015; O’Malley et al., 
2012; Wright et al., 2015; Chang et al., 2018). Currently recommended frontline therapy for 
malignant EOC comprises of upfront surgery followed by combination chemotherapy using 
platinum-based and paclitaxel drugs (González-Martín et al., 2014; Chang et al., 2018). For 
invasive or recurrent EOC, individualised assessments and optimised management are 
especially required (Rooth, 2013; Jordan et al., 2013; Chang et al., 2018). EOCs are grouped as 
type I or type II based on clinicopathologic and primary molecular factors that contribute to 
EOC type-specific genetic instability (Torre et al., 2018). Type I accounts for only 10% of the 
deaths from EOC. Type I EOCs develop from extraovarian benign lesions and are generally slow 
growing large unilateral or cystic tumours, and often present in early stages. Type I EOCs do 
not generally transform to malignant tumours; however, ovarian benign lesions may undergo 
a series of mutations resulting in malignant transformation (Torre et al., 2018). Type II EOCs 
are present in advanced stage (>75% of cases) and characterised by genomic instability, rapid 
development and associated with poor prognosis (Patch et al., 2015). Type II EOCs originate 
from the fallopian tube intraepithelial carcinoma and includes not only the ovaries, but also 
extra-ovarian sites, which probably accounts for their clinically aggressive behaviour (Nam and 
Kim, 2008; Foster, 2008). There is increasing evidence to indicate that type I and II ovarian 
tumours develop from different molecular pathways (Table 1.1, Kurman and Shih, 2010; 
Kurman and Shih, 2011). Various gene expression signatures for predicting survival in 
advanced stage EOC were produced by analysing the mRNA expression data obtained from 
several platforms. Some of these signatures were produced by the cancer genome atlas 
(TCGA) investigators and has been validated in multiple datasets. However, the performance 
of these prognostic signatures varies between independent cohorts; some poorly correlate 
with risk scores between different studies. Therefore, such signatures are yet to be utilised to 
assist in EOC patient management (Yoshihara et al., 2012). 
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Table 1.1 Molecular and clinicopathologic features of type I and type II EOCs 
Features Type I Type II 
Stage Frequently early stage Almost always advanced stage 
Tumour grade Low grade*y High grade 
Proliferative activity Generally low Always high 
Ascites Rare Common 
Response to chemotherapy Fair Good (but recur later) 
Early detection Possible Challenging 
Progression Slow and indolent Rapid and aggressive 
Overall clinical outcome Good Poor 
Risk factors Endometriosis Lifetime ovulation cycles; BRCA-germline 
mutations 
Origin Ovary benign lesions Mostly fallopian tube epithelium 
Precursors  Atypical proliferative 
(borderline) tumours 
STICs 
Chromosomal instability Low High 
p53 mutation Infrequent Almost always 
Homologous recombination 
repair 
Rarely defective Frequently defective 
   
      * Clear cell carcinoma is not graded, but many consider the tumour as high-grade. 
y Occasional progression to high grade can be observed. BRCA, breast cancer; STIC, serous tubal intraepithelial carcinoma 
(Kurman and Shih, 2016). 
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1.3 Gene Expression Profiling Studies of EOC 
Since different EOC histological subtypes are associated with different patient prognoses, 
many transcription profiling studies have focused on the discovery of markers that can 
discriminate between different subtypes (Schwartz et al., 2002). BRCA1- and BRCA2-positive 
EOCs are the most common forms, around 20% of these cases are associated with BRCA1 
and/or BRCA2 germline pathogenic variants (Miyamoto et al., 2013; Cannistra, 2004). Genetic 
defects were also detected in various double-stranded DNA repair-associated genes in EOC, 
including BRIP1, PALB2, RAD51, CHEK2 and BARD1 (Cannistra, 2004; King et al., 2003; Walsh 
et al., 2011; Loveday et al., 2011). Based on histopathology and molecular genetic profiles, 
type I EOCs are subdivided into four subtypes: endometrioid (10%), clear cell (10%), mucinous 
(3%), and low-grade serous (LGS, <10%, Prat, 2012). Whereas, type II EOCs are subdivided into 
high-grade serous (HGS, 70%), high-grade endometrioid, carcinosarcoma and undifferentiated 
(Prat, 2012). These subtypes represent distinct diseases, as indicated by differences in 
prognosis, precursor lesions, genetic risk factors, molecular events during oncogenesis and 
response to chemotherapy (Prat, 2012; Köbel et al., 2010). The genomic instability, as 
observed by global DNA copy number aberration, is the main molecular feature that 
differentiates between type I and the marked chromosomal instability present in type II EOC 
(Kurman and Shih, 2016). In addition, type II EOCs are characterised by ubiquitous p53 
mutations and BRCA-related abnormalities, in contrast to their infrequency in type I EOCs 
(Garziera et al., 2018). Other notable differences include homologous recombination repair 
(HRR), retinoblastoma protein, cyclin E1 (CCNE1), NOTCH3 and forkhead box M1 (FOXM1). 
Whereas type I carcinomas are characterised by frequent somatic mutations involved in the 
phosphatase and tensin homolog (PTEN)/phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit a (PIK3CA), BRAF proto-oncogene/Kirsten ras sarcoma viral oncogene 
homolog (KRAS), β-catenin 1 (CTNNB1), AT-rich interaction domain 1A (ARID1A) chromatin 
remodelling pathways and serine/threonine kinase (BRAF)/mitogen-activated protein kinase 
(MAPK) extracellular signal-related kinase (ERK, Figure 1.1). Although EOC can rarely harbour 
mixed histologic features (more than one histological type in a given tumour) and is estimated 
to <1% using the current immunohistochemical staining and diagnostic criteria. 
  
  
 5 
1.3.1 Morphologic and molecular features of type I EOC 
 
Endometrioid, LGS, clear cell and mucinous subtypes representing around 10%, <5%, 10% and 
<5% of EOC cases, respectively. These subtypes (both clinically and at the molecular level) are 
less common and represent distinct disease entities, both clinically and at the molecular level, 
from HGS EOC and from one another. Overall, and conversely to HGS EOC, they harbour 
activating oncogenic mutations specific to solid tumours but do not show high rates of p53 
mutations (Figure 1.1, Sato et al., 2005; Strickland et al., 2016). 
 
1.3.1.1 Endometrioid EOC 
Compared to HGS, endometrioid represents the group with the most positive clinical outcome 
due to their tendency to be diagnosed at earlier stages, and are mostly platinum-sensitive in 
the first-line setting (Gershenson et al., 2006; Gilks et al., 2008). Endometroid EOC harbour 
mutations involved in the  deregulation of PIK3CA pathway, including activating 
PIK3CA mutations that occur in 30% of cases, tumour suppressor genes PTEN and ARID1A; 
known to be associated with chromatin-remodelling gene  mutations which accounts for 20%-
30% of the cases, respectively (Chui et al., 2014; Schwartz et al., 2002; McConechy et al., 2014; 
Matsumoto et al., 2015; Obata et al., 1998). Activating mutations of KRAS and BRAF display 
<7% of the endometrioid carcinomas. A few cases of endometrioid EOC also harbour somatic 
mutations in the PPP2R1A gene that encodes a subunit of protein phosphatase 2A (Wiegand 
et al., 2010). Also, endometrioid frequently harbour mutations in the CTNNB1 (occurring in 
around 15%-40% of cases) leading to the activation of Wnt signalling pathway and resulting in 
the accumulation of β-catenin which was previously shown to associate with well-to-
moderately differentiated tumours with small size and good overall prognosis (Chui et al., 
2014; Schwartz et al., 2002; Guan et al., 2011).  
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1.3.1.2 Clear cell EOC 
As with endometrioid EOCs, clear cell is associated with endometriosis and can be diagnosed 
at earlier stages in comparison to HGS. However, advanced stage clear cell EOC correlates with 
low progression rate and relatively lower overall survival (OS) in patients, due to intrinsic 
platinum resistance (Zorn et al., 2005; Storey et al., 2008; Aysal et al., 2012). In addition, clear 
cell carcinomas harbour mutations that contribute in deregulating various genes, including 
ARID1A in around 50% of cases, PIK3CA in around 50% of cases and PTEN in around 10% of 
cases (Schwartz et al., 2002; Matsumoto et al., 2015; Shih et al., 2011; Sato et al., 2000). 
Similarly, few cases of clear cell display somatic mutations in PPP2R1A (Wiegand et al., 2010). 
However, unlike endometrioid, around a third of clear cell tumours (Schwartz et al., 2002)  
display amplification at chr20q13.2 and do not commonly harbour Wnt-activating CTNNB1 
mutations (Schwartz et al., 2002; Campbell et al., 2004). In addition to these genetic changes, 
a recent genome-wide methylation report suggested that clear cell carcinomas exhibit 
distinctive methylation profiles in comparison to other EOC histologic subtypes (Yamaguchi et 
al., 2014). For example, aberrant DNA methylation was observed in multiple genes involved 
in the Oestrogen receptor alpha (ERα) and hepatocyte nuclear factor 1A (HNF1A). DNA 
methylation of HNF1A could also play an important role in regulating additional cellular drug 
metabolism and transporter pathways (Soslow et al., 2012; Bélanger et al., 2010).  
 
1.3.1.3 Mucinous EOC 
In comparison to other EOC histological types, mucinous EOCs account for fewer cases (Prat, 
2012). Like endometriosis, mucinous EOCs have the propensity for diagnosis at earlier stages 
compared to HGS (Kuo et al., 2010; Zaino et al., 2011). However, mucinous EOCs often display 
platinum resistance in the first line setting, and advanced stages are typically associated with 
poor patient overall survival (OS, Sugiyama et al., 2000; Anglesio et al., 2013). As a result of its 
low occurrence, mucinous remains relatively poorly understood compared to other 
histological EOC subtypes, that largely hindered the extensive molecular characterisation of 
this subtype (Hollis et al., 2016). Common genetic defects representing mucinous tumours, 
include KRAS mutations, tumour suppressor RNF43 mutation and HER2 gene amplification, 
with around 50%, 21% and 20% of cases displaying these defects, respectively (Kuo et al., 
2010; Brown and Frumovitz, 2014; Ryland et al., 2013). In mucinous ovarian neoplasia, a 
mutation screening of the MAPK/ERK pathway  showed that  MAPK/ERK pathway alterations 
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and p16 loss are highly recurrent events, detected during early mucinous tumour 
development (Hunter et al., 2012). 
 
1.3.1.4 LGS EOC 
LGS EOCs occur in younger patients and is characterised by prolonged OS compared to HGS 
even when diagnosed at advanced stage (Schmeler et al., 2008). In contrast to HGS, LGSs 
typically have wild-type p53. Over 60% of LGS tumours harbour MAPK pathway-activating 
BRAF or KRAS mutations, but almost none harbour p53 mutations. Furthermore, it was 
suggested that LGS EOCs displaying mutation in KRAS and BRAF are associated with recurrent 
tumours (approximately 10% recur after surgery) and poor survival in comparison to wild-type 
BRAF and KRAS. These tumours are assumed to develop in a step-wise fashion from a subset 
of serous borderline tumours (SBT, Testa et al., 2018). Hunter and co-workers identified 
several oncogenes, including MAPK/ERK/oestrogen-related receptor B2 (ERBB2) mutations 
that were observed in 82% of SBTs, compared to 63% of LGS EOCs. In addition, copy number 
aberrations were observed in 100% of LGS EOCs, compared to 61% of SBTs. Interestingly, 
neuroblastoma RAS viral oncogene homolog (NRAS) mutations were detected only in LGS 
EOCs. Some genomic rearrangements resulting in DNA genomic 
rearrangements resulting in novel copy number alterations (CNV), such as homozygous 
deletions of Cyclin Dependent Kinase 2A (CDKN2A) locus and loss of 9p, are mostly observed 
in LGS EOCs (Hunter et al., 2015). 
 
1.3.2 Morphologic and molecular features of Type II EOC 
1.3.2.1 HGS 
Because HGS represents the majority of EOCs and it accounts for approximately all the 
remaining EOC cases, around 70%, gene expression studies have thus mainly focussed on this 
subgroup. HGS is characterised by extensive genetic heterogeneity, widespread DNA copy 
number or morphological aberrations and universal p53 mutations (Somigliana et al., 2006; 
Lynch et al., 2009; Seidman et al., 2012; Chan et al., 2008). Almost all of p53 mutations in HGS 
patients are missense variants, whereas, variants which result in complete loss of p53 protein 
commonly referred to as 'p53 nulls', including nonsense, frameshift (FS) or splice junction 
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account for around 30% (Salani et al., 2008). Additionally, the widespread copy number 
alterations reflect on the history of genomic instability, including ubiquitous p53 mutations 
and low occurrence (>5%) but statistically recurrent somatic mutations in nine further genes, 
including neurofibromin 1 (NF1, 8% deletion, 4% mutation), retinoblastoma protein 1 (RB, 8% 
deletion, 2% mutation), PTEN (7% deletion, <1% mutation), cyclin dependent kinase 12 
(CDK12, 3% mutation, gamma-aminobutyric acid type a receptor alpha6 subunit (GABRA6, 2% 
mutation) and CUB and sushi multiple domains 3 (CSMD3, 6% mutation), substantial 
significant focal DNA copy number aberrations and promoter methylation events. In addition, 
FOXM1 and NOTCH3 signalling pathways were also found to be associated with the 
pathophysiology of HGS EOC (Bell et al., 2011). However, recent whole genome analysis of 
HGS cases has identified common targets of previously unknown gene breakage occurrences, 
including NF1 and RB1, affecting 17.5% and 20% of cases, respectively. Therefore, highlighting 
the role of large structural-rearrangements leading to the inactivation of EOC tumour 
suppressors (Yemelyanova et al., 2011). A comprehensive view of the somatic alterations and 
germline variations in HGS carcinoma cohorts associated with higher cancer risk, led to the 
identification of various recurrent alteration in large copy number (22 losses and 8 gains) and 
genes, including BHLH transcription factor (MYC) proto-oncogene, MYC and KRAS (gain), PTEN 
(loss), RB1, and NF1 (loss). Many of these losses and gains were identified in almost all 
tumours, emphasising the importance of genomic instability of HGS (Testa et al., 2018). Other 
common genetic alterations in HGSs include, germline and somatic mutation of BRCA1/2, 
CNAs of CCNE1 amplification and other alterations affecting the regulatory pathways of HRR-
mediated DNA damage repair (Bell et al., 2011). Approximately 50% of HGS have an 
identifiable somatic, germline or epigenetic defects that occur in HRR pathway, as seen in  
BRCA1/BRCA2 germline or somatic mutations which together account for around 20% of cases 
(Vogelstein et al., 2013). Around 4% and 3%  of HGS patients harbour somatic BRCA1 and 
BRCA2 defects, respectively, while germline changes in each occur in around 8% and 6% of 
cases, respectively (Somigliana et al., 2006; Bolton et al., 2012; Patch, et al., 2015). BRCA1/2-
deficient HGS are characterised by relatively higher DNA copy number alterations, and they 
typically do not harbour CCNE1 amplification (Patch et al., 2015). 
Four HGS molecular subtypes, termed immunoreactive, proliferative, differentiated and 
mesenchymal, were initially identified from the gene expression analysis of approximately 300 
cases and subsequently validated in TCGA study (Tothill et al., 2008; Cancer Genome Atlas 
Research Network, 2011). However, the recapitulation of these subgroups in other datasets 
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has shown distinct clinical outcomes (Helland et al., 2011; Konecny et al., 2014). Zhang et al. 
(2003) showed that survival differed significantly between the four subtypes and this 
difference was best illustrated in immunoreactive subtype. Zhang group correspondingly 
reported similar findings, using histopathological analysis of HGS cases, demonstrating that 
significant numbers of  tumour-infiltrating lymphocytes were associated with good prognosis 
(Zhang et al., 2003). Moreover, other studies showed that BRCA1 mutations were also 
associated with immunoreactive HGS subtype (George et al., 2013). Collectively, these studies 
suggest that all HGS subtypes may display distinct oncogene activation patterns. In addition, 
these studies also suggested that the disruptions in DNA repair mechanisms are the leading 
cause of HGS development, followed by chromosomal instability, copy number changes and 
leading to the differentiation into molecular subtypes. While the emerging immune 
stimulation contributes to the improved survival outcome of HGS patients, it is important to 
successfully utilise these subgrouping methods, including the consensus molecular 
subgrouping of HGS, that can thereafter be used in a clinical context (Langie et al., 2015). 
 
1.3.2.2 Undifferentiated-carcinoma  
Undifferentiated-carcinoma subtype are uncommon (<5%) and show none of the distinctive 
pathologic features observed in HGS or high-grade endometrioid carcinoma. It remains 
unclear whether these are variants of poorly differentiated HGSs, distinct tumours or high-
grade endometrioid carcinomas. It was suggested that the gene expression patterns of this 
subtype are similar to the one observed in mesenchymal rather than epithelial cells 
(Hernández et al., 2012; Kurman and Shih, 2016). However, the molecular background that 
specifically evaluates this tumour type are currently unavailable; therefore, it remains poorly 
understood (D’Andrilli et al., 2008). 
 
1.3.2.3 Carcinosarcomas 
Carcinosarcoma are also referred to as malignant mixed Müllerian tumour, is a biphasic 
tumour comprised of sarcoma and carcinoma. Both components are distinct but also display 
intermixed molecular features. Carcinosarcomas and HGS share numerous molecular genetic 
abnormalities, including p53 mutations and CDKN2A upregulation (Jin et al., 2003; Kurman 
and Shih, 2016).  
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Figure 1.1 A dualistic model representing the pathogenesis of EOC. Type I carcinomas are 
comprised of clear cell, low-grade serous (LGS), mucinous carcinomas and endometrioid. Type 
II carcinomas are composed of mainly high-grade serous carcinomas (HGS). Type II 
carcinomas, including undifferentiated and carcinosarcoma cancers are relatively rare and 
therefore not included in this figure. The areas of individual histological subtypes represent 
their relative frequency. The origin of the different type I and type II EOCs is indicated in the 
inner circles. The cell of origin in mucinous carcinomas is not yet established, therefore, was 
indicated as unknown. The molecular pathway alterations characterising each tumour subtype 
are summarised in the square boxes.  Abbreviations: RB, retinoblastoma protein; BRAF, B-Raf 
proto-oncogene; ARID1A, AT-rich interaction domain 1A; MMR, DNA mismatch repair; PI3K, 
phosphatidylinositol 3- kinase; serine/threonine kinase; ERRB2, oestrogen-related receptor 
B2; KRAS, Kirsten rat sarcoma viral oncogene homolog; HR DDR, homologous recombination-
mediated DNA damage repair; MEK, mitogen-activated protein (MAP) extracellular signal-
related kinase (ERK) kinase; PTEN, phosphatase and tensin homolog; cyclin E1, CCNE1; NF1, 
nuclear factor 1 (Kurman and Shih, 2016). 
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1.4 Diagnosis of EOC 
The high mortality of EOC is largely explained by its asymptomatic/slow course of growth, 
therefore, two-thirds of all EOC cases are diagnosed at late stages; Stage III or Stage IV (Testa 
et al., 2018). The lack of effective molecular screening methods, specifically at early disease 
stages, also contributes to the high mortality of EOC (Yokoi et al., 2018). Early stage EOCs 
present symptoms that are similar to those of other conditions, including dyspepsia, 
menstrual irregularities, abdominal pain and other mild digestive disturbances, which may 
have existed for short periods of time. As the disease advances, discomfort from ascites and 
abdominal distention increases, and may be accompanied by respiratory symptoms from the 
fluid transudation into the pleural cavities or from elevated intra-abdominal pressure (Berek 
et al., 2015). To determine the possible risk factors, a detailed clinical and familial cancer 
history must be collected. Followed by a comprehensive physical examination, including rectal 
examination and general pelvic area. Prior to surgery, pleural effusion is screened using chest 
radiograph and computerised tomography (CT), to outline the extent of intra-abdominal 
disease (Cameán et al., 2016). 
 
1.5 Cytoreductive (debulking) surgery for advanced stage EOC 
Surgical debulking plays an important role in the treatment and early management of 
advanced EOC. The decision whether a patient is a good candidate for debulking surgery is 
built according to the surgeons’ experience, patient characteristics, complementary tests 
(serum biomarker levels and CT) and laparotomy or less-invasive imaging techniques, such as 
ultrasound, that are performed initially to detect metastatic and locally advanced 
disease (Fischerova et al., 2017; Nick et al., 2015; Rutten et al., 2015; Fotopoulou et al., 2010). 
For all the disease stages (specifically stages I to III) all visible tumour masses are removed, 
including total hysterectomy, peritoneal washings, inspection of all abdominal 
organs/peritoneal surfaces and bilateral salpingo-oophorectomy. In addition, tumour mass 
removal is coupled with total omentectomy, para-aortic lymphadenectomy and sampling of 
lymph nodes and adjacent tissues for biopsy from fixed locations throughout the abdominal 
cavity. There are three types of debulking  surgeries: (i) primary debulking; complete removal 
of macroscopic tumour, including diaphragmatic resection, splenectomy, liver resection, 
intestinal resection or any other abdominal organ affection, before any other treatment 
(Zapardiel et al., 2011; Peiretti et al., 2012) (ii) interval debulking; cytologically confirmed 
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stage IIIC and IV patients, may not be good candidates for surgical approach, and neoadjuvant 
taxanes chemotherapy may be used initially in 2 to 3 cycles, followed by interval surgical 
cytoreduction and additional adjuvant chemotherapy (Bristow and Chi, 2006) (iii) secondary 
debulking; recurred cancer removal surgery (Salani et al., 2007). Around 16% to 35% of the 
EOCs, that were assessed and initially classified as early stage disease are upstaged later 
(Colomer et al., 2008). After complete surgical staging for EOC, the new international 
federation of gynaecology and obstetrics (FIGO) staging system is used to determine patient 
prognosis and direct management. The new FIGO staging system was recently revised to 
incorporate ovarian, fallopian tube, and peritoneal cancer, approved since January 2014 as 
shown in (Table 1.2, Mutch and Prat, 2014; Berek et al., 2015). This evaluation system is vital 
and assists with categorising of patients according to survival rate (short survival and 
moderate/high-risk of relapse, Testa et al., 2018). However, recent innovations in 
chemotherapeutic drugs and their administration (i.e. intraperitoneal delivery) have largely 
eclipsed advances in surgery (Schorge et al., 2010).  
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Table 1.2 FIGO 2014 EOC staging. The 5-year survival for the various stages is reported. R, rate 
Primary 
EOC 
FIGO  
  Tumour Extension 
5-year 
Survival R 
Stage I   Tumour limited to the ovaries (one or both) 85–94% 
 IA  Tumour is l imited to one ovary; no malignant cells in ascites or 
peritoneal washings; capsule intact, no tumour on ovarian surface  
94% 
 IB  Tumour l imited to both ovaries; capsule intact, no tumour on ovarian 
surface; no malignant cells in ascites or peritoneal washings 
92% 
 
  IC  Tumour l imited to one or both ovaries with any of the following: 
85% 
 IC1 Surgical spill 
 IC2 capsule ruptures, tumour on ovarian surface 
 IC3 malignant cells in ascites or peritoneal washings 
Stage II   Tumour includes one or both ovaries with pelvic extension. 69–78% 
 IIA  Extension and/or implants in the uterus and/other tube(s); no 
malignant cells in ascites or peritoneal washings 
78% 
 
IIB 
 
Extension and/or implants in other pelvic tissues; no malignant cells 
in ascites or peritoneal washings 
 
73% 
Stage III 
  
 
Tumour includes one or both ovaries with microscopically 
confirmed peritoneal metastasis outside the pelvis and/or 
metastasis to the retroperitoneal lymph nodes 
 
17–59% 
 IIIA  Microscopic peritoneal metastasis extra pelvic (no macroscopic 
tumour) 59% 
 
 
IIIA1 
 
 
Positive retroperitoneal lymph nodes only; (i) metastasis ≤ 10 mm 
and (i i) metastasis > 10 mm 
  
 IIIA2  
Microscopic, extra pelvic (above the brim) peritoneal involvement ± 
positive retroperitoneal lymph nodes 
 IIIB  Macroscopic peritoneal metastasis extra pelvic, peritoneal 
metastasis ≤ 2 cm ± positive  39% 
 IIIC 
 
Macroscopic peritoneal metastasis extra pelvic >2 cm in greatest 
dimension and/or regional lymph node metastasis 
 
17% 
Stage IV   
 
Distant metastasis and or metastases to extra-abdominal organs 
excluding peritoneal metastasis 
12% 
 IVA  Pleural effusion with positive cytology  
 
IVB 
 
Hepatic metastasis, metastasis to extra abdominal organs (including 
inguinal lymph nodes and lymph nodes outside of the abdominal 
cavity) 
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1.6 Chemotherapy for EOC 
 
The platinum-based combination chemotherapy is the standard and most effective first-line 
treatment for EOC (specifically EOC advanced stages, Jazaeri et al., 2005). Platinating agent 
analogues, such as carboplatin (cis-(1,1-cyclobutanedicarboxylato) diammineplatinum(II)) or 
cisplatin (cis-diamminedichloroplatinum (II)), are commonly used in the treatment of EOC. 
These agents induce cancer cell death via interfering with DNA replication and transcription 
by forming cisplatin-DNA crosslinks between the purine bases to form 1,2- or 1,3- interstrand 
and intrastrand, triggering DNA damage and cell-cycle arrest at the growth 1 (G1) or growth 2 
(G2) phases, thereby preventing cell division and growth (Dekou et al., 2001). Other cisplatin-
mediated cytotoxicity mechanisms include altered axonal transport, microtubule changes, 
endoplasmic reticulum integrity alteration, reactive oxygen species (ROS) production, 
mitochondrial function impairment, activation of calpain and dysfunctions in sodium (Na+), 
calcium (Ca2+) and potassium (K+) channels and Ca2+ signalling changes (Kursunluoglu, Taskiran 
and Kayali, 2018). Cisplatin-induced DNA damage response is regulated by several factors, 
including protein kinase C that acts as a positive regulator for cisplatin-induced cell death, and 
transcription factors, such as p53, p21, p300 and p63. These transcription factors also play a 
critical role in cell apoptosis and pro-apoptotic gene activation (Figure 1.2). Other agents, such 
as taxane-based chemotherapy (e.g. paclitaxel) are also frequently used in the treatment of 
EOC in combination with other chemotherapeutic drugs, e.g. platinating agents (Chorawala et 
al., 2012). Taxanes inhibit cell division (mitotic inhibitor) by binding to α-tubulin and stabilising 
microtubules, consequently, resulting in cell apoptosis (Huizing et al., 1995; Jordan and 
Wilson, 2004). Chemotherapeutic treatments depend on several factors, including the extent 
of disease, cancer-specific pathological and molecular characteristics, its location, and patient 
health status (Chorawala et al., 2012). 
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Figure 1.2 The targets of cisplatin. Abbreviations: ROS, Reactive oxygen species; TNF, tumour 
necrosis factor; i[Ca2+], intracellular calcium.  
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1.6.1 Gene expression profiles associated with response to chemotherapy in EOC 
 
The integration of newer biologic drugs and molecular targeted therapies can provide 
enhanced medical management of EOC (Schorge et al., 2010). While platinum-based drugs 
are commonly used in cancer treatment, many tumours are entirely resistant to these drugs 
with no clinical response achieved.  Around 20% to 30% of patients diagnosed with advanced-
stage disease (75%) progress on or rapidly develop resistance to platinum-based drugs and 
similarly show low rates of response to other second-line agents. The early prognosis of these 
chemoresistant patient groups can benefit from the ongoing clinical trials or experimental 
therapeutic interventions. In practice, chemosensitive tumours are classified as such based on 
patient response to chemotherapy and a platinum-free interval of ≥13 months. In addition, it 
was suggested that the length of platinum-free interval, dictates the subsequent response 
rates of this group to additional chemotherapy. 
The vast majority of patients that were initially identified as chemosensitive, will eventually 
relapse and develop chemoresistance. Suggesting that chemoresistance can be acquired 
during treatment or may pre-exist at the outset of treatment (intrinsic resistance). The pre-
clinical assessment of molecular abnormalities in EOCs can help in defining the developing 
sites of precursor lesions and provided insight into the underlying mechanisms involved in 
tumour clonal aggregation processes that mediate chemoresistance, including natural 
evolution and drug-induced clonal selection (Kim et al., 2018; Testa et al., 2018; Murugaesu 
et al., 2013). In addition, these molecular studies were of profound importance in defining not 
only the inter-tumour heterogeneity, but also the intra-tumour heterogeneity that can be 
used to assist with the development of therapeutic treatments for advanced stages. 
Characterisation of the mechanisms involved in chemoresistance are required for successful 
treatment of EOC. The key molecular mechanisms involved in this resistance may include 
reduced intracellular accumulation by uptake/efflux transporters or alteration in platinum 
inactivation, increased adduct tolerance/repair or inhibition of apoptotic pathways. Several 
studies have explored clinical drivers that contribute to the acquired resistance to 
chemotherapic agents, including cisplatin and paclitaxel, in EOC patients. In this context, a 
recent study, using extensive molecular analysis of chemoresistant patients, showed that the 
acquired resistance to chemotherapy was linked with gene breakages inactivation at the level 
of known tumour suppressors, including RAD51B, NF1, RB1 and PTEN and resistant tumours 
are mostly associated with amplifications of CCNE1 (Patch et al., 2015; Testa et al., 2018). 
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Interestingly, in some chemoresistant tumours, reversion in BRCA1 or BRCA2 mutations or 
loss of BRCA1 hypermethylation was also observed. Prieske et al., (2017) correspondingly 
reported that high BRCA1 and BRCA2 mutations are linked to an increased risk of breast 
cancer; however, they found that BRCA-associated tumours respond better to platinum-based 
therapy. In another study, advanced ascitic EOC patients were screened to reveal common 
abnormalities of the PI3K signalling pathway that were detected in majority of the 
chemoresistant patients. These abnormalities include PI3KCA mutations found in 5% of 
samples; amplification of AKT serine/threonine kinase 2 (AKT2) and PI3KCA and deletion of 
PTEN were found in 10%, 12% and 27% of samples, respectively (Huang et al., 2011). At the 
protein level, several genetic and biochemical studies in vitro have shown that PTEN-mediates 
the downregulation of PI3K/AKT- signalling. Therefore, the loss of PTEN was associated with 
increased AKT activation and subsequent increased proliferation, migration and progression 
of various human cancers (Di Cristofano et al., 1998; Carracedo and Pandolfi, 2008; Keniry and 
Parsons, 2008). 
Other studies based on gene profiling analysis used microarray platforms to detect differential 
gene expression patterns and identify novel genes that correlate with EOC patient’s response 
or resistance following a standard treatment (Macgregor and Squire, 2002; Testa et al., 2018).  
In one report by Dressman et al., (2007), gene profiling analysis was carried out on a subset of 
83 advanced serous OC cases and identified deregulated genes whose expression correlated 
with patient response or resistance to platinum-based therapy. These deregulated genes, 
involved in non-receptor tyrosine kinase (SRC) proto-oncogene, MYC and E2F transcription 
factor 3 (E2F3) pathways, were shown to be associated with cancer growth and proliferation 
and correlate with a poor patient response to platinum treatment (Dressman et al., 2007; 
Gatza et al., 2014). Another study by Stronach et al., (2011), compared clinically derived 
tumour samples collected before and after chemotherapy treatment, which identified 
molecular signatures associated with the acquired resistance in patients. Further analysis 
suggested that histone deacetylase 4 (HDAC4) may serve as a molecular signature for OC and 
its upregulation mediates resistance by activating acetyl-signal transducer and activator of 
transcription 1 (STAT1) signalling pathways following platinum treatment (Stronach et al., 
2011). Furthermore, a number of studies attempted to identify membrane markers that may 
contribute to the development of serous EOC initiating cells. These studies used various 
methodologies, including molecular phenotyping and histological analysis, to assess 
heterogeneous populations of serous EOC cells (i.e. tumour xenografts in vitro tumour-
  
 18 
spheres, primary tumours and tumour cell lines). The results obtained from these studies 
indicated that the deregulation of CD44, CD117 (Zhang et al., 2008), CD24, CD133 (Baba et al., 
2009), Aldehyde dehydrogenase-1A1 (ALDH1A1) (Landen et al., 2010) and epithelial cell 
adhesion molecule (EpCAM) (Alvero et al., 2009), drives the development of serous tumour-
initiating cells.  
Similar to what was observed in chemoresesistant patients in clinical setup, in vitro 
chemoresesistant EOC cell lines also revealed the underlying molecular mechanisms involved 
in the emergence of this resistance. A number of studies reported several mechanisms of 
chemoresistance in vitro cell lines, including efflux pumps, DNA repair capacity via nucleotide 
excision repair pathway (EERC1) and deregulation of genes involved in survival pathways 
PI3K/AKT, MAPK, EGFR, mechanistic target of rapamycin kinase (mTOR), oestrogen signalling 
and deficiency in tumour suppressors  p53 and PRKC apoptosis WT1 regulator protein (Par-4) 
(Nicolantonio et al., 2005; Stapf et al., 2016). The biological processes associated with stress 
responses play a vital role in the normal development and homeostasis. While standard 
chemotherapy has been effective to some degree; however, the poor bioavailability, adverse 
side effects, high-dose requirements and development of multiple drug resistance 
mechanisms are the main drawbacks (Senapati et al., 2018).  
 
1.6.2 Targeted therapies for treatment of platinum-resistant EOC 
As with many other types of cancer, resistance to platinum-based therapies is an increasing 
concern in the treatment of EOC which must be addressed to advance therapeutics (Leamon, 
Lovejoy and Nguyen, 2013). Assessing the genetic profiling of resistant tumours before and 
after chemotherapy treatment will provide additional insight into the underlying mechanism 
mediating drug resistance (Tan et al., 2015; Leamon et al., 2013). The analysis of patient 
genetic profiles can predict the combination of therapies required for optimal effect and 
prevention of treatment escape (Leamon, Lovejoy and Nguyen, 2013). Currently developing 
approaches for EOC targeted therapy can be categorised into different groups, according to 
therapy-specific mechanisms of action as well as specific advantages. For example, some of 
these therapies target the Vascular endothelial growth factor (VEGF) pathway (e.g. 
bevacizumab and aflibercept humanised monoclonal antibody (mAb)), whereas others inhibit 
DNA repair mechanisms in platinum-resistant patients, specifically those who harbour BRCA 
mutations (e.g. iniparib, olaparib and veliparib), or the folate pathway (farletuzumab, 
pemetrexed, and vintafolide) and p53 mutation in platinum-resistant HGS EOC (Pujade-
  
 19 
Lauraine et al., 2014; Kaye et al., 2011; Gray et al., 2018; Birrer et al., 2011; Naumann et al., 
2013; Lehmann et al., 2012). An overview of some key clinical trials that are testing the 
potential combinational therapies and new drugs in platinum-resistant EOC (often in 
combination with chemotherapy) (Al-Bahlani et al., 2011; Leamon, Lovejoy and Nguyen, 
2013). It has been shown that the demonstration of oral supplements, such as Ca2+ or folic 
acid, reduce or avert some of chemotherapy drugs side effects (Leamon, Lovejoy and Nguyen, 
2013). Therefore, it appears that elevated calcium levels, via calcium supplementation, may 
act as another mean of cytoprotection, by competing for binding sites with cisplatin and 
averting various cisplatin-associated toxicities (Aggarwal, 1998). Cisplatin-mediated 
disruption of Ca2+ homeostasis can affect multiple cellular functions and initiate anti-tumour 
immunity.  It can also induce apoptosis through blocking potassium channel subfamily K 
member 3 (TASK-3) in EOC (Innamaa et al., 2013; Bose et al., 2015). More recently, PLC-
mediated i[Ca2+] signalling has been proposed as a promising target to overcome cisplatin 
resistance (Wang and Bourguignon, 2006). Cisplatin-induced Ca2+ influx damages the cells 
through depletion of adenosine triphosphate (ATP), inhibition of mitochondrial function and 
other cofactors. These damages are recognised by cytotoxic T lymphocytes (CTL) and natural 
killer (NK) cells, leading to cell apoptosis and tissue necrosis (Florea and Büsselberg, 2006; 
Splettstoesser et al., 2007; Tomaszewski and Büsselberg, 2007). Cisplatin-Ca2+ homeostasis is 
regulated by BRCA1-mediated inositol trisphosphate (IP3) and Voltage-dependent anion-
selective channel 1 (VADC-1) ion channels.  The activation of IP3-and VADC-1 receptors 
attenuates cisplatin induced Ca2+-influx activating calpain-mediated cell apoptosis (Figure 1.3, 
Hedgepeth et al., 2015; Thinnes, 2009). 
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Figure 1.3 Schematic presentation of the existent and emerging EOC treatments.  
Immunotherapy targeting regulatory T cell can be targeted with therapies, such as oncolytic 
virotherapy or mAB-redirected T-cell–based adoptive immunotherapy, aiming to increase the 
pre-existing antitumoral immunity effector functions. The PARP inhibitors, block the PARP 
complex, leading to a disturbance of single stranded DNA repair. Inactivation of cancer 
inducing pathway by pathway inhibitors, such as PI3K/Akt/BRAF/mTOR. SMDC comprising of 
folic acid linked to vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), a potent 
microtubule destabilizing agent, induce apoptosis.  Radiotherapy and chemotherapy induce 
DNA damage and apoptosis via p53, P73, Ca2+/calpain-dependent mechanism. Simultaneous 
targeting of BRCA-mutated platinum-resistant with PARP inhibitor olaparib or mAbs or 
pathway inhibitors in combination with cisplatin can achieve significant antitumoral 
responses. Abbreviations: NF-κB, nuclear factor κB; PI3K, phosphatidylinositol 3- kinase; miR, 
microRNA; JAK, Janus kinase; STAT, acetyl- signal transducer and activator of transcription; 
NADPH, nicotinamide adenine dinucleotide phosphate; p53, tumour protein 53; BRCA, breast 
cancer gene; AKT, AKT Serine/Threonine Kinase; MAP, mitogen-activated protein; SMDC, 
small molecule drug conjugate; VEGF, vascular endothelial growth factor; mAB, monoclonal 
antibody; ADC, antibody–drug conjugate; ERK, extracellular signal-related kinase; EGFR, 
Epidermal growth factor receptor. 
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1.7 Prognostic biomarkers and oncogenes in EOC: current options and future promise 
 
Recently, the study of protein expression and genomic alterations involved in breast 
carcinogenesis has identified a growing number of gene targets for drug development in the 
setting of EOC, substantially improving the prognosis (Toss et al., 2017). Recently developed 
drugs (e.g. trastuzamab, etc.) can target these molecular abnormalities, therefore, leading to 
improved survival outcome in cancer patients (Toss et al., 2017). Accordingly, clinical trials 
provided emerging evidence that the genetic context of a tumour may dictate its resistance 
or sensitivity to certain drugs (Toss et al., 2017). In addition, some studies have previously 
shown that treating tumours with therapies corresponding to their molecular alterations 
achieved longer survival and higher objective response rates. Predictive molecular biomarkers 
may optimise patient-specific treatment selection of effective therapies, subsequently 
reducing treatment cost and side effects (Figure 1.4, Toss and Cristofanilli, 2015).  
 
1.7.1 Current Biomarkers for EOC 
The most commonly used biomarkers for EOC clinical screening and prognosis are 
carbohydrate antigen 19-9 (CA19-9), cancer antigen 125 (CA125), human epididymis protein 
4 (HE4) and vascular cell adhesion molecule 1 (VCAM1, Montagnana et al., 2011; Antalis and 
Hodge, 2013). These biomarkers can detect EOC at earlier stages in patients and healthy 
subjects with 86% sensitivity at 98% specificity (Yurkovetsky et al., 2010). CA125 and CA19-9 
antigens are glycoproteins commonly expressed by primary non-mucinous EOC and non-
gynaecologic cancers, including those of the pancreas, breast, colon, lung and thyroid 
(Montagnana et al., 2011). Following cytoreduction, a steep decline in CA125 levels in patient 
serum indicates optimal surgical outcome, the failure to demonstrate this response is 
associated with suboptimal surgical outcomes and higher risk of relapse (Nolen and Lokshin, 
2014). CA125 serum levels are elevated in 80% of advanced-stage EOC patients but are 
increased in only 50–60% of patients with early-stage disease (Al-Ibraheemi and Wahed, 
2013). Downregulating CA125 promotes epithelial-to-mesenchymal transition (EMT), and re-
establishes EGFR signalling through increasing AKT and ERK1/2 phosphorylation (Comamala 
et al., 2011).   Human epididymis 4 (HE4), VCAM1 and CA19-9 are slightly less sensitive than 
CA-125 in the detection of EOC at early-stages but have greater specificity for distinguishing 
malignant from benign pelvic masses, particularly in premenopausal women (Antalis and 
Hodge, 2013).   
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Recently discovered protein biomarker candidates include mesothelin glycoprotein, 
osteopontin glycoprotein, apolipoprotein A1 (ApoA1) and kallikreins (KLKs, Rastogi, Gupta, et 
al., 2016). Similar to CA125 and CA19-9, osteopontin and mesothelin facilitate tumour 
progression and cell survival by inducing NF-KB and the calcium-dependent proteolytic 
enzyme, matrix metalloproteinases-7 (MMP-7), through MAPK/ERK and C-Jun N-terminal 
kinases (JNK) pathways.  In addition, the upregulation of osteopontin and mesothelin induce 
drug resistance through PI3K/AKT and MAPK/ERK signalling pathways (Chang et al., 2012; 
Chang et al., 2009; Ye et al., 2011; Yurchenco and Schittny, 1990). Likewise, KLK-6 and KLK-7 
are proteases used in the early detection and diagnosis of serous subtypes and advanced-
stage disease in primary human EOC (Tamir et al., 2014). Higher KLK expression levels promote 
cell proliferation, migration, and invasion by inducing E-cadherin shedding  (Klucky et al., 2007; 
Johnson et al., 2007). Moreover, Transthyretin (TTR) prealbumin is an anti-oncogene and its 
downregulation serves as an important marker in cancer (Zhang et al., 2004). TTR blocks 
retinol uptake and cell signalling by stimulating retinoic acid-induced STRA6 (Holo-retinol-
binding protein receptor) and janus kinase (JAK)/STAT signalling cascade (Berry et al., 2012). 
In contrast, higher levels of ApoA1 in serum are associated with increased OS and better 
prognosis in EOC patients (Marinho et al., 2019). The ApoA1-mediated anti-tumourigenic 
mechanisms include tumour microenvironment modulation, neoangiogenesis inhibition, 
regulation of inflammatory signalling (i.e. STAT3 pathway) and decreased pro-invasion factors 
levels (e.g. matrix metalloproteinase-9 (MMP-9), Marinho et al., 2019). Furthermore, it was 
demonstrated that ApoA1 and ApoA1-mimetic peptides also mediate anti-tumourigenic and 
increased platinum drug efficacies in EOC by binding to the pro-inflammatory pro-oncogenic 
phospholipids, such as lysophosphatidic acid (LPA, Zamanian-Daryoush et al., 2013; Gkouskou 
et al., 2016; Jia et al., 2017).  
 
1.7.2 Novel biomarker development in EOC 
Similar to other cancers, the initiation and development of EOC is characterised by disruption 
of oncogenes and tumour suppressor genes by both epigenetic and genetic mechanisms 
(Kobayashi et al., 2012). Recent advances in nucleic proteomics technology and acid–based 
analyses demonstrated promising discoveries of novel and more valuable serum biomarkers, 
which cumulatively represents the next generation of EOC screening tool (Figure 1.4, 
Kobayashi et al., 2012). 
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1.7.2.1 EOC biomarkers with angiogenic features 
 
1.7.2.1.1 Vascular endothelial growth factor (VEGF)  
It is well established that angiogenesis (i.e. the formation of new blood vessels) is essential for 
the growth and metastasis of solid tumours (Folkman, 1990). Tumour angiogenesis is 
regulated by a complex of angiogenic stimulators, such as fibroblast growth factors (FGF) 
family members and inhibitors (e.g. endostatin and thrombospondin-1, Rajabi and Mousa, 
2017; Hanahan and Weinberg, 2000) The most studied angiogenic stimulator is VEGF or 
vascular permeability factor (VPF). VEGF levels have been known to be elevated in EOC 
patients, where it contributes to the accumulation of ascites. A number of groups have since 
evaluated the prognostic potential of serum VEGF levels in women with EOC. However, its 
therapeutic effect is largely limited to newly forming tumour vessels and is dependent on 
complicated interactions with other factors, such as EGF, platelet derived growth factor 
(PDGF), interleukin 8 (IL-8), EPH receptor A2 (EPHA2), and the matrix metalloproteinases. 
Meanwhile, there is a lack of effective biomarkers for monitoring response to new antivascular 
agents (Hurwitz et al., 2004; Jain et al., 2006). The upregulation of VEGF and intracellular 
signalling in angiogenesis has been correlated with the activation of the JAK-STAT pathway 
components, PI3K/AKT pathway and MAPK (Zhang et al., 2003; Xu et al., 2004; Chen et al., 
2004; Bermudez et al., 2007). 
 
 
1.7.2.2 Cell aggregation pathway biomarkers 
 
1.7.2.2.1 Claudin family members  
In tumour cells, the loss of cell-cell adhesion is essential for metastatic potential and cellular 
transformation. The claudins are integral components of tight junctions, such as apical cell-
cell adhesions, that regulate epithelial paracellular permeability and are critical for epithelial 
cell polarity (Singh et al., 2010). Certain members of the claudin gene family, such as claudin-
3, 4 and 7, are abnormally regulated in several human cancers, including EOC and show 
increased invasiveness in vitro, which is mediated through MMP-2 overexpression (Michl et 
al., 2003). Claudin-3 is upregulated in 90% of ovarian tumours, including all four major 
subtypes (i.e. clear cell, mucinous, serous and endometrioid) and is also associated with 
shorter survival (Gao et al., 2011). Although claudin proteins are known to activate MMPs, 
they were also shown to regulate migration and cell-cell adhesion, however, the exact roles 
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of claudin in invasion are controversial (Dahiya et al., 2011). Claudin-3 expression also 
promotes migration, invasion, and survival of EOC cells. in addition, one study suggested that 
Claudin-7 upregulation was associated with a net increase in invasion as a result of MMP 
activation but also a decrease in cellular migration. The reduced expression of Claudin-3 and 
-4 increased both cell migration and invasion in EOC in vitro assays (English and Santin, 2013; 
Dahiya et al., 2011). 
 
 
1.7.2.3 Cell migration and invasion pathway biomarkers 
 
1.7.2.3.1 Focal adhesion kinase (FAK) 
Cell motility and migration is a major component of oncogenesis and requires a series of 
repeated adhesion attachment and detachment events from ECM. These events are mainly 
regulated by integrins. FAK, an integrin-linked protein tyrosine kinase component of the 
integrin-signalling pathways, is an important mediator of signalling pathways that occur 
between cells and their ECM, thereby facilitating migration and invasion (McLean et al., 2005). 
The calcium-dependent FAK activation is facilitated by an intramolecular autoinhibitory 
interaction, thereby, disrupting the interactions between its central kinase and amino 
terminal domains. The activated FAK generates a FAK-Src family kinases complex, therefore,  
initiating various downstream signalling pathways regulating diverse cellular functions via 
protein phosphorylation (Zhao and Guan, 2011). 
 
 
1.7.2.4 Apoptotic and signalling pathway biomarkers 
 
1.7.2.4.1 p53 mutation 
p53 mutation is the most frequent genetic alteration in EOC occurring in 60% - 80% of all 
sporadic EOCs and correlates highly with high-grade tumours. Subtype-specific mutations in 
p53 have been found in 60%-100% of HGS tumours but only in 16% of mucinous tumours, 
which suggests a prominent role for p53 mutation in carcinogenesis of HGS but not mucinous 
EOC. For example, p53 promotes p21 expression, thereby, activating p53-dependent cell cycle 
arrest at the G1 phase and senescence. p21-induces expression of Puma, Bax or miR-34, which 
are also critical for the p53-dependent apoptosis (Zhang et al., 2016). A recent study showed 
that as well as inducing apoptosis, p53 also induces ferroptosis, a special type of cell death 
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caused by ROS, in lung cancer by activating the expression of solute carrier family 7 member 
11 (SLC7A11), a key component of the cystine/glutamate antiporter (Jiang et al., 2015). 
 
1.7.2.4.2 BRCA1/2 carriers 
The BRCA1 and BRCA2 tumour suppressor genes help regulate transcription, chromosomal 
stability, promote cellular proliferation, DNA repair via Homologous recombination (HR) and 
control cell cycle checkpoints through p53-dependent and independent mechanisms. Females 
carrying BRCA1 or BRCA2 germline mutations have higher lifetime risk of developing EOC by 
16%–60% and 16%-27%, respectively (Scully and Livingston, 2000; Piura et al., 2001). 
Interestingly, recent studies indicate that women with a BRCA1 or 2-related EOC have better 
survival outcome than non-carriers, particularly if they receive platinum-based therapy 
(Chetrit et al., 2008; Ben David et al., 2002). BRCA1 regulates DNA damage response during 
synthesis (S)/G1 phase by mediating HR to maintain replication fidelity and may also play a 
role in other DNA repair processes, such as non-homologous end joining (NHEJ, Rosen, 2013). 
BRCA2 is primarily involved in HR, by mediating the phosphorylation of BRCA1 by ataxia 
telangiectasia and RAD3 related (ATR) or ataxia telangiectasia mutated (ATM) at G1/S-
checkpoint, facilitating subsequent phosphorylation of p53, thereby, initiating of the cyclin 
dependent kinase (CDK) inhibitor P21 and ionizing radiation-induced G1/S checkpoint 
activation and finally inducing apoptosis (Siliciano et al., 1997; Roy et al., 2012). BRCA1 also 
recruits RAD51 to DNA damage sites through its interactions with partner and localizer of 
BRCA2 (PALB2) and BRCA2 (Moynahan et al., 2001). Therefore, deleterious mutations in 
BRCA1/2 was shown to increase the risk of breast and EOC in women (Roy et al., 2012). 
 
1.7.2.4.3 EGFR (HER) family members 
The human EGF receptor (HER) family mediates crucial cellular processes, including growth, 
proliferation, and progression. This receptor family consists of four transmembrane receptors: 
HER1, 2, 3, and 4. Each receptor has an extracellular binding domain, an intracellular domain 
and a transmembrane domain. A range between 60%-98% of EOCs express high levels of HER. 
In contrast to HER1, 2 and 4 proteins, HER3 do not contain tyrosine kinase activities, but can 
dimerise with other HER family members leading to the activation of HER pathways (Vaidya 
et al., 2005). HER family members activate downstream signalling pathways, such as 
phosphatidylinositol-3 kinase (PI3K)/AKT and external signal-regulated kinase (ERK) pathways 
(Tanaka et al., 2011). The roles of HER1/2 have been established in breast cancer and the 
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combination of cytotoxic chemotherapy and EGFR/HER inhibitors, such as HSP90 blockade and 
tyrosine kinase inhibitors, yield better clinical response (Amler, 2010). Tyrosine kinase 
inhibitors (TKI) are biologically targeted antibodies directed towards ErbB1/EGFR/HER1 
(erlotinib, gefitinib and cetuximab) and ERBB2/HER2 neu in rodents (trastuzumab), and more 
recently toward ERBB4/HER4 and ERBB3/HER3, are currently being investigated as potential 
therapy for patients with EGFR/ERBB/HER proto-oncogene-driven malignancies (Baron et al., 
2009). Ongoing trials of these agents alone or in combination with traditional 
chemotherapeutic agents are currently under investigation (Poliaková et al., 2018; Canonici 
et al., 2018) 
 
 
1.7.2.5 Biomarkers with immune signatures 
 
1.7.2.5.1 IL-6, IL-7, IL-8 
There has been a recent emerging interest in the role of cytokines in the biology of EOC. 
Interleukins are potent cell chemo-attractants and are closely related to vascular formation 
and stimulates defective angiogenesis in EOC (Gopinathan et al., 2015). Current investigations 
have focused on IL-6, -7 and -8 as a prognostic factor in EOC. The elevated levels of IL-6, -7 and 
-8 in serum correlate with overall poor prognosis. Increased IL-6 and IL-8 expression correlates 
with poor initial response to paclitaxel chemotherapy and elevated expression of IL-6 also 
correlates with poor final outcome. The resultant activation of NF-κB by several cytokines (i.e. 
IL-1 and TNFα) and EGF, upregulates the expression of growth regulatory cytokines; anti-
apoptotic genes (CFLAR), angiogenic factors (IL-8), IL-6 or growth regulated-α (GRO1) and 
antioxidant proteins (e.g. superoxide dismutase or ferritin heavy chain, Bast et al., 2009).  
Subsequent upregulation of IL-6 activates JAK2, facilitates the phosphorylation and nuclear 
translocation of STAT3, leading to the inhibition of apoptosis and increased angiogenesis and 
proliferation (Rosen et al., 2006; Bast et al., 2009). In addition to new STAT3 inhibitors, such 
as decoy oligodeoxynucleotides, antibodies against IL-6 and inhibitors of JAK2 are currently 
being developed to target most EOCs (Soldevilla and Pastor, 2018; Burke et al., 2001; Duan et 
al., 2007; Bast et al., 2009). 
 
1.7.2.5.2 B7-H4 
It has been reported that the B7 family, including B7-H1 and B7-H4 are co-stimulatory 
molecules responsible for inhibiting T-cell activation. High B7-H4 levels in serum correlate with 
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poor prognosis (Fan et al., 2014). It has also been reported that B7-H4 promote malignant 
transformation by inhibiting cell cycle progression, cytokine production, and T-cell 
proliferation (Simon et al., 2006). While, the functional role of B7-H4 in tumour biology and 
immune evasion was previously established, stand-alone or combinatorial anti-B7-H4 
targeted therapies to overcome B7-H4-mediated hypo-function of T cells in the EOC 
microenvironment are currently under investigation (Smith et al., 2014).  
 
 
1.7.2.6 Tissue-based microRNAs (miRs) biomarkers 
 
Recently, miRs have been emerging as potential epigenetic markers of EOC. miRs are non-
protein-coding single stranded RNA molecules that function as negative regulators for gene 
expression (Rastogi et al., 2016; Kinose et al., 2014). miRs, as regulatory molecules, are known 
to act as tumour suppressors or oncogenes. A variety of miR candidates are aberrantly or 
differentially expressed in EOC. Changes in tumour miR expression prolife are mediated by 
various mechanisms, including epigenetic regulation, genetic alterations, or altered 
expression of transcription factors (Soto-Reyes et al., 2012; Kobayashi et al., 2012). Previous 
analysis of miR expression profiles by Iorio et al., (2007) has indicated that miRs expression 
was deregulated in EOC tissues/cell lines compared to normal tissues. miR-200a, miR-141, 
miR-200c, miR-200b and were most significantly upregulated in cancer samples, whereas, 
miR-140, miR-199a, miR-125b1, and miR-145 were downregulated in cancer samples (Rastogi 
et al., 2016). In platinum-resistant EOC cell lines, the overexpression of miR-136 was shown to 
promote cisplatin-induced apoptosis (Kuroda et al., 2013; Testa et al., 2018). Other studies 
also showed that miR-136 overexpression contributes to lower activity in cancer stem cells 
and promotes paclitaxel efficacy in chemoresistant EOC cells by regulating NOTCH3 
(Bhattacharya et al., 2009; Testa et al., 2018). 
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Figure 1.4 Summary of EOC biomarkers. The molecular and protein EOC biomarkers: current 
options and future promise are summarised in the square boxes. Currently used biomarkers 
for prognosis and diagnosis of EOC are shown in orange. Novel and newly developed 
biomarkers for prognosis and diagnosis of EOC are shown in green. Biomarkers with high 
expression levels were associated with improved patient overall survival. Abbreviations: NF-
κB, nuclear factor κB; ERK, extracellular signal-related kinase kinase; PI3K, phosphatidylinositol 
3- kinase; miR, microRNA; JAK, Janus kinase; STAT, acetyl- signal transducer and activator of 
transcription; NADPH, nicotinamide adenine dinucleotide phosphate; p53, tumour protein 53; 
BRCA, breast cancer gene; AKT, AKT Serine/Threonine Kinase; MAP, mitogen-activated 
protein; EGFR, Epidermal growth factor receptor. 
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1.8 The role of PADI-mediated citrullination in disease pathogenesis  
Post translational modifications of proteins are crucial as they play an essential role in various 
cellular processes (Darling and Uversky, 2018; Bürkle, 2001). PTMs modulate various chemical 
and physical properties, including folding, stability, conformation and activity of proteins by 
covalently binding small chemical molecules to specific amino acid residues, thus allowing 
proteins to respond to various environmental stimuli or developmental signals (Audagnotto 
and Dal Peraro, 2017). These modification also alter target protein interactions with ligands 
or other proteins, some of which are involved in diseases, such as cancer and neurological 
disorders (Darling and Uversky, 2018; Bürkle, 2001). One such PTM, citrullination, corresponds 
to the post-translational deimination or demethylimination of protein-bound arginine to 
citrulline residues mediated by a family of Ca2+-dependent peptidyl arginine deiminase (PADI) 
enzymes (Chavanas et al., 2006). Recently, citrullination has become an increasingly 
investigated type of PTM, as it significantly effects physiological functions of the targeted 
proteins and may exhibit important roles in cell differentiation, cell apoptosis embryonic 
development, nerve growth and gene expression regulation (Chavanas et al., 2006; György et 
al., 2006; Bicker and Thompson, 2013). This modification alters the charge of residues from 
positive to neutral, resulting in substrate protein loss of conformation, increased aggregation 
ability, and in some cases, causes denaturation. Beta-sheets and intrinsically disordered 
proteins are structures most prone to citrullination, and their identified deiminated targets 
include mitochondrial, cytoplasmic and nuclear proteins (György et al., 2006). Moreover, 
citrullination is involved in the innate immune response by regulating chemokine activity and 
development of neutrophil extracellular traps (Mortier et al., 2011; Pingxin Li et al., 2010). 
Also, citrullinated proteins are recognised as non-self-proteins and can subsequently promote 
various autoimmune conditions, including rheumatoid arthritis (RA) and multiple sclerosis 
(MS, Darrah et al., 2012; Klareskog et al., 2014). Increased levels of PADIs and 
hypercitrullination have been associated with various chronic inflammatory diseases, such as 
neurodegenerative conditions (e.g. Alzheimer’s disease, Anzilotti et al., 2010; Ceuleneer et al., 
2012; Chang, 2005; Chang and Han, 2006; Jones et al., 2009).  In addition, Jiang et al., (2013)  
reported that citrullinated proteins were detected in breast, liver, ovarian, lung, kidney, 
cervical, gastric and pancreatic tumour cell lines. 
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1.8.1 The PADI family of enzymes structure and Ca2+ dependency 
Recently, vertebrate PADIs were categorised into five isotypes (PADI1, 2, 3, 4, and 6), based 
on their amino acid sequences, molecular weights, tissue localisation and substrate 
specificities. Three PADI isotypes were found in birds (Gallus gallus), whereas only one seems 
to exist in fish species (Takifugu rubripes, Danio rerio, Oncorhynchus mykiss and Tetraodon 
nigroviris) and amphibians (Xenopus laevis, Vossenaar et al., 2003; Ying et al., 2009b; Rebl et 
al., 2010). In mammals, all five isotypes of PADIs are present in rat (Rattus norvegicus), mice 
(Mus musculus) and humans (Homo sapiens, Terakawa et al., 1991; Erik R Vossenaar et al., 
2003). Mammalian PADI genes are thought to have arisen by gene duplication of an ancestral 
homologue, PADI2, and are all encoded as a cluster of genes on chromosome 1p36.1 
(Chavanas et al., 2004). The five mammalian PADI isozymes display highly conserved amino 
acid sequence with 70-95% homology between human paralogs (Méchin et al., 2007). 
Although high resolution structures of PADIs 1, 3 and 6 have yet to be reported, significant 
work has been done to elucidate the structure of PADI4 both with and without Ca2+ bound, as 
well as with PADI4 substrates (i.e. benzoyl-l-arginine amide (BAA), histone 3 (H3), and histone 
4 (H4)), and the PADI inhibitor Cl-amidine (Jones et al., 2012; Luo et al., 2006; Causey et al., 
2011). More recently, the PADI2 crystal structure has been determined by Slade et al., 
providing more structural and functional information about this isozyme. This work has 
indicated that PADI2 contains two distinct domains (i.e. N- domain (1–300 amino acids) and 
C-terminal domain (301–663 amino acids)) and contains a total of six Ca2+ binding sites. Two 
of these Ca2+ binding sites are located in the C-terminal domain and the remaining four binding 
sites are in the N-terminal domain, which is further divided into two immunoglobulin-like 
subdomains, one of which (i.e. PAD_M) contains the PADI2-Ca2+ activating switch that 
mediates highly ordered α-helices in the presence of Ca2+ (Arita et al., 2004; Slade et al., 2015). 
It is hypothesised that this Ca2+-regulated conformational change regulates PADI2 protein-
protein interactions (Slade et al., 2015). In the C-terminal domain, Ca2+ binding induces large 
conformational shifts, generating the active cleft site allowing substrate binding, thereby 
activating the enzyme (Arita et al., 2004; Liu et al., 2013; Slade et al., 2015).  
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1.8.2 PADIs substrate target  
PADI family members have broad substrate specificity, therefore, not all arginine residues in 
a protein are equally likely to be citrullinated by PADIs. PADI specificity is dependent on the 
structure, location, and abundance of the arginine residues in a protein (Knuckley et al., 2010; 
Tarcsa et al., 1996). PADI-mediated citrullination can also cause various changes in protein-
protein interactions or induce denaturation. Mainly, filaggrin and H3 and H4 are known PADI 
protein substrates are the most extensively studied. The citrullination sites in these proteins 
have been identified; thus, the synthetic peptides derived from these proteins were used to 
determine the sequence specificity of PADI protein substrates (Liu et al., 2017). The main 
targets of every PADI isozyme are the following: PADI1 targets keratin and filaggrin (Senshu et 
al., 1995); PADI2 targets myelin basic protein (MBP), vimentin, actin, inhibitor of growth family 
member 4 (ING4), p65, C-X-C motif chemokine ligand 8 (CXCL8), β-catenin, glycogen synthase 
kinase 3 beta (GSK3β), nucleophosmin 1 (NPM1) and H3 (Lamensa and Moscarello, 1993; Hsu 
et al., 2014; X. Zhang et al., 2012); PADI3 targets filaggrin, trichohyalin, apoptosis-inducing 
factor (AIF), and vimentin (Senshu et al., 1995; U et al., 2014); PADI4 targets a range of nuclear 
proteins, such as inhibitor of growth 4 (ING4), p300, p21, p53, H3 and H4 and apoptosis 
(nucleophosmin, nuclear lamin C, Arita et al., 2004; Kan et al., 2012; Guo and Fast, 2011; Lee 
et al., 2005; Li et al., 2008); PADI6; regulates the function of microtubules during early embryo 
development (Maddirevula et al., 2017; Kan et al., 2011, Table 1.3).  
 
Table 1.3 PADI family isozymes-specific target substrates.  
Isozyme Substrates 
PADI1 Filaggrin and keratin 
PADI2 Myelin basic protein (MBP), vimentin, actin, ING4, P65, CXCL8, β-catenin, GSK3 β, 
NMP1 and histones (H3 and H4) 
PADI3 Filaggrin, trichohyalin, vimentin and apoptosis-inducing factor 
PADI4 Inhibitor of growth 4 ING4, p21, p300, nuclear lamin C, nucleophosmin and 
histones (H3 and H4) 
PADI6 Microtubules 
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1.8.3 PADIs function  
Under normal physiological conditions, PADIs exist in an inactive form due to low physiological 
i[Ca2+] levels (10−8 to 10−6 M, György et al., 2006; Takahara et al., 2014). PADIs become 
activated by elevated Ca2+ levels (above the normal physiological concentration) that occur 
during certain events, such as terminal epidermal differentiation and apoptosis (Takahara et 
al., 2014). Interestingly, PADI-mediated citrullination function in gene regulation and is 
implicated several cellular processes, such as apoptosis, NETosis and autophagy, at 
physiological concentrations of Ca2+ (György et al., 2006). Ca2+ acts as a signalling molecule to 
coordinate multiple cellular processes, including apoptosis and autophagy; therefore, it is 
needed at high concentrations within apoptotic cells (Valesini et al., 2015). 
 
1.8.3.1 The role of PADI in structural support 
PADIs are also involved in organising structural proteins found in hair follicle and epithelial 
cells undergoing terminal epidermal differentiation (György et al., 2006; Senshu et al., 1996). 
This PADI-mediated differentiation is regulated by Ca2+. Higher Ca2+ concentrations were 
shown to activate the PADIs. Within the epidermis, PADIs can citrullinate structural proteins, 
such as keratin, vimentin, and filaggrin. The epidermal barrier filaggrin protein, known to have 
a key role in atopic dermatitis, is a 4061 amino acids long, with a relatively high arginine 
content (10.8%); which provides higher potential target sites for PADIs-mediated citrullination 
(Pruitt et al., 2014). Upon Ca2+-mediated terminal differentiation of epidermal cells, the PADI-
mediated  citrullination of these proteins is subsequently activated, causing incomplete 
protein unfolding, and consequent protein degradation by proteases (Pearton, Dale and 
Presland, 2002; György et al., 2006). In the epidermis, PADI1, 2 and 3-mediated citrullination 
of cytokeratin keratin factor 1 and filaggrin, modulates epidermis cornification (Yamamoto et 
al., 2002). Citrullinated filaggrin also helps maintain healthy skin through its role in the 
formation of natural moisturising factor (NMF) in the superficial keratinised epidermal cell 
layers (Senshu et al., 1996; Cau et al., 2017). The cytokeratin citrullination and subsequent 
loss of charge leads to the disassembly of the cytokeratin-filaggrin complex and proteolytic 
degradation of these targets (Mohanan et al., 2012). PADI3 expression is only detected in the 
hair follicle and epithelium. In addition, in the epithelium, PADI3-mediated citrullination of 
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filaggrin and keratin 1 leads to terminal differentiation of keratinocytes, subsequent alteration 
of epidermal homeostasis and loss of barrier function (Nachat et al., 2005).  
 
1.8.3.2 PADI regulation of gene expression under normal physiological conditions 
In addition to their role in disease, PADI isozymes can regulate gene expression under normal 
physiological conditions (Wang and Wang, 2013). Most research on PADIs’ involvement in 
gene regulation has been performed on PADI4 and more recently on PADI2 (Mohanan et al., 
2012; Guo and Fast, 2011; Cherrington et al., 2012; Cantarino et al., 2016). One of the best 
studied systems of PADIs’ function is their role in histone citrullination and p53 pathway 
regulation, suggesting the importance of PADI-induced citrullination in apoptosis. PADI4 
citrullinates ING4, another tumour suppressor protein known to bind p53, once modified, this 
protein does not bind to p53, subsequently repressing p53 acetylation, thereby, inhibiting 
downstream p21 expression (Guo and Fast, 2011). Another mechanism involves the 
citrullination of methylated arginine on histones. In this mechanism, PADI4 was shown to 
citrullinate histone 4 arginine 3 (H4R3) and H3R2, R8, and R17 and the modification is 
associated with gene repression (Kan et al., 2012). For example, PADI4 is involved with the 
regulatory domain of p53 that targets p21 at the p53-binding sites on the promoter region. 
PADI4 interaction with these proteins causes citrullination of histones on the p21 promoter 
region, preventing p21-to-p53 binding and subsequently repressing p21 transcription (Li et al., 
2008). This impaired binding occurs due to changes in protein charge that can affect the 
hydrogen bond formation during protein-protein interactions. Also, citrullination of histones 
on the promoter region that includes p53-binding sites, may induce conformational changes 
that sterically hinder p53 binding. Correspondingly, Li et al., (2010) reported similar findings, 
but they further found that both PADI4 and histone deacetylase 2 (HDAC2) regulate gene 
expression, by targeting p53 and simultaneously associating with p21 promoter in response 
to DNA damage (Yuzhalin, 2019). Consistent with these reports, PADI4 overexpression in 
hematopoietic cancer cell lines was found to be associated with increased p21 and p53 
expression leading to apoptosis (Liu et al., 2006; Yuzhalin, 2019). However, the mechanisms 
regulating PADI4 activation at physiological Ca2+ levels and its recruitment to specific 
promoter sites remain largely unknown (Slack et al., 2011; Denman, 2005). Wang and Wang, 
(2013) proposed a mechanism by which PADI4 carries out its function by binding to the 
promoter region of p53 of target genes, such as p21 (CIP1/WAF1), DNA damage inducible 
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alpha (GADD45) and PUMA. PADI4 represses these target genes expression by histone 
citrullination during periods where the damage response pathways are not needed. After DNA 
damage, PADI4 dissociates from the promoter regions, thereby, activating target genes once 
again. There is also evidence that PADI4 can act as a transcriptional coactivator. In this process, 
PADI4 mediates the citrullination of methylated arginine2142 in glutamate receptor 
interacting protein 1 (GRIP1) binding domain of the transcriptional coactivator p300, thereby, 
enhancing p300-GRIP1 complex modulation of tissue-specific gene expression (Lee et al., 
2005). The mechanisms regulating PADI activation is not fully established, but György et al., 
(2006) hypothesised that at low levels of Ca2+, PADIs might still be active with strict substrate 
specificity and this could explain PADI involvement in gene regulation. However, this is unlikely 
to be accurate because different substrates have similar Ca2+ dependencies (Slack et al., 2011). 
 
1.8.3.3 The role of PADI-mediated citrullination in cancer pathogenesis 
1.8.3.3.1 The role of PADIs in apoptosis and proliferation 
PADI isozymes exert a complex regulatory role in numerous cellular activities, including cell 
death. In particular, the overload or influx of extracellular e[Ca2+] mediates various signalling 
molecules to coordinate cell apoptosis. Therefore, Ca2+ is found at high concentrations within 
apoptotic cells (Mattson and Chan, 2003). PADIs are activated by these elevated Ca2+ 
concentrations in pro-apoptotic cells. Once activated, PADIs may target proteins that are 
arginine-rich or have arginine-rich regions within their amino acid sequence. For example, 
vimentin, is found to be citrullinated during ionomycin-induced macrophage apoptosis (Hsu 
et al., 2014). Citrullinated vimentin peptides stimulate strong anti-tumour immunity (Durrant 
et al., 2016). The vimentin protein is 466 amino acids long with 9.2% arginine residues. Inagaki 
et al., (1989) previously reported that PADIs citrullinate the non-α-helical head domain of the 
vimentin protein. In this non-α-helical head domain (2–95 amino acids), there are 12 arginines 
that are citrullinated by PADIs (Pruitt et al., 2014). Citrullination of vimentin impairs the 
polymerisation of vimentin filaments resulting in filament disassembly and subsequent 
structural breakdown and further completion of apoptosis (Inagaki et al., 1989; Katsumoto et 
al., 1990). The increased expression of vimentin has been detected in several epithelial 
cancers, including breast cancer, gastrointestinal tumours, prostate cancer and other types of 
cancers (Hsu et al., 2014). Citrullinated vimentin is also expressed on the cell surface of PADI2-
overexpressed and Jurkat-activated cancer cells during apoptosis (Hsu et al., 2014). This 
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presentation induces cytotoxic CD4+ T-cell responses, thus providing evidence for the use of 
citrullinated peptides as vaccination targets in cancer therapy (Brentville et al., 2016). Like 
citrullinated vimentin, other citrullinated proteins, such as the ubiquitous glycolytic enzyme 
α-enolase (ENO1), can be presented on the cell surface as citrullinated peptides or 
citrullinated epitopes, thus, stimulating potent antitumor responses (Cook et al., 2018). 
Overall, PADI2 activation (due to amplified Ca2+ levels during the early stages of apoptosis) can 
facilitate apoptotic cell death via citrullinating several nuclear and cytoskeletal proteins that 
can cause structural changes resulting in the disintegration of secondary and tertiary protein 
structures or induce citrullinated epitopes presentation on cell surfaces, thereby, activating 
anti-inflammatory response  (Figure1.5, Inagaki et al., 1989; Vossenaar et al., 2003; György et 
al., 2006). 
Likewise, histones and nucleophosmin are known targets of PADI2 and PADI4, and their 
citrullination can cause the nucleosome and nuclear lamina to collapse, triggering apoptosis 
(Vossenaar et al., 2003; György et al., 2006). The oligomerisation of nucleophosmin is 
necessary for nucleolar localisation and inhibits the mitochondrial apoptosis pathway in a p53-
independent manner (Durbin et al., 2010; Dhar and Clair, 2009). Chang and Fang, (2010)  
correspondingly reported that PADI4 overexpression upregulates p53 and stimulates 
mitochondrial-associated apoptosis. A recent study in breast cancer, reported that PADI2-
mediated citrullination of a key residue (i.e. arginine 1810 (cit1810)) at RNA polymerase II 
(RNAP2) recruits protein complexes that affect transcription elongation and activate the 
transcription of thousands of genes (Sharma et al., 2019). The inhibition of (RNAP2 
citrullination site) equally reduced cell proliferation via inducing cell-cycle arrest at the G1 
phase (Yuzhalin, 2019). Interestingly, in breast cancer cells, other members of the PADI family 
(PADI3 and PADI4) were unable to catalyse the citrullination of RNAP2 and induce the above-
mentioned effects (Figure1.5, Yuzhalin et al., 2019; Sharma et al., 2019). 
 
1.8.3.3.2 The role of PADIs in cell migration 
Cell migration is involved in various normal and oncogenic biological processes, including 
immune response and embryonic development, and its dysregulation plays a key role in 
metastasis and invasion (Cyster, 2005; Luster et al., 2005; Aman and Piotrowski, 2010; Friedl 
and Wolf, 2003; Yamaguchi et al., 2005). PADI4 suppresses breast cancer cell migration via 
citrullinating nuclear GSK3β and subsequent activation of transforming growth factor beta 
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(TGFβ) signalling, thereby, inducing epithelial-to-mesenchymal transition (EMT, Stadler et al., 
2013). Another mechanism involves inducing p53 transactivation during DNA damage 
response. In this mechanism, PADI4 binds to the intronic p53-binding site forming a p53/PADI4 
network, thereby, inducing citrullination in histone chaperone protein, nucleophosmin 
(NPM1).  In the nucleoli, NPM1 was shown to be associated with various process, including 
ribosome subunit assembly, pre-rRNA processing, and rRNA transcription, which are essential 
for cellular homeostasis (Tanikawa et al., 2009). The PADI4-mediated NPM1 citrullination, 
resulted in NPM1 translocation from the nucleoli to the nucleoplasm, subsequently inhibiting 
ribosomal biogenesis leading to inhibition of tumour cell growth (Tanikawa et al., 2009; 
Matsuda et al., 2002; Zhu et al., 2013). Aside from PADI4, PADI2 was also found in mammary 
tissues and is deregulated in breast cancer. Unlike PADI4, PADI2 was shown to regulate 
mammary carcinoma cell migration possibly through epidermal growth factor (EGF) signalling 
pathway (Figure 1.5, Horibata et al., 2017).  
 
1.8.3.3.3 The role of PADIs in autophagy 
Autophagy plays a crucial role in physiology and pathophysiology, such as ageing, cancer, 
infectious diseases and autoimmune diseases (Glick et al., 2010; Nicholas and Bhattacharya, 
2014). Autophagy is upregulated in response to intra- or extracellular stress and signals, 
including growth factor deprivation, starvation, deregulated Ca2+ homeostasis, and 
endoplasmic reticulum stress. It was demonstrated that autophagy was involved in the 
generation of citrullinated peptides by antigen presenting cells (APCs), which was associated 
with increased PADI activity detected in purified autophagosomes (Valesini et al., 2015). 
Processing of proteins in autophagy vesicles of APC generates citrullinated peptides which are 
presented on cells, such as B cells, and recognised by the MHC-II molecules that stimulate 
CD4+ T-cell responses (Durrant et al., 2016; Mohamed et al., 2018). The authors suggested 
that citrullination may represent a “biochemical marker of autophagy” (Figure 1.5, Ireland and 
Unanue, 2012). 
 
1.8.4 The role of PADI2-mediated citrullination in cancer pathogenesis  
In recent years, studies have found that citrullination is correlated with tumour progression in 
majority of human cancers, suggesting that PADIs are potential therapeutic targets for cancer. 
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While the apparent function of PADIs activity in most diseases are associated with 
inflammation, the role of PADIs in cancer progression remains unclear. As explained previously 
in this chapter, PADI2 is the ancestral homologue of all PADI family isozymes and is widely 
expressed in mammalian tissues. Recently, PADI enzymes, particularly PADI2, have been 
identified as potential biomarkers and therapeutic targets in many diseases, including cancer 
(McElwee et al., 2012; N. Cantarino et al., 2016). Wang et al., (2016) reported that PADI2 is 
associated with increased breast cancer risk, and its expression contributes to tumorigenesis 
via the deregulation of acyl-CoA synthetase long chain family member 4 (ACSL4), BINC3 and 
carbonic anhydrase 9 (CA9) signalling pathways (Wang et al., 2016). Furthermore, 
Bhattacharya et al., (2006) detected high PADI2 expression and citrullination in glaucoma, and 
McElwee et al., (2014) also reported that overexpressing PADI2 induces spontaneous skin 
neoplasia in transgenic mice. McElwee et al., (2012) found that EGF plays an important role in 
the proliferation of normal mammary epithelium and appears to regulate PADI2 expression in 
mammary cancer cells. They also found that PADI2 mRNA expression significantly correlates 
with HER2, a known biomarker and oncogene in breast cancer. Following oestradiol exposure, 
it was suggested that ER directly or indirectly induces PADI2-mediated citrullination of histone 
H3 arginine 26 (H3R26), subsequently inducing Ubiquitin Conjugating Enzyme (E2)-mediated 
activation of endoplasmic reticulum-target genes. H3R26 citrullination abbreviates core 
nucleosome particles and shifts its DNA size from 149 to 125 bp. Thus, inducing altered 
conformation of the nucleosome allows for a more stable interaction between the 
endoplasmic reticulum and its nucleosomal binding sites (Guertin et al., 2014). Cherrington et 
al., (2010) correspondingly reported that EGF upregulates PADI2 transcription and translation 
in CMT25 canine mammary tumour cells. It was previously shown that PADI2 modulates 
epithelial-mesenchymal plasticity in mammary carcinoma by deregulating the expression of 
the cytoskeletal regulatory proteins, including ras homolog family member A (RhoA), rac 
family small GTPase 1 (Rac1), and cell division cycle 42 (Cdc42), and downregulating 
intracellular junctions, such as E-cadherin (Horibata et al., 2017). Collectively, these studies 
suggest that PADI2 potentially function as an ER cofactor, thus regulating the expression of 
the canonical ER target gene, such as trefoil factor 1 (TFF1, Figure 1.5, Zhang et al., 2012).  
Whilst high PADI2 expression levels and histone citrullination are known to associate with 
metastatic features, such as cell proliferation, recently Guertin et al., (2014) identified a strong 
correlation between H3R26 citrullination and high PADI2 expression with increased survival in 
oestrogen receptor (EGFR)/HER2+ tumour patients. The authors also suggested that histone 
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citrullination may be valuable for sub classification of HER+ tumours into clinically relevant 
subsets. Tanday, (2016) recently reported that inhibiting PADI2 expression may prevent the 
progression of myeloma. In addition, Cantarino et al., (2016), demonstrated that the 
downregulation of PADI2 is an early event in colorectal carcinogenesis. These observations 
further suggest the potential role of PADI2-mediated citrullination as a tumour suppressor or 
promoter mark in cancer. Therefore, further studies are required to elucidate the 
comprehensive role of PADI2 during tumour development and to emphasise whether it 
functions as a tumour suppressors or oncogene. Therefore, the effect of PADI2 on the 
tumourigenic process and regulatory mechanisms should be comparatively studied among 
different tumours. The detailed regulatory mechanisms of PADI2 and its function during the 
tumourigenic process in OC are not fully explored. Preliminary unpublished tissue microarray 
data (TMA) indicated that high PADI2 expression in tumours is protective and may represent 
an independent prognostic marker. To gain more insight into the tumourigenic role of PADI2, 
the present study analysed the expression levels of PADI2 in EOC cells and the effect of PADI2-
overexpression on EOC tumorigenesis.  
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Figure 1.5 Schematic presentation of the proposed mechanism of PADI2 function in cancer. 
PADI2 is activated by various factors, including receptor signalling (i.e. ER, EGFR, HER2, HER3), 
oxidative stress which leads to membrane disruption and i[Ca2+] influx, and hypoxia, which 
initiate autophagy and DNA damage. Increased expression and activation of PADI2, catalyses 
the citrullination of histones and other proteins, subsequently promoting cell proliferation, 
epithelial-mesenchymal transition, migration and inflammation. PADI2-mediated 
citrullination of proteins generate citrullinated peptides that stimulate CD4+ T cell responses. 
In high PAD2 expressing cells, Rho family of small GTPases are upregulated whereas, E-
cadherin is downregulated, subsequently promoting cell migration. At the tissue level, this 
increased cell migrating ability (motility) may lead to increase cell invasion. PADI2-mediated 
citrullination of R1810 (Cit1810) at repeat 31 of the CTD on RNAP2 recruits P-TEFb kinase 
complex to chromatin, facilitating RNAP2 pause release resulting in transcription activation of 
several signalling pathways. Initiating RNAP2-mediated transcription activation, leads to 
increased gene expression and cancer cell proliferation. Abbreviations: P-TEFb, positive 
transcription elongation factor b; ER, oestrogen receptor; EGFR, epidermal growth factor 
receptor; HER2/3, human epidermal growth factor receptor 2/3; RNAP2, RNA polymerase II; 
AB, antibody; Cit, citrulline; p65, tumour protein 65; CXCL8, C-X-C motif chemokine ligand 8; 
CTNNB1, β-catenin; ING4, inhibitor of growth family member 4; GSK3-β, Glycogen synthase 
kinase 3 beta; NPM1, nucleophosmin 1; ENO1, α-enolase; Ca2+, calcium, E[Ca2 ], extracellular 
calcium; i[Ca2+], intracellular calcium; HER, Oestrogen-related receptor; CDC42, cell division 
cycle 42; RAC1, rac family small GTPase 1; RhoA, ras homolog family member A. 
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1.9 AIMS AND OBJECTIVES 
 
This research focuses on the relationship between PADI2 expression and EOC. More recently, 
research investigating PADI2-mediated post-translational citrullination has garnered 
increased attention due to its emerging role in various human and animal cancers. Although 
the molecular mechanisms are not yet fully understood, PADI2 seem to exhibit a key role in 
regulating various tumourigenic processes. PADI2 provides a novel biomarker and therapeutic 
target in breast cancer and research to date has focused on its expression impact on patients’ 
overall survival and on in vitro cellular activity. The role of PADI2 and its associated regulatory 
mechanism in EOC has never been investigated. The preliminary unpublished tissue 
microarray data indicated that high PADI2 expression in tumours is protective and may 
represent an independent prognostic marker. Based on this, the primary aims of this thesis 
were to:  
 
1. Assess the relationship between PADI2 expression and overall survival of EOC patients 
 
2. Investigate the interaction of PADI2 with other genes to provide an improved 
understanding of the molecular regulatory pathways and novel gene targets by which 
PADI2 carries out its role in EOC.  
 
3. Elucidate the evolutionary history of PADI2 by comparing orthologues sequences and 
detecting evolutionarily conserved amino acid residues to predict functionally 
important residues for PADI2 function. 
 
4. Explore the role of PADI2 as a potential EOC biomarker and therapeutic target by 
analysing its expression and function in vitro. 
 
5. Develop CRISPR/Cas-sgRNA complex tool to gene edit PADI2 in vitro. 
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The objectives of this thesis were:  
 
 
1. To determine whether high PADI2 gene expression confers a survival advantage in EOC 
patients, in silico analyses were employed to assess gene expression data obtained 
from online cancer databases the cancer genome atlas program (TCGA).  
 
2. To identify the molecular regulatory pathway, co-expression data obtained from TCGA 
were analysed to identify the highest correlating genes. Candidate genes were further 
analysed regarding their interaction with PADI2 in vitro.   
 
3. To establish the phylogenetic orthology relationships and identify divergence events 
of PADI2 across various species, in silico analyses were utilised to analyse full length 
orthologues (obtained from NCBI database) and construct PADI2 3D and 2D structures. 
 
4. To explore the role of PADI2 in EOC, the impact of PADI2 overexpression on 
downstream effect on cellular activity, including proliferation, apoptosis, autophagy, 
necrosis and cellular aggregation in vitro. 
 
5. To employ CRISPR/Cas9 tools with specific sgRNAs to genetically delete PADI2 
expression in vitro human and mouse cells lines. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1 TCGA and cBioPortal databases for Cancer Genomics 
2.1.1 Collecting and processing the cBioPortal EOC clinical data 
Clinical patient and gene expression data retrieved from microarrays and RNA-seq were 
downloaded from the TCGA cBioPortal OC cohort. The mRNA expression values of the primary 
tumours from patient samples with serous OC were determined via RNA-seq or agilent 
microarray analysis (Agilent Technologies, Inc., Santa Clara, CA, USA). These data were 
downloaded from the cBioPortal (cBioPortal online - accessed April 2015)  
(http://www.cbioportal.org/). These data sets were used in line with (Gao et al., 2013; Cerami 
et al., 2012) recommendations. All publicly available TCGA tumour data is compliant with US 
law protecting patient confidentiality and maintains high ethical standards. These patient 
datasets were used to investigate the relationship between PADI2 mRNA expression and EOC 
patient OS time. Data regarding gene expression determined using Log2 median-cantered 
intensity in OC and normal controls were analysed using Pearson’s correlation coefficients by 
comparing the gene expression values of PADI2 with other (11813 genes) deregulated genes 
in the EOC dataset.  
 
2.1.2 Survival analysis of patients with high or low expression of PADI2mRNA transcript  
X-tile software was used to dichotomise samples into high and low expressing groups by 
providing cut point values using a minimal p-value approach. Vital status (dead/alive), OS time 
of EOC patients and PADI2 mRNA gene expression data was used to determine PADI2 
expression cut-points. Followed by the SPSS-Kaplan-Meir curve survival analysis using the cut 
points obtained from X-tile (Camp et al., 2004). Samples were then recoded into high and low 
expressing groups and Kaplan Meier plots were generated. The significant difference in 
survival outcomes between groups was determined using the log-rank test (p < 0.05 for 
statistical significance). 
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2.2 PADI2 structure and phylogenetic analysis 
2.2.1 PADI2 sequence alignment and phylogenetic reconstruction 
PADI sequences were retrieved from Ensembl (http://www.ensembl.org/index.html ) and 
NCBI (https://www.ncbi.nlm.nih.gov/ ). The nucleotide sequences of PADI2 orthologues were 
aligned and translated to protein using the molecular evolutionary genetics analysis version 
7.0 (MEGA7) software (Kumar et al., 2016). Phylogenetic relationships of the PADI2 aligned 
nucleotide sequences in diverse species was inferred using the Phylogenetic Analysis by 
Maximum Likelihood (PAML) v.1.3.1 in Mega7 (Yang, 2007). Nodal support was assessed using 
bootstrap analysis with 1000 replicates. The analysis involved 31 PADI2 ortholog sequences 
from species representing a range of taxa: human primate, non-human primates: Rhesus 
monkey, Chimpanzee and Olive Baboon; Rodents: Mouse, Rat, Alpine Marmot and Molerat; 
Chioptera; bats: Rousette, Flying Fox and Opterus Natalensis; Artiodactyla: Wild Camel; 
ungulates: Horse and Ass; Carnivora: Dog and Giant panda; Aves class birds: Canary, Ruff, Eagle 
and Chicken; teleost: Bony Tongue, Piranha, Catfish, Molly, Vulus, Rhinocerous, Barramundi 
Perch and Poecilia Mexicana; Celastrales flowering plants: Japonicus; amphibia: Frog 
(Appendix Table S.1). 
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2.2.2 3D and 3D visualisation of PADI2 
The aligned PADI2 amino acid sequence produced from PAML was employed by the molecular 
visualisation program; PyMOL version 1.8. to generate 3D and 2D structures (Schrödinger., 
LLC, n.d.).   The individual amino acids were colour coded according to the selection status 
(positive, neutral and conserved selection). The previously determined ligand binding sites 
and Ca2+ binding sites were also mapped on the truncated PADI2 amino acid sequence. 
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2.3 Cell culture of EOC cell lines 
 
Table 2.1 Ovarian cancer cell lines used in this study 
Cell line Source Chemotherapy treatment Histology Reference 
Tissue 
site 
SKOV-3  ECACC Platinum- resistant HGS G1/2 
(Novetsky et al., 
2013; Liang et al., 
2012) 
Ascites 
ID8-Luc2  John B. Liao N/A Epithelial EOC (Hernandez et al., 2016) 
Mouse 
ovary 
OVCAR-3 Nottingham Hospital 
Platinum-
resistant 
HGS 
adenocarcinoma 
G2 
(Mitra et al., 2015; 
Liang et al., 2012) Ascites 
OVCAR-4 Nottingham Hospital 
Platinum-
resistant 
HGS 
adenocarcinoma 
G2 
(Mitra et al., 2015; 
Lengyel et al., 
2014) 
N/A 
OVCAR-5 Nottingham Hospital N/A 
HGS 
adenocarcinoma 
G1 
(Mitra et al., 2015) N/A 
OVCAR-8 Nottingham Hospital N/A 
HGS 
adenocarcinoma 
G3 
(Mitra et al., 2015) N/A 
OVCA-433 Nottingham Hospital N/A HGS 
(Novetsky et al., 
2013) N/A 
OAW42 Nottingham Hospital 
Platinum-
resistant Serous or HGS 
(Beaufort et al., 
2014) N/A 
TOV-112D ATCC Untreated Endometrioid G3 (Beaufort et al., 2014) N/A 
Abbreviations: G1, grade 1 (well differentiated); G2, grade 2 (moderately differentiated); G3, grade 3 (poorly 
differentiated); N/A, not available; HSG, high grade serous; ECACC, The european collection of authenticated 
cell cultures; ATCC, The global bioresources center. 
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2.3.1 Recovery of cryopreserved cell lines 
Human EOC cell lines: SKOV-3, OVCAR-3, OVCAR-4 OVCAR-5, OVCAR-8, OVCA-433, and 
OAW42 were kindly provided by professor Lindy Durrant (University of Nottingham).  TOV-
112D was purchased from the ATCC. The murine EOC cell line ID8-Luc2 was kindly provided 
by Professor John B. Liao, (University of Washington). All cell lines were received frozen in 1ml 
cryovials shipped on dry ice. Frozen cells were stored in liquid nitrogen for long term storage 
or -80oC for short term use. The vials were thawed by gentle agitation in a 37°C water bath 
(Clifton NE2D, NE2-14D) and removed immediately upon thawing. The content of the vials 
was diluted with 10ml pre-warmed cell growth medium and harvested by centrifugation at 
300g for 5 minutes at 25oC. The cells were then re-suspended in fresh culture medium and 
transferred to the T25 flask containing 10ml pre-warmed growth medium (described below) 
and grown at 37°C with 5% CO2. Medium was replaced after the first 24 hours and then 
replaced as required (Table 2.1). 
 
2.3.2 Growth Medium 
All SKOV-3, OVCAR-3, OVCAR-4 OVCAR-5, OVCAR-8, OVC-14433, OAW42 and TOV-112D were 
cultured in RPMI-1640 (RPMI 1640 Medium, GlutaMAX™ Supplement, Fisher Scientific, USA) 
growth medium. The RPMI medium was supplemented with 10% FBS (foetal bovine serum 
(heat inactivated E.U approved South America origins)), 100 IU/ml penicillin and 100 IU/ml 
streptomycin (Fisher Scientific, USA). ID8-Luc2 were cultured in DMEM medium (Dulbecco’s 
modified eagle medium, GlutaMAX/High glucose, supplement and 25mM HEPES, Fisher 
Scientific, USA) growth medium supplemented with 4% FBS, 5ml insulin transferrin selenium 
(ITS-G) 1X (Fisher scientific, USA, 41400045), 100 IU/ml penicillin and 100 IU/ml streptomycin. 
All cells were grown at 37°C in a humidified atmosphere of 5% CO2. All cell lines were tested 
for mycoplasma every 6 months (EZ-PCR mycoplasma test kit, Bioind). 
 
2.3.3 Sub-culturing of cell lines 
Upon reaching approximately 70-80% confluence, cells were sub-cultured into T75 and/or 
T175 flasks at a ratio of 3:10 for SKOV-3, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8 OVCA-433, 
OAW42 and 1:10 TOV-112D and ID8-Luc2. First, cells were detached from the flask by 
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treatment with 1-2 ml of 0.25% trypsin-EDTA (Fisher Scientific, USA) for approximately 1-3 
minutes at 37oC. Trypsin was neutralized by the addition of serum-containing growth medium. 
Cell-medium suspension was then centrifuged at 300g and supernatant containing trypsin was 
removed. Cell pellets were then re-suspended in fresh pre-warmed growth medium and 
seeded into new T75/T175 flasks at the dedicated ratios mentioned above and incubated at 
37°C in a humidified atmosphere of 5% CO2. 
 
2.3.4 Cell counting and viability 
After harvesting, cell pellets were re-suspended in growth medium, mixed with gentle 
agitation to avoid cell lysis. 10µl of cell suspension was mixed with 10µl of Trypan blue (VWR, 
USA), the sample was again mixed gently. 10µl of trypan/cell solution was then added to a 
haemocytometer cells numbers were then determined by counting the total number of cells 
from 16 squares and dividing by 16.  Cell viability was then measured by dividing the live cell 
count by total cell count. 
 
2.3.5 Cryopreservation of cell lines 
Cells were periodically frozen to maintain a stock of the cell line for future use. Cells were 
trypsinised and harvested as described above (method section 2.3). Cell pellets were then re-
suspended in enough pre-chilled (4oC) recovery cell culture freezing medium; supplemented 
with 10% (v/v) DMSO (Fisher Scientific, USA) in 1ml pre-chilled (4oC) cryovials (Sarstedt), to 
create a cell suspension of 1x106- 10x1010 cells per 1ml. Cryovials containing cells were then 
transferred immediately to freezing container containing isopropanol and cooled in a 
controlled fashion and then stored at -80oC.  
 
2.4 Plasmids used for transfection studies 
2.4.1 CRISPR plasmids 
RNA-guided CRISPR/Cas9 plasmids were obtained from Genscript (U7802BD260, pX459-
puromycin cassette, USA). These plasmids were used to genetically delete PADI2 locus in OC 
cell lines; SKOV-3 and ID8-Luc2, by gene editing. Two sgRNAs were designed to target 
homologous sequences on both the human and mouse PADI2 loci in exon one and exon seven 
  
 50 
(chr1:17,066,761-17,119,435). The chosen sgRNAs were designed using a CRISPR online tool 
(open access online, http://crispr.mit.edu) according to their higher on-target percentage and 
lower number of mismatches (Table 2.2).  
 
Table 2.2    Sequences of sgRNA 
sgRNA sequence 
Chromos
ome/Exo
n 
Start/End position on 
chromosome (Hg18) 
on-target 
locus: 
On-
target 
score 
% 
sgRNA1: 
CGTGGAGGCGGTGTACGTGC 1/1 17119311/17119330 
Chr1: -
17119307 91 
sgRNA2: 
AGGCCTCTGTTTCCCCGACG 1/7 17086577/17086596 
Chr1: -
17086573 80 
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2.4.2 Preparation of chemically Competent E. coli cells 
Frozen glycerol stocks of XL1 Blue (E. coli) bacterial cells were streaked onto LB agar (Lysogeny 
broth 40g/l in 400ml) containing 10µg/ml tetracycline and incubated overnight at 37°C for 24 
hours. A single colony of E. coli was inoculated into 10 ml starter culture of LB broth (25g/l) 
containing 10µg/ml tetracycline as selective antibiotic and incubated overnight at 37°C 
(shaker) for 6-8 hours. 100ml of LB broth (25g/l) was inoculated into 1 ml starter culture 
containing 10µg/ml Tetracycline and incubated until optical density (OD) of 0.1. After the 
detection of 0.1 OD, the cell broth was further incubated at 37oC (shaker) until reaching an OD 
of 0.4-0.6. Cells were then harvested by centrifugation at 800g for 15 minutes at 4oC and re-
suspended in 100ml of pre-chilled 50mM calcium chloride (CaCl2) (VWR, USA). After 
incubation for 45 minutes on ice, cells were then harvested as described above (method 
section 2.3). For long term storage of competent cells, harvested cells were re-suspended in 
1ml of 25% glycerol and 75% 50mM CaCl2 at -80oC. 
 
2.4.3 Transformation of E. coli (XL1 Blue) with plasmid DNA and maxi preparation of plasmid 
DNA 
CRISPR/Cas9 sgRNA1, CRISPR/Cas9 sgRNA2, PADI2 overexpression (pCDNA3.1 PADI2-+DYK) 
and negative control empty vector (pCDNA3.1-+DYK) were purchased from Genscript, USA. 
Green fluorescent plasmid (GFP) plasmid was purchased from Addgene, USA (pCMV-GFP). To 
transfer plasmid DNA into competent cells, 1µg of plasmid DNA was mixed with 45µl of 
competent cells and incubated on ice for 15 minutes. DNA plasmid-transformed E. coli LB 
broth was then streaked on a selective plate of LB agar containing 100µg/ml Ampicillin and 
incubated at 37°C for 48 hours. A single colony was selected from a freshly streaked selective 
plate and re-inoculated into a starter culture of 10 ml LB broth (10g/L NaCl, 5 g/L LB-Lennox 
NaCl, 0.5g/L NaCl LB-Luria) containing 100µg/ml Ampicillin as a selective antibiotic and 
incubated at 37°C for 12 hours with shaking at 300rpm. 1ml of the starter culture was then 
diluted in 500ml selective LB broth and incubated at 37°C for 12 hours with shaking at 300rpm. 
DNA plasmid-transformed E. coli cells were harvested by centrifugation at 11,000g for 15 
minutes at 4°C. Cell pellets were re-suspended in P1 buffer (50mM Tris-Cl, 10mM EDTA 
100µg/ml RNase). Cells were then lysed using P2 lysing buffer (20mM NaOH, 1% SDS (w/v)) 
and neutralized in P3 buffer (3M potassium acetate pH 5.5). The cell lysate was incubated in 
a QIAfilter Cartridge for 10 minutes at room temperature, followed by extraction with a liquid 
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vacuum. After filtering the lysate, the QIAfilter was washed using FWB2 (1M potassium 
acetate 15–25°C pH 5.0) and 12.5ml ER buffer was added to the filtered lysates. The filtered 
lysate was applied to the equilibrated QIAGEN-tip 10000 in QBT buffer (750mM NaCl, 50mM 
MOPS pH 7.0; 15% isopropanol (v/v); 0.15% Triton® X-100 (v/v)). After all the lysates had 
passed through the filter, the QIAGEN-tip was washed using the QC buffer (1.25M NaCl, 50mM 
Tris.Cl pH 8.5 and 15% isopropanol) and QN (1.6M NaCl, 50mM MOPS pH 7.0, 15% 
isopropanol) elution buffer was added to elute the DNA. The DNA pellet was air-dried for 20 
minutes after DNA was precipitated and washed from the tip using Isopropanol and 70% 
ethanol (Endotoxin free). To confirm the success of the extraction and to quantify the total 
concentration of plasmid DNA, the eluted DNA solution was measured using a Nanodrop 2000 
spectrophotometer (Thermo Fisher Scientific, USA).  
 
 
2.4.4 Restriction digest analysis of CRISPR/Cas9, Empty vector and PADI2 overexpression 
plasmids using agarose gel electrophoresis (DNA) 
 
The purified plasmid DNA structure and quality was then determined using restriction digest 
enzyme method. Plasmid maps were constructed to determine compatible restriction 
enzymes using Snap gene editor software using primary plasmid sequences provided by 
Genscript, USA (Figure 2.1). Restriction enzymes used for CRISPR/Cas9 was SacI–HF New 
England Biolabs (NEB), USA at (2,000units/ml) and for empty vector and PADI2 overexpression 
plasmids were HindIII-HF and EcoR1-HF NEB, USA at (2,000units/ml). Plasmid DNA-restriction 
digest mix was prepared and incubated for 15 minutes at 37oC (Table 2.3). Digested DNA was 
then analysed using gel electrophoresis (1% (w/v) agarose gel in TAE buffer). DNA fragments 
sizes were estimated using DNA ladder quick-load purple NEB, USA. The numbers and sizes of 
fragments were then compared to the plasmid maps predicted sizes (Figure 2.1).  
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Table 2.3   Restriction digest analysis using restriction end protocol by NEB  
 
Reagent  Volume (µl) 
Restriction enzyme 
(2,000units/ml)  1 
Plasmid DNA  1µg/µl 
10X NEBuffer  5 
Molecular grade water  43 
Total  50 
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Figure 2.1    Plasmid maps indicating restrictions digest enzyme sites in CRISPR/Cas9 and 
pcDNA3.1-+DYK Empty vector and PADI2 overexpression vector. Predicted DNA fragment 
sizes are represented at every enzyme cutting site. 
 
 
 
Fragment 1 (2598) 
Fragment 2 (6579) 
Fragment 2 (2037) 
Fragment 1 (5390) 
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2.5 Antibiotic kill curves: optimization of mammalian antibiotic selection conditions 
The minimum concentration of mammalian antibiotic (i.e. puromycin or G418) required to kill 
non-transfected (plasmid DNA) cells was determined by generating antibiotic kill curves 
before transfection. Cells were plated equally at cell density of 0.8–3.0 × 105 cells/ml in 0.2ml 
of complete growth medium per well in 24-well tissue culture plate 24 hours prior to 
introducing antibiotic selection. Prior to adding the selection antibiotic, cells were sub-
confluent (60-80%). Growth medium was removed and then 0.2ml fresh media was added 
with varying concentrations of antibiotic G418 (0-1,000μg/ml) and puromycin (0-10μg/ml) and 
incubated at 37°C in 5% CO2 for 7-8 days. All samples were then analysed for variability in 
duplicates. Cell density and viability were counted/calculated using a haemocytometer after 
having stained cells with trypan blue (VWR, USA). 
 
2.6 Transfection of ovarian cancer cell lines with plasmid DNA 
Purified DNA; CRISPR/Cas9 sgRNA1, CRISPR/Cas9 sgRNA2, PADI2 Overexpression and negative 
control empty vector were transfected into EOC cell lines; SKOV-3 and ID8-Luc2. PADI2 
overexpression and negative control empty vector were transfected into OVCAR-4 and ID8-
Luc2. All transfection/co-transfection studies were performed using Lipofectamine 3000 
reagent (Fisher Scientific, USA). Initially, SKOV-3, OVCAR-4 and ID8-LUC2 cell lines, were 
seeded at cell density of 0.5x105 cells/ml in 6-well tissue culture plates containing 2 ml 
complete growth medium and incubated for 24 hours at 37°C in a humidified atmosphere of 
5% CO2. Prior to transfection, cell growth medium was replaced with 1ml/well of Opti-MEM 
medium (antibiotic-free without FBS). Cells were then incubated for 10 minutes at 37°C. 
Meanwhile, Lipofectamine 3000 reagents were incubated with plasmid DNA at room 
temperature. Lipofectamine 3000/plasmid DNA mixture was then added to the cells and 
incubated at 37°C in a humidified atmosphere of 5% CO2 for 48 hours under. Growth medium 
was not replaced during the first 48 hours post-transfection. 48 hours post-transfection, 
CRISPR/Cas9 or expression plasmid-transfected cells were either subjected to 48-72 hours of 
antibiotic selection with puromycin or G418 respectively.  post transfection and selection, cells 
were then employed in downstream functional assays. Transfected cells were also harvested 
as explained above (method section 2.3) and re-suspended in 10%FBS phosphate-
buffered saline (PBS) to measure transfection efficiency using Flow cytometer analysis 
(Coulter EPICS Elite ESP, equipped with a water-cooled argon laser emitting at 525 nm). Flow 
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cytometry results were analysed using Flowing software Ltd in New Zealand. Distinct 
populations of cells were visible on the flow histograms; therefore, determination of the 
percentage of transfected cells was based on the inclusion of only cells that had the correct 
forward and side scatter characteristics (Kovala et al., 2000). To optimise co-transfection 
efficiency of CRISPR/Cas9 or overexpression plasmids with GFP plasmid, different plasmid 
concentrations were tested (2.5µg, 3µg and 4µg). All samples were analysed in duplicate to 
demonstrate statistical measurement of analytical precision as well as comparisons among 
methods (Colón et al., 2001). 
 
2.7 Cell functional studies 
2.7.1 Measurement of cell proliferation  
Cell proliferation was detected using a WST-1 assay (Sigma Aldrich). OVCAR-4 and ID8-Luc2 
cells were transiently transfected with empty vector and PADI2 overexpression vector and 
seeded at a density of 1 × 104 per well and 0.7 x 104 cells per well respectively into 96-well 
microplates (Sarstedt) containing 200μl medium per well. Cells were allowed to adhere for 24 
hours by incubation at 37°C in a humidified atmosphere of 5% CO2. Cells were then treated 
with cisplatin (anti-cancer drug dissolved in DMSO, Sigma Aldrich) at a dose range of 0-
100µg/ml or CaCl2 at a dose range of 0-2.5mM or cisplatin at a dose range of 0-100µg/ml in 
the presence of 1mM CaCl2. After further 24 hours incubation, the proliferation of cells was 
then measured by adding 20µl of WST-1 reagent to each well every 24 hours for 3 days. The 
absorbance was measured using BioRad (model 680XR) microplate reader at 595nm after 4 
hours of incubation at 37°C in a humidified atmosphere of 5% CO2 and in ID8-Luc2 at 450nm 
after 1 hour of incubation at 37°C in a humidified atmosphere of 5% CO2. All experiments 
were performed three times.  
 
2.7.2 Measurement of cell apoptosis and necrosis  
Cell apoptosis and necrosis was detected using apoptosis/necrosis detection kit (blue, green, 
red, Abcam, UK, ab176749). OVCAR-4 cells were transiently transfected with empty vector 
and PADI2 overexpression vector and seeded at a density of 5×105 cells/well into 96-well 
microplates containing 100μl medium per well and allowed to adhere for 24 hours. Cells were 
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then treated with 50µg/ml cisplatin or 1mM CaCl2 or cisplatin at two different doses 10 µg/ml 
and 50µg/ml in the presence or absence of 1mM CaCl2. Cells were further incubated at 37°C 
in a humidified atmosphere of 5% CO2 for 48 hours and apoptosis was measured every 24 
hours for 2 consecutive days. First, growth medium was removed, and cells were washed by 
assay buffer containing 5% FBS. Cells were then stained by adding 202µl of Apopxin Green dye 
diluted in assay buffer. Finally, stained cells were washed with assay buffer and analysed by 
BioRad Fluorescent microplate reader. Excitation and fluorescence emission spectra 
(490/525nm). All experiments were performed three times. 
 
2.7.3 Measurement of cell Autophagy  
Cell autophagy was detected using a florescent autophagy detection kit (Abcam, UK, 
ab139484). OVCAR-4 cells were transiently transfected with Empty vector and PADI2 
overexpression vector and seeded at a density of 2×104 cells/well and 1x104 cells/well 
respectively into 96-well microplates containing 100μl growth medium per well and allowed 
to adhere for 24 hours by incubation at 37°C in a humidified atmosphere of 5% CO2. Cells were 
then treated with CaCl2 at a dose range of 0-3mM. Earle's balanced salt solution (EBSS) an 
100µM chloroquine were used as a positive control treatment in this experiment. EBSS is an 
autophagy inducer, whereas chloroquine is autophagy inhibitor. The cells were further 
incubated at 37°C in a humidified atmosphere of 5% CO2 for 48 hours. Autophagy was 
measured every 24 hours for 2 consecutive days. first, growth medium was removed, and cells 
were washed once by 1X assay buffer containing 5% FBS. Cells were then stained by adding 
100µl of dual detection buffer. Finally, stained cells were washed with 1X assay buffer and 
analysed by BioRad fluorescent microplate reader. Excitation and fluorescence emission 
spectra (463/534nm) for autophagy green detection reagent and (350/461nm) for nuclear 
stain. All experiments were performed three times. 
 
2.7.4 Measurement of cell aggregation (Spheroid)  
OVCAR-4 cells were transiently transfected with empty vector and PADI2 overexpression 
vector. Single-cell suspensions were adjusted to 2.5x106 cells/ml in the presence and absence 
of 1mM CaCl2. Aliquots containing 20µl of the cell suspension were placed as droplets on cell 
culture plates lids and incubated at 37°C in a humidified atmosphere of 5% CO2 for 48. (Figure 
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2.2) Cell aggregates were transferred to autoclaved glass bottles containing 5ml complete 
growth medium in the presence or absence of 1mM CaCl2. Cells were then further incubated 
in a water bath at 37°C in a humidified atmosphere of 5% CO2 for 48 hours. Cell aggregates 
were observed under Olympus inverted microscope. All images of cell aggregates were 
analysed using ImageJ software. All experiments were performed at least three times. 
                                                           
 
  
 
 
 
 
 
 
 
Figure 2.2 Hanging drop assay for creating OVCAR-4 cell aggregates. 10μl drops on the inner 
side of a 100 mm dish lid. The lid was placed with drops upside down and on top of the plate 
filled with 10 ml PBS. 
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2.8 Western blotting analysis 
 
2.8.1 Protein quantification using bicinchoninic acid assay (BCA) 
Western blot analysis was carried out using whole-cell extracts. Whole-cell extracts were 
prepared from cell pellets with cell density of 5x106, harvested as described above (method 
section 2.3) then washed in 1X PBS and stored at -80°C. Initially, proteins were extracted from 
cell pellets using 500 µl of pre-chilled cell lysis RIPA buffer (Radioimmunoprecipitation lysis 
buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), 
Fisher scientific, USA) containing 1% protease inhibitor cocktail (Fisher scientific, USA). The 
cell lysate-RIPA mixtures were incubated at -20°C for 60 minutes. Cell lysates were centrifuged 
for 30 minutes at room temperature at 12,100g. Protein concentration in lysates was then 
determined by BCA (Pierce Labs, Rockford, IL) test prior to gel loading to ensure equal protein 
loading. Protein standard Albumin (BSA) dilutions were prepared in a concentration range 
from 0-10mg/ml. BCA working reagent (WR) was prepared and 200µl were added to every 
well in 96-well plate to each of standards or unknown sample replicate. After incubation at 
37°C for 30 minutes, absorbance was determined at 595nm on a BioRad microplate reader. 
The protein concentration in cell lysates was calculated by plotting a standard curve (average 
Blank-corrected 562nm measurement for each BSA standard vs. its concentration in µg/ml). 
 
 
2.8.2 Polyacrylamide gel electrophoresis 
Total amount of protein loaded/well was 30-70µg. The extracted proteins were prepared for 
loading SDS-PAGE by adding 1XLaemmli reducing buffer. Samples were boiled at 100oC for 5 
minutes, followed by brief incubation on ice (samples were kept on ice until use to prevent 
protein degradation). Samples were then subjected to SDS polyacrylamide gel electrophoresis 
on a 10% Bis-Tris NuPAGE polyacrylamide gel (Biorad), along with 10µl Magicmark molecular 
weight ladder (Fisher Scientific, USA) and 5µl Seablue marker (Fisher Scientific, USA). Gel 
electrophoresis was performed at 100V for the first 15 minutes and then 180V for 30 minutes.  
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2.8.3 Protein transfer and membrane Immunoblotting 
Proteins were transferred from the SDS gel onto a PVDF membrane for 60 minutes at 35V. To 
prepare the transfer cassette, four pieces of Whatman paper and 2 sponges were pre-socked 
in pre-chilled transfer buffer. Also, PVDF membrane was activated in 100% methanol for 5 
minutes and washed in distilled water for 2 minutes. The transfer cassette was organised in a 
specific manner (Figure 2.3). Transfer tank was filled with pre-chilled 1Xtransfer buffer. 
Immunoblotting was performed at 35V for 1 hour at room temperature. After incubating the 
PVDF membrane were incubated in blocking buffer (5% BSA diluted in PBS) for 1 hour at room 
temperature. PVDF Membranes were then incubated for 1 hour at 4°C with primary 
antibodies; mAB Beta actin (β-actin, Sigma) 1µg/ml, mAB PADI2 (Santa Cruz, USA) 0.2µg/ml, 
monoclonal PADI4 (Abcam, UK) and mAB citrulline (Sigma) 1µg/ml, diluted in 5ml blocking 
buffer. Blots were washed and then incubated with secondary antibodies for 1 or 12 hours at 
4°C; Goat anti-Mouse secondary (Dako) 0.26µg/ml and Goat anti-Rabbit secondary (Dako) 
0.26µg/ml diluted in 5ml blocking buffer. All membranes were washed for 30 minutes (3×10 
minutes) with PBS-Tween after primary and secondary antibody incubation and then 
visualized by Gnome machine using ECL detection reagent (Fisher Scientific, USA).  
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Figure 2.3    The preparation of the gel-membrane sandwich for transfer from SDS-PAGE to 
PVDF in preparation for an immunoblot 
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2.9 Detection of PADI2 locus specific cleavage by CRISPR/Cas9  
Locus specific cleavage of PADI2 gene in EOC cell line genome was detected using GeneArt 
genomic cleavage detection kit (Fisher Scientific, USA) and Sanger Sequencing (Eurofins 
TubeSeq services, UK).  
 
2.9.1 Cell lysis and DNA extraction 
 
After transfection, non-transfected and CRISPR/Cas9 sgRNA1/sgRNA2 transfected SKOV-3 and 
ID8-Luc2 cell pellets were harvested, as described (method section 2.3). Cell pellets were lysed 
in a solution containing 50µl cell lysis buffer (provided by the kit) and 2µl protein degrader to 
obtain genomic DNA and incubated in Techne TC0512 thermocycler to provide lysing 
conditions required (Table 2.4). 
 
 
Table 2.4 Thermal cycling Lysis and extraction conditions 
Step/Stage Step 1 Step 2 Step 3 
Temperature 68oC 95oC 4oC 
Time (mm:ss) 15:00 10:00 ∞ 
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2.9.2 Gradient PCR and primer optimisation 
 
Specific primers were designed using NCBI primer blast and IDT primer quest tools, to target 
the PADI2 gene Locus where the CRISPR-induced-double-strand breaks (DSBs) occur. The 
specific position of the DBS breaks was predicted by the CRISPR design online tool. Two primer 
pairs were designed for each sgRNA1 and sgRNA2 to amplify around PADI2 locus in human 
and mouse genome (Table 2.5). The designed oligonucleotide primers were obtained from 
Sigma Aldrich. All primer sequences were subjected to gradient PCR using AmpliTaq Gold DNA 
Polymerases (Fisher Scientific, USA, 10156624) to determine the optimum annealing 
temperature and optimise PCR reaction specificity. PCR amplification was performed on 
purified human and murine genomic DNA (Promega) using the designed primer 
oligonucleotides.  The PCR amplification was achieved by using the Techne TC0512 
thermocycler under conditions recommended by the manufacturer’s protocol (Table 2.6). The 
length of the amplified sequences was estimated to 400bp.  
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Table 2.5   sgRNA1 and sgRNA2 oligonucleotide primer sequences 
Target 
                                              Sequence 5’-3’ 
 Forward primer  Reverse primer 
Human sgRNA1 CTGCTGCAGGTGCTCCC AACTGGAGAGGGCCAGACG 
Human sgRNA2 CCAACGCTATATCCACATCCTGG ACACAGGCGTGGAGTGTGTC 
Murine sgRNA1 CTGCAGCAGGTGCTTATTCC TGAAAGGGGCGTGTTACAGA 
Murine sgRNA2 GCGCTATATCCACATCCTGGG CTGGGCTGGGCAAATGAACT 
 
 
Table 2.6   Thermal cycling PCR conditions 
Stage/Step Enzyme 
activation 
Thermal Cycling (40 cycles) 
Denature Anneal Extend 
Final 
extension 
Hold 
Temperature 95oC 95oC 
55oC (SKOV-3) 
63oC (ID8-Luc2) 
72oC 72oC 4oC 
Time (mm:ss) 10:00 00:30 00:30 00:30 7:00 ∞ 
GeneArt® Genomic Cleavage Detection Kit by Thermo Fisher scientific (A24372).  
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2.9.3 Preparation of PCR amplification product for Sanger sequencing  
 
The purified PCR products of non-transfected and CRISPR/Cas9 sgRNA1 and CRISPR/Cas9 
sgRNA2 transfected SKOV-3 and ID8-Luc2 cell lines were first quantified by Nanodrop. Samples 
were then prepared for Sanger sequencing by adding 15µl of purified 5ng/µl DNA and 2µl of 
10µM optimised gRNA primer into each sample tubes.  
 
 
2.9.4 Use of PCR amplification product for GeneArt genomic cleavage assay  
 
The purified PCR product was further analysed using a cleavage assay. Products were run on 
a 2% agarose gel. The PCR product was denatured and reannealed so that mismatches are 
generated as strands with n re-annealed indel to strands with a different indel or no indel. The 
Gene editing tool-induced mismatches are subsequently detected and cleaved by detection 
enzyme and then the resultant bands are analysed by gel electrophoresis.  
 
 
2.10 Reverse transcription-qPCR 
 
2.10.1 RNA extraction 
Total RNA was extracted from cultured cells at cell density of 1x106 using an RNA extraction 
kit (RNeasy mini kit, Qiagen). Cell pellets were lysed using 350-600µl of RLT buffer. Cell lysates 
were homogenised by adding 70% ethanol and transferred into spin columns placed in a 2ml 
collection tubes and centrifuged for 15 seconds at 8000g. All flow through was discarded and 
700µl RW1 Buffer was added to the RNeasy spin column and centrifuged for 15 seconds at 
8000g. All flow through was discarded again and 500µl of RPE Buffer was added to the RNeasy 
spin column and centrifuged for 2 minutes at 8000g. Finally, 30µl RNase-free water was added 
to the spin column and centrifuged for 60 seconds at 8000g. Flow through was collected in 
RNase free tube and stored at -80oC. RNA concentration and quality were analysed by 
Nanodrop. 
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2.10.2 Reverse transcription and cDNA synthesis  
 
cDNA was synthesized from total RNA using (Applied Biosystems™ TaqMan™ High-Capacity 
RNA-to-cDNA Kit, Fisher Scientific, USA). The reaction consists of 1µl of 20X enzyme mix 
(MultiScribe Reverse Transcriptase (50U/μl)), 10µl 2X RT Buffer Mix (includes dNTPs) and 20X 
random primers ad 1µg/µl RNA (Table 2.7). Reverse transcription was performed using Techne 
TC0512 thermocycler as follows: 37°C for 60 minutes, and 95°C for 5 minutes. 
 
Table 2.7    Reverse transcription and cDNA synthesis protocol 
Reagent  Volume (µl) 
2X RT Buffer Mix  10 
20X RT Enzyme Mix  1 
RNA sample  1µg/µl  
Nuclease-free H2O  Up to 20 
Total per reaction  20 
 
 
2.10.3 RT-qPCR 
The expression of PADI2 mRNA levels were measured by qRT-PCR TaqMan gene expression 
assays (Fisher Scientific, USA, 11967021) using the comparative Ct (2−ΔΔCt) method. RT-qPCR 
was performed on wild type and PADI2 overexpression and empty vector transfected EOC cell 
lines. Reaction was prepared by adding 10μl of master mix TaqMan (Universal PCR Master 
mix, Fisher Scientific, USA), 1µl TaqMan PADI2 primer (Human Hs01042505_m1 and Murine 
Mm01341648_m1) or eukaryotic 18S reference gene primer (Hs03003631_ g1).  qRT-PCR was 
also used to detect the mRNA expression of PADI-possible target genes that are deregulated 
in EOC. Target genes TaqMan primers are, KRTZ (Hs00559840_m1); ARHGEF10L 
(Hs00737842_m1); FZD5 (Hs00258278_s1); RPS6KA1 (Hs01546657_m1). The qPCR reaction 
was done using applied Biosystems StepOnePlus RT PCR system, reaction conditions (Table 
2.8). 
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Table 2.8   Thermal cycling PCR conditions 
Stage/Step Enzyme 
activation 
Thermal Cycling (40 cycles) 
Denature Extend 
Final 
extension 
Hold 
Temperature 50oC 95oC 95oC 60oC 4oC 
Time (mm:ss) 02:00 10:00 00:15 1:00 ∞ 
 
 
Statistical analysis 
All statistical analyses were performed using Microsoft Excel, SPSS 24 software (SPSS Inc., 
Chicago, IL), X-tile 3.6.1 software (Yale University School of Medicine, New Haven, CT, USA) 
and GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). The cut-point for gene 
expression scores was obtained using X-tile 3.6.1 software. X-tile plots were conducted for 
assessment of gene expression scores; this was expressed as optimisation of cut points based 
on survival outcome. Categorical data were analysed using Chi-square test or Fisher's exact 
test, and continuous variables were analysed using the analysis of variance test (ANOVA). 
Gene expression cut-points generated by X-tile were modelled using the Kaplan-Meier 
method using univariable Cox regression to compare cumulative event rates between groups 
using SPSS 24 software.  Gene expression association with overall survival was reported as 
means and clinical characteristics and variant burden were compared using log-rank test. The 
Pearson correlation analysis was used to determine the correlations coefficients between two 
variables using Microsoft Excel. P<0.05 was considered statistically significant in all cases.  
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CHAPTER 3: Gene expression analysis of PADI2 mRNA expression from The Cancer Genome 
Atlas (TCGA) and cBioPortal for serous EOC. 
 
3.1 INTRODUCTION 
 
PADI2 function has been reported in different biological contexts, such as H3 citrullination 
during breast cancer oncogenesis, the oestrus cycle in the uterus or in gonadotropic cells, as 
well as citrullination during colon cancer oncogenesis and induction of T-cell apoptosis (i.e. 
Jurkat cells, Hosokawa et al., 2018; Hsu et al., 2014). One of the major functions of PADI2, is 
its role in H3 citrullination, first proposed upon the discovery of exposed chromatin 
architecture around ERE regions at the promoters of a subset of 17 β-E2-induced genes; 
known to promote global citrullination of H3R26 on chromatin (Cherrington et al., 2010; Zhang 
et al., 2012). There is also in vitro evidence to suggest that PADI2 can citrullinate arginine 
residues on histone H4 (Cherrington et al., 2010). These histone modifications deregulate the 
transcription of thousands of genes under the control of the oestrogen receptor (Cherrington 
et al., 2010; Sharma et al., 2019). Taken together these studies highlight the important role 
for PADI2 in the tumourigenic process of some tumours and suggest that PADI2 plays a key 
role in gene transcriptional regulation in models of human disease (Slade et al., 2014). 
However, the role of PADI2 in EOC has not been described. 
Whilst gene mutation and DNA alterations are important in cancer pathogenesis, deregulated 
gene expression may represent important cancer driving events (López-Cortés et al., 2018). 
To better understand the impacts of the genetic composition of tumours on clinical prognosis, 
gene expression profiling has been increasingly incorporated with and accepted for clinical 
diagnosis (Aldape et al., 2015; Chin and Meyerson, 2008). Herein, a combination of 
comprehensive genome-wide gene expression collections such as The Cancer Genome Atlas 
(TCGA) has been used to provide a genome-wide overview of the association of PADI2 
expression with survival of EOC patients and the identification of functionally related gene 
sets. Such analysis identifies associated or co-expressed genes based on their correlating 
expression profiles obtained from high-throughput gene expression profiling data analysed 
using microarray (U133) and RNA-seq experiments. While similar in purpose, there are 
fundamental differences between the two technologies. U133 methods measure the intensity 
of fluorescence of hybridised samples, which reflects the corresponding gene expression 
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levels, whereas RNA-seq methods measure sequence read depth which is used to calculate 
gene expression levels (Guo et al., 2013).  
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3.2 AIMS AND OBJECTIVES 
 
In this chapter, the relationship between PADI2 expression and EOC tumorigenesis was 
investigated. Preliminary data (generated by Dr Lee Machado) indicates that PADI2 high 
expression in tumours is protective and may represent an independent prognostic marker. To 
explore the mechanistic basis underpinning this, in silico analysis will be employed to 
determine the association of PADI2 mRNA expression with survival in EOC patient. PADI2 
interaction with other genes will be explored to provide new understanding of PADI2 
regulatory pathways and novel gene targets by which it carries out its role in EOC. Candidate 
genes will be further analysed regarding their interaction with PADI2 in the tumour cell.   
 
1. Employ in silico analysis of gene expression data from TCGA cBioPortal, to determine 
whether high PADI2 gene expression confers a survival advantage in EOC patients. 
 
2. Determine the genes that are co-expressed with PADI2 expression and reassess their 
association with PADI2 expression in PADI2 overexpressing EOC cell line.   
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3.3 RESULTS 
 
3.3.1 PADI2 expression levels are associated with serous EOC patient overall survival  
To explore the association of PADI2 mRNA expression levels with clinical outcomes in EOC 
patients of serous subtype, TCGA was used to extract data with the aid of cBioPortal. RNA-seq 
(262 EOC patients) and U133 (564 EOC patients) data cohorts allowed the assessment of PADI2 
expression association with OS of EOC patients. When performing survival analysis, the 
acquired patient’s clinical data (i.e. survival status, PADI2 expression levels and overall patient 
survival time) were analysed using X-tile software to determine PADI2 expression cut-point 
values (i.e. high and low expression). These cut-point values were used to define high or low 
expression groups for survival analysis. Using SPSS, Kaplan-Meier curves were then 
constructed to demonstrate the effect of PADI2 high or low expression on the cumulative 
survival of EOC patients. The mean OS was 52.3 and 41 months for RNA-seq and U133, 
respectively. Although the prediction did not show statistically significant results in the mean 
expression, the high PADI2 expression was significantly associated with poor OS in both RNA-
seq and U133 cohorts, with p-values of 0.008 and 0.0112, respectively (Figure 3.1). 
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Figure 3.1. High PADI2 expression is associated with poor survival in serous EOC patients. 
Kaplan-Meier survival analysis was used to estimate the association between PADI2 
expression and OS of serous EOC patients. The RNA-seq and U133 patient data were retrieved 
from TCGA cBioPortal. X-tile was used initially to determine the high and low expression cut-
point values of PADI2. Kaplan-Meier curves were then constructed using SPSS to demonstrate 
the effect of PADI2 high or low expression on the cumulative survival of EOC patients. Number 
of EOC patients at risk with higher PADI2 expression (red) and lower PADI2 expression (black). 
Data were analysed using the log-rank test. OS: overall survival; U133: microarray. 
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3.3.2 The correlation between PADI2 expression and other co-expressed genes in EOC 
To identify the correlation between PADI2 expression and co-expressed genes in EOC, 
correlation analysis was conducted using the TCGA (i.e. U133 and RNA-Seq gene expression 
data collected 182 primary tumour samples).  Around 16,000 genes common to both 
platforms were used for correlation analysis. Gene-wise comparison of U133 and RNA-Seq 
data revealed that 82% had a Pearson’s correlation coefficient greater than 0.2. Further 
analysis indicated high correlation between U133 and RNA-Seq with the highest Pearson's 
correlation coefficients in only 15 genes. These genes are either positively or negatively 
correlated with PADI2 expression.  The correlation was measured as the absolute value of 
Pearson's correlation coefficient. The range of expression values was between -0.2and 0.44 
(Table 3.1).  
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Table 3.1. The correlation between PADI2 expression and other co-expressed genes in EOC. 
The correlation was measured as the absolute value of Pearson's correlation coefficient. RNA-
seq (green) and microarray (U133) (blue).  
Gene 
abbreviation Gene name 
Gene 
accession 
number 
Pearson 
correlation  P-values 
ARHGEF10L Rho guanine nucleotide exchange factor 
(GEF) 10-like 
NC_000001.11 
NT_032977.10 
NC_018912.2 
0.37 
0.42 
2.29e-11 
2.59e-10 
BMPR1B Bone morphogenetic protein receptor, 
type IB 
NC_000004.12 
NT_016354.20 
NC_018915.2 
-0.26 
-0.28 
8.24e-4 
1.65e-5 
DACH1 Dachshund family transcription factor 1 
NC_000013.11 
NT_024524.15 
NC_018924.2 
-0.23 
-0.25 
1.14e-3 
1.12e-4 
EPB41L1 Erythrocyte membrane protein band 4.1-
like1 
NC_000020.11 
NT_011362.11 
NC_018931.2 
0.35 
0.42 
3.12e-8 
8.06e-7 
FUS FUS RNA binding protein 
NC_000016.10 
NT_187260.1 
NC_018927.2 
-0.23 
-0.30 
1.33e-6 
1.11e-6 
FUT8 Fucosyltransferase 8 
NC_000014.9 
NT_026437.13 
NC_018925.2 
-0.24 
-0.26 
2.84e-4 
1.65e-6 
FZD5 Frizzled class receptor 5 
NC_000002.12 
NC_018913.2 
NT_005403.18 
-0.31 
-0.37 
8.47e-8 
1.11e-4 
 
KRT7 Keratin 7, type II 
NC_000012.12 
NT_029419.13 
NC_018923.2 
0.42 
0.43 
1.32e-10 
1.48e-4 
LDLRAP1 Low-density lipoprotein receptor adaptor 
protein 1 
NC_000001.11 
NT_032977.10 
NC_018912.2 
0.36 
0.35 
5.42e-6 
6.54e-7 
NPTXR Neuronal pentraxin receptor 
NC_000022.11 
NC_018933.2 
NT_011520.13 
0.40 
0.33 
2.91e-7 
3.45e-7 
PFKM Phosphofructokinase 
NC_000012.12 
NT_029419.13 
NC_018923.2 
-0.26 
-0.28 
3.95e-3 
4.76e-4 
RPS6KA1 Ribosomal protein s6 kinase 
NC_000001.11 
NT_032977.10 
NC_018912.2 
0.38 
0.42 
5.33e-8 
4.30e-7 
SNRPE Small nuclear ribonucleoprotein polypeptide E  
-0.24 
-0.35 
9.17e-7 
3.56e-7 
ZNF22 Zinc finger protein 22 
NC_000010.11 
NC_018921.2 
NT_030059.14 
-0.24 
-0.27 
2.62e-5 
1.33e-6 
ZSCAN12 Zinc finger and scan domain containing 12 
NC_000006.12 
NT_007592.16 
NC_018917.2 
-0.21 
-0.29 
1.80e-5 
3.59e-4 
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3.3.3 The association between PADI2 mRNA level in EOC cell lines and other co-expressed 
genes  
The human derived OVCAR-4 EOC cells were transfected with the PADI2 expression plasmid. 
OVCAR-4 cells transfected with empty vector were used as negative control. The 
overexpression of PADI2 was confirmed in the cultured cells using qRT-PCR. In the section 
above (3.3.2), the correlation analysis of co-expressed genes revealed that 15 genes have the 
highest correlating values. Ideally, all 15 genes can be further analysed to verify whether 
modulating PADI2 expression may impact their mRNA abundance. However, based on the 
limitations of this study, two candidate genes, including FZD5 and ARHGEF10L, were chosen 
for further expression analysis. These genes were chosen on the basis of their functional 
relevance in the EOC pathogenesis according to the literature. After cell transfection and 
PADI2 overexpression confirmation, qRT-PCR was used to determine which of the candidate 
genes from the correlation analysis are affected by modulating PADI2 expression in OVCAR-4 
cells. The qRT-PCR analysis of FZD5 and ARHGEF10L mRNA expression showed consistent 
results with those observed in the correlation analysis. For example, ARHGEF10L, was 
positively correlated with PADI2 expression in primary tumours and was also positively 
associated with PADI2 mRNA in PADI2 overexpressing OVCAR-4 cells. (Figure 3.2). 
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Figure 3.2. The determination of mRNA expression levels of PADI2, FZD5, and ARHGEF10L in 
PADI2 overexpressing OVCAR-4 cells using qRT-PCR. Cells were transiently transfected with 
a control empty vector and PADI2 overexpression vector. At 96 hours post-transfection and 
enrichment, expression levels were determined by qRT-PCR (a) PADI2 expression in OVCAR-4 
cells. Representative bar graphs of average PADI2 transcription levels normalised to 18S 
mRNA levels. (b) FZD5 and ARHGEF10L in PADI2 overexpressing OVCAR-4 cells. The 
transcription levels of the target genes in the transfected cells were normalised with their 
mRNA levels to cells transfected with control empty vector. (c) The comparison of the gene 
expression status between qRT-PCR (mRNA) and correlation analysis (Pearson’s coefficient 
values). Results are representative of the average fold change ± SD of triplicate independent 
experiments relative to the untreated controls. Bars are presented as mean ± SD (n = 3). 
*p≤0.05, ***p 0.001.  
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3.4 DISCUSSION 
 
3.4.1 The correlation between PADI2 mRNA and OS of EOC patients 
The effects of protein citrullination are widespread and vary according to the genomic context 
and interactions with PADIs (Ying et al., 2009). While PADI2 was initially characterised as an 
important epigenetic transcriptional regulator through H3 citrullination, recent studies 
suggest that PADI2 promote the migration ability in breast cancer cells and participates in the 
apoptotic mechanisms of activated T lymphocytes (Hsu et al., 2014; Wang et al., 2016; 
Hosokawa et al., 2018). Recently, McElwee reported that PADI2 mRNA expression highly 
correlates with HER2 in HER2/ERBB2-positive breast cancer subtype; one of the main breast 
cancer transcriptional subtypes (McElwee et al., 2012c).  Moreover, the up- or down-
regulation of PADI2 expression was largely investigated in many types of cancer (Lin Wang et 
al., 2017; Funayama et al., 2017). However, the function of PADI2 in EOC is not yet established. 
The aim of this chapter was to determine the novel role of PADI2 mRNA expression in EOC by 
utilising both its correlation with the mRNA expression of co-expressed genes and its 
association with OS of EOC patients. This was achieved by employing in silico analysis of gene 
expression data from online cancer databases, including TCGA. Dr L. Machado initially 
explored the relationship between PADI2 expression and EOC by analysing primary tumour 
tissue microarrays arrays (TMA) collected from EOC patients with different disease subtypes 
(not only serous subtype). Given this unpublished data, PADI2 expression was found to 
positively correlate with improved patient survival (Appendix Figure S.3). Based on the TMA 
data, the involvement of PADI2 with EOC and extend that to patient prognosis was 
furthermore delineated. It is important to note that in contrast to the TMA EOC cohorts 
conducted on multiple EOC subtypes, the current study survival analysis of TCGA data was 
obtained from EOC patient cases with only serous EOC subtype. Thereafter, the analysis of the 
expression data collected from TCGA cBioPortal U133 and RNA-seq presented contrasting 
outcome to that observed in the TMA data; and that is PADI2 mRNA expression is associated 
with a lower survival rate of EOC patients. This is not surprising, given that the underlying 
assumption that PADI2 expression patterns were measured in different patients’ cohorts. The 
discrepancy of both outcomes resides not only in the fact that different data pools were used 
in each analysis, but in the inconsistency of the histological subtypes of EOC patient cases 
tested (Xue et al., 2018). Thus, the current study outcome can represent the PADI2 association 
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with OC patient with serous disease subtype and not the other subtypes, such as 
endometrioid, mucinous and clear cell. In addition, several possible explanations might also 
be considered for the observed lack of consistency. For example, in mRNA expression analysis, 
the choice of fold change threshold for when genes are considered up- or downregulated may 
have a significant impact on the results. In addition, mRNA expression level is not always a 
good indicator for protein expression level, and this may alternately influence experimental 
outcomes. While this does not imply that mRNA detection cannot be utilised to produce 
meaningful results, but it does suggest that more sophisticated analysis may be required, such 
as multi-omics or include a wider/diverse data pool. Also, these gene expression detection 
and evaluation methods do not explain the effect of the tumour microenvironment on 
transcriptional regulation, gene expression and associated gene regulatory networks.  
 
3.4.2 Determining the possible regulatory pathway of PADI2 in EOC  
Several studies have used different transcriptional profiling and protein-protein interaction 
(PPI) to potentially predict the function of genes and their downstream signalling pathways 
(Kabir et al., 2018). The availability of extensive gene expression and PPI publicly-available 
data improved the detection of potential key regulators and molecular signatures in various 
diseases including cancer. However, these pathways are not universally defined, and different 
tools identify different signalling pathways for the same datasets. For example, in the current 
study, RNA-seq and U133 identified a number of highly regulated genes in EOC patients that 
are also co-expressed with PADI2; however, these genes were not previously known targets 
of PADI2. In a comprehensive and systematic genomics study by Wang et al., (2016), using 
tumourigenesis-related PCR arrays and qRT-PCR, it was suggested that PADI2 contributes to 
breast cancer tumorigenesis by deregulating the expression of ACSL4, BINC3 and CA9 (Huifeng 
Wang et al., 2016). Similar approaches were used in the current study. The second aim of this 
chapter was to determine the correlation and validate the association of the identified 
candidate genes with PADI2 expression. This was achieved by analysing the correlation of co-
expressed genes (obtained from TCGA), thereafter, the highest correlating genes were 
validated using qRT-PCR. The highest two correlating genes, including FZD5 and ARHGEF10L, 
were also validated in PADI2 overexpressing OVCAR-4 cells. The qRT-PCR analysis identified 
that all the co-expressed genes analysed, including FZD5 and ARHGEF10L, were also 
significantly deregulated in PADI2 overexpressing OVCAR-4 cells. ARHGEF10L was found to be 
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positively correlated and associated with PADI2 expression, whereas, FZD5 was inversely 
correlated/associated with PADI2. Collectively, these observations suggest that FZD5 and 
ARHGEF10L, may be involved in the tumourigenic pathway of PADI2 in EOC.  
Previous studies have shown that EOC progression and metastasis is a multistep process in 
which ECM and cancer cell cytoskeleton interactions play an important role (Smolle et al., 
2013; Gkretsi and Stylianopoulos, 2018). FZD5 is known to increase the adhesion to ECM 
components, including collagen IV, fibronectin and vitronectin, its high expression also 
correlates with poor EOC patient prognosis. The upregulation of FZD5 by the DNA-binding 
protein AT-Rich interactive Domain 3B (ARID3B), results in the activation of WNT5A/β-catenin 
signalling pathways, thereby, increasing tumour cell proliferation and development (Bobbs et 
al., 2015). This finding agrees with other reports of EOC which indicated that FZD5 expression 
correlates with advanced malignancy (Barbolina, Burkhalter and Stack, 2011; Bobbs et al., 
2015). Yoshioka et al., (2012) also reached a similar conclusion. Several studies also suggested 
that FZD5 can serve as both a biomarker and potential therapeutic target gene in cancer 
(Weeraratna et al., 2002; Carmon and Loose, 2008). The present study showed that PADI2 
overexpression in human EOC cell lines led to the downregulation of FZD5. Combined with the 
above findings, the present study also suggests that increased expression of PADI2 may be 
involved in the biology of EOC by stimulating FZD5 expression, subsequently hindering 
WNT5A/β-catenin signalling and leading to reduced proliferation. In addition, variants in 
genes encoding small GTPases, such as ARHGEF10L, which govern processes, including signal 
transduction, vesicle transport, cell proliferation and cell motility, are known to be associated 
with EOC (Earp et al., 2018). While several Rho GTPases represent oncogenic activity by 
promoting cancer cell invasion, and progression in various cancers, other family members 
appear to act as tumour suppressors and are frequently mutated, deleted or downregulated 
in some cancers (Vega and Ridley, 2008). SNP rs2256787 is a common germline variation in 
ARHGEF10L, which encodes the Rho guanine nucleotide exchange factor 10-like protein, and 
is associated with 33% increased invasive endometrioid EOC risk (Earp et al., 2018). PADI2 
overexpression was shown to increase ARHGEF10L in EOC cells. Collectively, these findings 
and the current study supports the hypothesis that the PADI2-mediated downregulation of 
FZD5 and upregulation of ARHGEF10L expression may contribute to decreased adhesion and 
advanced tumour progression in EOC.  
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3.5 CONCLUSIONS 
 
In summary, the results of TCGA data analysis in this chapter show that PADI2 expression is 
associated with lower OS and poor prognosis in EOC patients. This chapter also exploits a novel 
gene network interaction with PADI2 using qRT-PCR. The data obtained from this analysis 
suggests that higher PADI2 expression contributes to decreased EOC carcinogenesis by 
deregulating FZD5 and ARHGEF10L. This chapter also outlines the basis of this thesis and the 
downstream studies observed in the coming chapters (4-6). In addition, this study potentially 
had basic methodology limitations. For example, some genes that may play vital roles in the 
biology of EOC were not included in the qRT-PCR analysis. Also, 0.7-fold change in gene mRNA 
expression was considered biologically significant, based on the instructions of the 
manufacturer. In addition, cultured cell lines were used to investigate the tumourigenic 
mechanisms. The observed mechanisms may not be entirely similar to the ones observed in 
tumour tissues or patient blood samples. 
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CHAPTER 4: The evolutionary history and structure and of PADI2 
 
 
4.1 INTRODUCTION 
 
Although PADI2-mediated citrullination is linked to the pathogenesis of many diseases 
including cancer, this PTM also contributes to protein moonlighting, an evolutionary acquired 
phenomenon that allows proteins to perform more than one biophysical or biochemical 
function within one polypeptide chain (Henderson and Martin, 2014). Studies based on 
experimental and computational analysis have indicated that the physiological and 
pathophysiological roles of PADI genes are conserved throughout evolution from bacteria to 
mammals (Vossenaar et al., 2003).  This conservation of PADI roles was linked to their highly 
conserved promoter regions that are associated with key regulatory elements and signalling 
pathways, such as transcription factors (e.g. SP1, SP3, NF-KB, etc., Adoue et al., 2008). 
Interestingly, among the five PADI isoforms, PADI2 is the most widely expressed member and 
phylogenetically most conserved isozyme suggesting it is the ancestral homologue of the PADI 
family of isozymes (Vossenaar et al., 2003). A significant number of multigenic families' 
annotation studies have examined the phylogenetic relationship of PADI isozymes paralogues; 
however, the evolution of PADI2 orthologues and its phylogenetic relationship across species 
was not fully explored.  
Because important functions are conserved during evolution, the first step in analysis is to 
determine the homology of ortholog sequences. In contrast to the multigenic families' 
annotations of gene paralogs, gene orthologues annotation provide more accurate 
determination of evolutionary relationships and reveal significant functional similarities 
(Mirny and Gelfand, 2002). Various ortholog identification methods use sequence 
comparisons to test of homology and morphology, such as molecular phylogenies (Reaume 
and Sokolowski, 2011). Parsimony and maximum likelihood (ML) methods are the most 
established means of generating phylogenies (Ludwig et al., 2011). Given the large amount of 
genome sequencing data, the construction of ortholog groups using phylogenetic trees can 
identify functional divergence events of PADI2 across species (Weissenbach, 2016; Fang et al., 
2010).   
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4.2 AIMS AND OBJECTIVES 
 
The aim of this chapter is to study the evolutionary history of PADI2 based on the phylogenetic 
analysis of different orthologues sequences. This study will also focus on PADI2 in its 
phylogenetic context to detect the evolutionarily conserved amino acid residues and predict 
functionally important catalytic residues. 
 
1. Phylogenetic analysis of full length PADI2 orthologues (from NCBI database) to 
determine the orthology relationships and identify divergence events of PADI2 across 
various species.  
 
2. Reconstruction of PADI2 protein sequence and the assembly of 3D and 2D structures. 
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4.3 RESULTS 
 
 
 
4.3.1 Phylogenetic analysis and evolutionary divergence of PADI2 among 31 species 
4.3.1.1 Phylogenetic analysis 
The evolutionary analysis was performed on PADI2 orthologues collected from 31 distinct 
species. The Mega7 codon-based alignment method and PhyML software were used to 
construct the PADI2 phylogenetic tree. PADI2 orthologues were identified in mammals, 
including human primate (Homo sapiens), non-human primates (Rhesus monkey, Chimpanzee 
and Olive baboon), Rodents (Mouse, Rat, Alpine marmot and Molerat), chioptera bats 
(Rousette, flying fox and Opterus natalensis), Artiodactyla (Wild camel), ungulates (Horse and 
Ass), Carnivora (Dog and Giant panda), Aves class birds (Canary, Ruff, Eagle and Chicken) , fish 
(Bony tongue, Piranha, Catfish, Molly, Vulus, Rhinocerus,  Barramundi perch and Poecilia 
mexicana) and Celastrales flowering plants (Japonicus) and amphibia (Frog). After sequence 
alignment, a total length of 1839bp nucleotide sequences was retrieved. The evolutionary 
relationship between PADI2 orthologues was inferred using PhyML software ML phylogenetic 
tree. The reliability of the inferred phylogenetic tree was evaluated by bootstrap analysis 
(1000 replications), and bootstrap values were represented with branch support percentage 
(BSP) at each node. Bootstrap proportions of ≥70% that corresponds to a probability of ≥95% 
indicate the reliability of the population parameter in clades (Hillis and Bull, 1993). The 
bootstrap analysis of PADI2 genes across 31 species corresponds to an overall reliable 
phylogenetic tree. However, low bootstrap values were detected in some tree branches; 41%, 
69%, 43%, 36% and 32%. The ML phylogenetic tree showed the first major divergence event 
that separated the lineage into two clades; I and II with BSP of 100% and 99% respectively.  
The major separation logically appears between the two clades; clade-II which contains only 
teleost species and other invertebrate aquatic organisms and clade-I was formed from 
vertebrates’ sequences, including mammals, aves and plants with the frog appearing basal to 
this clade. Clade-I gave rise to four sub-clades; Ia, Ib, Ic and Id. It is commonly known that sub-
clades of a phylogenetic tree share more common ancestor than the one shared between 
clades, therefore, the tree subclades share a more common ancestor than that shared 
between clade-I and clade-II.  it was also observed that each subclade is represented by a 
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different organism class. For example, subclade-Ia is represented by mammals, subclade-Ib is 
represented by plants, subclade-Ic is represented by aves or birds and subclade-Id is 
represented by amphibians. In clade-I, the separation of frog in subclade-Id from the other 
PADI2 orthologues and its longest phylogenetic branch suggests that this lineage did undergo 
the least sequence variation. This may also indicate that this lineage occurred at an early stage 
and is likely to retain ancestral characteristics or may even be the ancestor of other organisms 
in the phylogeny (Crisp and Cook, 2005, Figure 4.1).  
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Figure 4.1. Phylogenetic analysis of PADI2 orthologues obtained from 31 species. A 
bootstrapped unrooted phylogenetic tree was reconstructed using the maximum likelihood 
(PhyML) method using 31 aligned sequences of PADI2 orthologues. Bootstrap values and 
numbers assigned to the branches are represented above and below the branches of each 
tree. 
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4.3.1.2 Phylogenetic analysis by maximum likelihood  
PADI2 orthologues were further analysed to detect evidence of selection at codon sites using 
PAML software. The maximum likelihood method was used for detecting adaptive evolution 
in PADI2. The parameter (ω) ratios and the likelihood of sequence evolution was estimated by 
Empirical Bayes and represented in Models 0, 1a, 2, 3, 7 and 8. The likelihood results were 
then compared to detect variation in the ω ratio between sites and lineages. Therefore, the 
loglikelihood values from the null hypothesis models; M0, M1a and M7, were compared to 
the alternative analysis models; M3, M2 and M8 respectively. 2*(log likelihood M1a – log 
likelihood M2) χ2. The difference between the null and alternative hypothesis was measured 
by calculating the probability between the different models. In PAML, the comparison 
between site models detects positive selection only if the ω ratio averaged over all branches 
of the tree is (>1, Gharib and Robinson-Rechavi, 2013). The calculated p-values for likelihood 
ratio tests were not above 1 (≤1), therefore, were not significant between different 
models. This is indicative that there is no evidence of PADI2 positive selection amongst all 31 
species (Table 4.1). 
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Table 4.1. Log-likelihood values and parameter estimates for PADI2 sequence in 31 vertebral species 
using PAML analysis  
  
Null Hypothesis 
 
Alternative Hypothesis 
 
Test 
 
Model 
 
Model 
description 
 
Parameters 
 
Log-
likelihood 
 
Model 
 
Model 
description 
 
Parameters 
 
Log-
likelihood 
 
P-
value 
 
Codon 
variation 
0 One ratio ω 23802.53 
 
3 
 
Discrete 
ratios ω0, ω1 ω2 -23046.06 0 
 
Natural 
selection 
1a Nearly 
neutral 
0 < ω0 < 1 
ω1 = 1 
-23476.14 2a 
Positive 
selection 
ω0 < 1 
ω1 = 1 
ω2 > 1 
-23476.14 1 
 
Alternative 
selection 
(beta) 
7 Beta p, q -23039.21 8 Beta & ω 
 
ωs > 1 
 
-23039.21 1 
Positive selection sites are with P>95% 
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4.3.2 Overall amino acid sequence conservation in PADI2  
Accurate sequence alignment of protein functions is the key to understanding their cellular 
physiology. The aligned nucleotide sequences of PADI2 orthologues were used to predict the 
evolutionary status of the subsequent amino acid sequence. Full-length human PADI2 
contains 664 amino acid residues, whereas sequence alignment analysis of PADI2 orthologues 
resulted in a truncated protein sequence with a total length of 613 amino acids. The truncated 
PADI2 amino acid sequences were then colour coded by PyMOL to depict the evolutionary 
status of the corresponding amino acid (red: neutral, green: positive and yellow: conserved). 
The sequence alignment between more divergent species (e.g. between bonytongue and 
human) can result in minimal aligned sequence, subsequently leading to the identification of 
only highly conserved protein regions (McCauley et al., 2007). The amino acid residues, which 
play an important role in protein function, are often conserved. These residues are usually 
clustered together in a functionally important locations, such as protein-ligand binding sites 
(Ahmad et al., 2008). Therefore, an analysis of residue conservation is a reasonable approach 
to identify functionally important residue/sites in the PADI2 protein. Previously determined 
PADI2 domains (PAD, PAD_M and PAD_N), protein ligands (MPD, CA, ACT) (supplementary 
material S3) and Ca2+ ion binding sites by Slade et al., (2015) were also mapped on the PADI2 
amino acid sequence in the current study. Interestingly, PAD and PAD_M domains harbouring 
the active site and calcium binding sites (Ca3-5), have a higher proportion of conserved amino 
acid sequences (11%) and (16%), respectively, compared to PAD_N domain (37.5%). Also, 
highly conserved amino acid sequences were observed at Ca1, 2 and 6 binding sites (Figure 
4.2). 
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Figure 4.2. The retrieved amino acid sequence of human PADI2. The amino acids sequence 
alignment from phylogenetic analysis across 31 vertebral species as determined by Bayes 
Empirical Bayes output from PAML. The amino acid residues are represented by different 
colours, i.e. yellow; conserved, red; neutral selection and green; positive selection. The 
position of amino acid residues that correspond to the catalytic sites, including ligand binding 
sites and Ca2+ binding sites (Ca1-6), according to (Slade et al., 2015) were mapped. The ligand 
binding sites of ACT, MDP and CA, are represented by different coloured shapes. ACT, acetate 
ion; MPD, (4S)-2-methyl-2,4-pentanediol; CA calcium ion.  
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4.3.3 Overall PADI2 3D/2D structures 
Structural genomics efforts have enabled exponential growth in the determination of 
structure-based prediction of proteins' function. The aligned PADI2 codon selection data, 
were mapped to the published 3D/2D structures. The relationship between structure and 
conserved sequence features was examined by establishing the tertiary and secondary 
structure elements distribution. The PADI2 structure was shown in a similar orientation using 
the same colour scheme. The PADI2 sequence signatures (i.e. ligand binding sites) and protein 
domains were previously determined by Slade et al., (2015). These signatures were re-
mapped onto the truncated PADI2 3/2D structure. Online available tools, such as Pfam 
(HMMR), superfamily, Gene3D and EMBL-EBi were used to identify the position of the 
corresponding residues on the truncated PADI2 amino acid sequence. Collectively, these tools 
identified the different domains of PADI2 (i.e. N- and C- terminal domains) and recognised the 
positions of Ca2+ (Ca1-6) binding sites and ligand binding sites (MDP, CA and ACT). The C-
terminal domain (residues 269–613), also known as PAD or α/β propeller domain, is a highly 
conserved domain that includes the proteins’ active site and Ca1 and Ca6 binding sites (Linsky, 
2012).  The N-terminal domain is subdivided into two immunoglobulin-like subdomains: 
Immunoglobulin (Ig) subdomain or PAD_N (residues 3−94) and Immunoglobulin (Ig) 
subdomain II or PAD_M (residues 95−268). The majority of ligand binding sites are projected 
out of the binding pockets, which is formed by a relatively large external cavity that is highly 
accessible to solvents. These binding pockets mainly consist of conserved amino acid side 
chains, suggesting that these residues do not only play a role in ligand binding specificity, but 
also in interaction with partners, such as receptors (Figure 4.3). 
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Figure 4.3 PADI2 3D and 2D structures. The amino acid residues are represented by different 
colours, i.e. yellow; conserved, red; neutral selection and green; positive selection. The 
position of amino acid residues that correspond to the catalytic sites, including ligand binding 
sites and Ca2+ binding sites (Ca1-6), according to (Slade et al., 2015) were mapped. (a) PADI2 
shows neutral and conserved selection. (b) An alternative view of PADI2 (rotated-180 
degrees). (c) Ribbon presentation PADI2 tertiary structure including PADI2 domains. The 
ligand binding sites of ACT, MDP and CA, are represented by different coloured shapes. ACT, 
acetate ion; MPD, (4S)-2-methyl-2,4-pentanediol; CA calcium ion.  
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4.4 DISCUSSION 
 
4.4.1 In silico identification and phylogenetic analysis of PADI2 sequences across diverse 
species 
PADI genes are expressed widely in various species and share significant identities at the level 
of their coding nucleotide sequences (Chavanas et al., 2004). Although PADI isozyme 
sequences display high homology and their patterns of expression were suspected to concur 
this homology; however, each PADI gene has its specific pattern of expression depending on 
the tissue, cell type or cellular differentiation stage (Guerrin et al., 2003). Previous work on 
PADI genes, along with the rapidly expanding availability of genomic sequence data, has 
enabled the examination and comparison of PADIs across diverse genomes. Several recent 
reports confirmed the expression of all five PADI isotypes in mammals, such as human (Homo 
sapiens), rat (Rattus norvegicus) and mouse (Mus musculus), (Ying et al., 2009). The five 
mammalian PADI isozymes are highly conserved with 70-90% amino acid sequence homology 
between human paralogs (Méchin et al., 2007). Furthermore, PADI genes are clustered on a 
single chromosomal locus (chromosome 1p36.1) and display high nucleotide sequence 
homology in exons with the same exon/intron structure (Ying et al., 2012).  
It has been proposed that genes with highly conserved sequences is suggestive of functional 
significance and therefore are likely to be under selective constraint (Bergmiller et al., 2012; 
Davies et al., 2015). Mammalian PADI2 is the most phylogenetically conserved PADI isozyme, 
and it contains amino acid residues corresponding to two highly conserved domains involved 
in the enzymes’ catalytic activity and Ca2+ binding sites (Rebl et al., 2010). The importance of 
PADI2  enzyme and hypercitrullination have been established in many neurodegenerative 
human disorders and cancers (Chirivi et al., 2013). However, the mechanisms regulating PADI2 
activation and its physiological roles in a non-pathologic setting remain poorly understood 
(Chirivi et al., 2013). While the origin and evolution of the PADI isotypes have been previously 
studied, the evolutionary history of PADI2 in various organisms is not yet elucidated. The aim 
of this chapter was to determine the protein structure and evolutionary relationships of PADI2 
orthologues across various species. This was achieved by employing various tools to establish 
the phylogenetic relationship of full length PADI2 orthologues and the reconstruction of PADI2 
3D and 2D structures. The phylogenetic analysis of gene expression in diverse species can 
serve as the foundation for "evolutionary synthetic biology," to provide better understanding 
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of cellular pathway evolution, macromolecular machines and other emergent properties of 
early life (Losos et al., 2013; Yuan et al., 2014). While this approach was devised for PADI2 
individually in this thesis, this gene has been previously explored in a multigene family 
phylogenetic analysis that includes all PADI isoforms and other comparative methods for the 
analysis of gene evolution (Magnadóttir et al., 2018; Wang and Wang, 2013; Witalison et al., 
2015). However, a limited number of studies have investigated PADI2 phylogenetic evolution, 
among a small range of different species, including rhesus monkey, chimpanzee, mouse, dog, 
chicken, rat, frog and zebrafish (Hosokawa et al., 2018). These studies showed that human 
PADI2 orthologues were found to be conserved amongst all five organisms. Likewise, the 
current study included a larger number and more diverse species (i.e. 31 organisms), including 
fish, aves, mammals and amphibians, in addition to newly available sequences from species, 
such as Miniopterus Natalensis bat (Stoffberg et al., 2004). While the oldest marsupial and 
placental mammals divergence were estimated between 125 and 175 million years ago, 
various estimates place the teleost-bony fish divergence at almost 400 million years ago 
(Grimholt et al., 2015). The identification of PADI2 in teleost fish (bony fish species, e.g. 
Catfish, Piranha, Molly, Bonytongue and Vulus) is exciting, as it indicates that PADI2 is of a very 
ancient origin and will likely be found in most, if not all, cartilaginous and teleost fish species. 
The bony tongue fish (Osteoglossomorpha), belong to the most ancient living teleost groups, 
this fish represent a phylogenetic link between the old world fish and the modern teleost 
(O’Neill et al., 1998). However, the much more diverse and familiar species of teleost arose at 
about the same time as modern birds and placental mammals including humans (Homo 
sapiens), Olive baboon, about 120 to 60 million years ago (Near et al., 2012). PADI2 also 
occurred in more recently evolved species such as horse (55 million years), Donkey (Ass, 5000 
years) and variety of bat species (35 million years). This study provides evidence for 
conservation and concerted evolution of PADI2 sequence in some of the oldest and newly 
diverged species.  
The most important finding presented in this study is that PADI2 is highly conserved 
throughout evolution. The use of 31 different species, with diverse annotation levels and 
evolutionary distances, contributed to the robustness of the results obtained from both 
phylogenetic and structural analysis of PADI2 in the current study. The PADI2 sequence 
conservation resulted in a reliable phylogenetic relationship that may correlate with the 
structural and physiological traits of the organisms associated. It may also contribute to 
further the understanding of the conserved roles of PADI2 throughout phylogeny. Indeed, the 
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depth and breadth of conservation of PADI2 sequence is indicative of possible vital regulatory 
and/or developmental roles (Carroll, 2008; Rokas, 2008; Ingham et al., 2011).  
 
4.4.2 Functional analysis of PADI2 domains 
While sequence and phylogenetic analysis provide a relatively simple way of viewing protein 
sequence divergence, the comparison of protein tertiary structure 3D models can provide 
more insight into a protein’s evolution.  Previously, researchers have examined the detection 
of functional 3D patterns associated with atom interactions or/and active sites (Nebel et al., 
2007). Slade et al., (2015) previously determined the PADI2 3D structure using its full-length 
amino acids component (human PADI2 comprises of 668 amino acids) to build the crystal 
structure. They also showed the organisation of PADI2 domains and identified functionally 
significant residues that are associated with the active site and other functionally important 
sites, such as Ca2+ binding sites (Slade et al., 2015). Herein, the aligned PADI2 codon selection 
data obtained from the sequence alignment of 31 species, were mapped to the published 
3D/2D structures. The previously identified PADI2 domains and key residues were also re-
mapped on the truncated PADI2 3D structure in this study. The findings in this study illustrate 
the important utility of 3D protein structure in the interpretation of important information 
about the function of the PADI2 protein (Medvedeva et al., 2015). The most important 
functional residues reside in relatively more conserved domains of PADI2 protein. For 
example, among the identified PADI2 domains, the PAD domain which includes the active site 
and PAD_M domain that contains the calcium switch, show the highest amino acid sequence 
conservation; 89% and 84% (conserved amino acid sequence), respectively. Whereas, PAD_N 
domain shows the least amino acid sequence conservation (62.5%). This is not surprising, since 
it was previously hypothesised that the calcium-switch (Ca3−5) is a key regulator of PADI2 
function and may be evolutionarily maintained to sustain its function. By convention, domains 
are defined as conserved, functionally independent protein sequences, which use a core 
structural motif  to bind or process ligands (Castagnoli et al., 2004; Kuriyan and Cowburn, 
1997; Doolittle, 1995). The folding of a domain is mainly based on a complex network of 
sequential inter-molecular interactions in time. These interactions have significant 
implications for domain integrity, particularly if the core of a protein domain is largely 
structurally conserved (Slade et al., 2015). 
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Moreover, del Sol et al., (2006) showed that residues mediating the enzyme’s function, such 
as catalytic residues, those forming the ligand-binding pocket, or residues involved in protein-
protein interactions, have high centrality values (residues located in a central position of 
protein crystal structure). A more detailed study by Sol et al., (2015) on 46 different protein 
families, revealed that a total of 80% of these proteins central domains/positions 
corresponded to active site residues or residues in direct contact with catalytically important 
sites. Furthermore, the geometrical analysis of the functional sites of these enzymes also 
revealed that centrally conserved amino acids can be predictors for the catalytic site residues 
and are clustered with functionally important active site residues situated in protein surface 
clefts or cavities. These studies show that residue centrality, as an inherent fold characteristic, 
maybe evolutionarily maintained to sustain a proteins’ function (del Sol et al., 2006b). While, 
mammalian PADI2 shares 70–95% amino acid sequence homology with other PADI family 
members, the residues corresponding to the calcium-binding sites (Ca3− 5) that reside in the 
centrally located PAD_M domain are highly conserved throughout evolution (Raijmakers et 
al., 2007). Given that the centrally located calcium switch (Ca3−5) are highly conserved among 
PADI2 orthologues and all the PADI paralogs, this may furthermore indicate its importance as 
a key regulator of PADI2 activity/function. It may also suggest that it is likely a universal feature 
of the PADIs. In contrast to Ca3-6, the Ca1 and Ca2 sites are located in the PAD domain 
containing the active site. Ca1 and Ca2 bind calcium ions independently of the other calcium 
binding sites. The active site of PADI2 was found to be highly conserved, even where sequence 
identity was very low. Collectively, residues that correspond to both active site and Ca2+ 
binding sites are highly conserved as a results of evolutionary constraints placed upon the 
residues corresponding to these sites, which need to be in an optimal position to be most 
effective during catalysis (Jack et al., 2016).  
 
4.5 CONCLUSIONS 
In summary, the PADI2 gene was found in diverse vertebrate and invertebrate organisms with 
conserved gene and protein characteristics. The important characteristics of the PADI2 
protein structure were identified/re-mapped and found to be conserved among various 
species. These characteristics include important amino acid residues that correspond to 
functionally important catalytic sites, such as Ca2+ binding sites and ligand binding sites. These 
findings are particularly important as they imply that PADI2 is evolutionarily maintained to 
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sustain its important function and is also suggestive of a role for PADI2 in regulation and/or 
development (Carroll, 2008; Rokas, 2008; Ingham et al., 2011). 
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CHAPTER 5: Potential role of PADI2-mediated citrullination in EOC pathogenesis  
 
5.1 INTRODUCTION 
 
The identification of new biomarkers specific to cancer subtypes and individual patients is 
crucial for developing personalised treatment, in terms of evaluating both disease risk and 
therapy response (Hayes et al., 2014). Thus, cancer biomarkers can also serve in diagnosis and 
contribute to improving the outcome of cancer chemotherapy (Kamel and Al-Amodi, 2017). 
The PADI2 enzyme and citrullinated proteins are associated with various human diseases 
including cancer. In addition, increasing clinical evidence suggests that PADI2 has important 
roles in tumour progression. PADI2 was previously identified as an oncogene, potential 
biomarker and important therapeutic target in breast cancer (McElwee et al., 2012; Wang et 
al., 2016). The dysregulation of PADI2 expression was shown to affect cellular activity in 
various cancers, such as breast, prostate and colorectal; however, the role of PADI in EOC is 
yet to be investigated. This study aims to elucidate the role of PADI2 in EOC. Given the 
emerging links between PADI2 and tumorigenesis, a better understanding of the upstream 
mechanisms that induce PADI2 expression, and the downstream mechanisms by which PADI2 
regulate cell activity will contribute to better understanding of the EOC biology. Furthermore, 
the overexpression of PADI2 enzyme and its activity at critical points of tumour progression 
raises the possibility that this enzyme, and the resulting post-translational modifications, may 
have utility as a novel EOC biomarker and therapeutic target. There have been conflicting 
studies on the role of PADI2 in cancer. On the one hand, numerous reports have revealed that 
PADI2 expression contributes to the tumorigenesis of some cancers and is associated with 
poor patient prognosis (McElwee et al., 2012; Wang et al., 2016; Horibata et al., 2017). 
Conversely, other studies indicated that PADI2 expression reduced tumour growth and its 
downregulation is an early event of carcinogenesis (Cantarino et al., 2016; Funayama et al., 
2017). Collectively, these inconsistent observations suggest that PADI2 can act as either a 
tumour promoter or a suppressor in a context. These observations also suggest that PADI2 
may have different roles in different cancers or cancer subtypes. For this purpose, 
investigating PADI2’s role in different molecular EOC subtypes may provide more insight into 
the mechanisms regulating PADI2-subtype specific function and downstream effect on cellular 
activity, including proliferation, apoptosis, autophagy, necrosis and aggregation.   
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It was previously determined that PADIs are Ca2+-dependent enzymes that require Ca2+ 
concentrations ranging from 40μM to 3.3mM to efficiently citrullinate protein substrates 
(Damgaard et al., 2014). Furthermore, according to a crystallographic study by Slade et al., 
(2015), they confirmed that Ca2+ is a key regulator and a critical prerequisite for PADI2 
enzyme-substrate binding. However, the conditions required for this reaction to take place in 
in vitro cultures are unknown. The current novel work aims to elucidate whether high Ca2+ 
concentrations are required to induce PADI2 function in in vitro.  
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5.2 AIMS AND OBJECTIVES 
 
The aim of this chapter is to elucidate the role of PADI2 overexpression and explore its Ca2+-
dependent regulation in vitro. The effect of PADI2 overexpression on downstream effect on 
cellular activity, including proliferation, apoptosis, autophagy, necrosis and cellular 
aggregation was evaluated in human OVCAR-4 and mouse ID8-Luc2 cells. In addition, this work 
determines whether PADI2 expression contributes to tumorigenesis by increasing resistance 
to cisplatin chemotherapy in EOC cells. The objectives were to: 
 
1. Determine the endogenous expression levels of PADI2 in a panel of nine EOC cell lines. 
 
2. Transfect a human PADI2 overexpression construct into the mouse ID8-Luc2 and 
human OVCAR-4 cell lines to determine the effect upon citrullination within these cells. 
 
3. Measure the functional effect of overexpressing PADI2 in EOC cell lines on cell 
proliferation apoptosis, autophagy, necrosis and cellular aggregation. 
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5.3 RESULTS 
 
5.3.1 Detection of PADI2 endogenous expression in EOC cell lines 
The deregulation of PADI2 expression was previously linked to human cancer development 
and progression (Liu et al., 2014). To study the function of PADI2 in EOC and assess whether 
it affects cellular chemoresistance to cisplatin, PADI2 expression was initially evaluated in a 
panel of nine EOC cell lines.  
 
5.3.1.1 Optimisation of PADI2 and PADI4 monoclonal antibodies for Western blotting 
It is possible for an antibody to be sensitive for a protein of interest but still cross-react with 
other closely related proteins and therefore lack specificity. To optimise the specificity of 
PADI2 monoclonal antibody, PADI4 recombinant protein was also used as an experimental 
validation control to determine if there was a cross-reactivity with Western blotting 
experiments. A PADI4 monoclonal antibody was also used to detect the optimum amount of 
PADI4 recombinant protein required to be detected by Western blotting. 
Both anti-PADI2 (Santa Cruz, USA) and anti-PADI4 (Abcam, UK) antibodies’ sensitivity were 
initially optimised using serial dilutions of recombinant proteins and thereafter analysed using 
SDS-page and Western blotting. 1µg was determined as the optimal recombinant protein 
concentration required as loading positive control for both PADI2 and PADI4 recombinant 
proteins (Figure 5.1). 
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Figure 5.1. Western blotting and SDS-page analysis of the recombinant PADI2 and PADI4 
proteins different concentrations. Both anti-PADI2 and anti-PADI4 antibodies’ sensitivity 
were initially optimised using serial dilutions of recombinant proteins and thereafter analysed 
using SDS-page and Western blotting. Results are representative of three independent 
experiments. 
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5.3.1.2 Expression of endogenous PADI2 in EOC cell lines  
To determine whether endogenous PADI2 is expressed in EOC cell lines, qRT-PCR and Western 
blot analysis was performed on a panel of nine EOC cell lines, including SKOV-3, ID8-Luc2, 
OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, OVCA-433, OAW42 and TOV-112D (Figure 5.2a and 
5.2b). Although, PADI2 mRNA expression levels were significantly higher in TOV-112D, OVCAR-
8, and OVCAR-3 compared with the remaining cell lines. However, the subsequent analysis by 
Western blotting showed that PADI2 protein was not expressed in any of the cell lines tested. 
In parallel, recombinant PADI2 protein and C2C12, murine muscle cell line, were used as 
positive controls to confirm PADI2 antibody’s sensitivity. 
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Figure 5.2. The expression of endogenous PADI2 in EOC cell lines. (a) Transcript levels of 
PADI2 were determined by qRT-PCR. Representative bar graphs of average PADI2 
transcription levels normalised to 18S mRNA levels.  Results are representative of the average 
fold change ± SD of triplicate independent experiments relative to the untreated controls. Bars 
are presented as mean ± SD (n = 3). ****p ≤ 0.0001. (b) Cell lysates were analysed by SDS-
PAGE and Western blotting using antibodies specific to PADI2. Recombinant PADI2 and C2C12; 
murine muscle cell line, were used as positive controls. Results are representative of 
independent experiments. 
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5.3.2 PADI2 overexpression analysis in EOC cell lines 
 
5.3.2.1 Determination of pcDNA3.1+-DYK PADI2 and empty vector plasmids transfection 
efficiency in EOC cell lines by flow cytometry  
PADI2 overexpression vector (pcDNA3.1+-DYK) and empty vector (pcDNA3.1+-DYK) were co-
transfected with a fluorescent GFP containing plasmid (pCMV-GFP) into SKOV-3 and ID8-Luc2 
cell lines. Transfection efficiency was then assessed using flow cytometry. Plasmid DNA 
(pcDNA3.1+-DYK and GFP plasmids) was transfected into cells at different ratios (1:1 and 3:2, 
to give a total amount of 5µg). At 48 hours post-transfection, cells were trypsinised and re-
suspended in PBS/10% FCS. Transfection efficiency was then assessed by measuring the 
intracellular GFP expression using flow cytometry. To determine the transfection efficiency of 
the co-expressed plasmid in cells, the collected flow cytometry data was then analysed using 
Flowing software. In the analysis, cellular debris were excluded by gating cells on the forward 
and side scatter (FSC linear and SSC log) parameters and the background fluorescence 
intensity of mock-transfected (treated with Lipofectamine 3000) cells were subtracted to 
eliminate background fluorescence (Figure 5.3a). The histograms produced by the Flowing 
software, represented the transfection efficiency (x-axis) percentages of control empty vector 
and PADI2 overexpression vector in SKOV-3 and ID8-Luc2 cells. The transfection efficiency at 
2.5µg DNA of co-transfected control empty vector and PADI2 overexpression vector in SKOV-
3 cells were 50.8% and 51.9%, and in ID8-Luc2; 51.1% and 30.3%, respectively. Whereas the 
transfection efficiency at 3µg DNA in SKOV-3 cells were 42.4% and 38.6%, respectively (Figure 
5.3b). 
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Figure 5.3. Flow cytometry analysis of PADI2 expression vector and empty vector 
transfection efficiency in SKOV-3 and ID8-Luc2 cell lines. Cells were transiently co-transfected 
with 2.5 µg GFP (pCMV) at different concentrations (2.5-3µg) of the PADI2 overexpression 
vector or control empty vector using Lipofectamine 3000. The concentration of the co-
transfected GFP vector with each of the expression vectors are also indicated with ratio values 
(for clarification). At 48 hours post-transfection, cells were resuspended in PBS/10% FBS and 
then analysed by flow cytometry. (a) Representative dot plot of side scatter and forward 
scatter displaying the gated events of viable cells (R-1). The flow cytometric histograms were 
analysed to determine the transfection efficiency percentages by measuring the average 
fluorescence intensity relative to the control (Lipofectamine 3000). The marker H-2 that 
encompasses the GFP fluorescent peak in histograms was used to evaluate transfection 
efficiency percentages. (b) Bar graph representation of plasmids transfection efficiency 
percentages in EOC cell lines.  
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5.3.2.2 Enrichment of SKOV-3 and ID8-Luc2 cells transfected with PADI2 gene 
To allow more accurate interpretation of the effects of PADI2 overexpression in EOC cell lines, 
optimal concentrations of the mammalian antibiotic, geneticin (G418), enrichment was 
determined. This was achieved by applying different antibiotic concentrations to non-
transfected cells for seven days. The cell viability was then determined using trypan blue 
method (Figure 5.4a). On day two of enrichment, IC50 values were then determined by 
plotting the cell viability percentages on a semi-log-dose-response graph. 50% of the cell 
population died in SKOV-3 and ID8-Luc2 lines at G418 concentrations; 988.6µg/ml and 
729.7µg/ml in SKOV-3 and ID8-Luc2, respectively (Figure 5.4b). 
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Figure 5.4. The percentage of cell viability in SKOV-3 and ID8-Luc2 cells after treatment with 
G418 (200-1000µg/ml). (a) Cells were incubated for total of seven days and cell viability was 
measured every 24 hours using 1% trypan blue. Percentage viability values were represented 
in time-kill curves. (b) G418 Log-dose response curves were used to determine the IC50 values 
at day two; 988.6µg/ml and 729.7µg/ml in SKOV-3 and ID8-Luc2, respectively. Results are 
representative of the average percentages of ± SD of duplicate independent experiments 
relative to the untreated controls. Bars are presented as mean ± SD (n = 3).  
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5.3.2.3 PADI2 overexpression was absent in the human cell line SKOV-3 and did not affect 
protein citrullination in the murine cell line ID8-Luc2 
To determine whether PADI2 expression levels affect the total citrullination in SKOV-3 and 
ID8-Luc2 cell lines, first, cell lines were transfected with 2.5µg PADI2 overexpression vector or 
control empty vector for a duration of 48 hours. The transfected cells were then subjected to 
G418-enrichment for additional 48 hours. The surviving cells were resistant to G418, indicating 
successful delivery of plasmids into cells. At 96 hours post transfection and enrichment, the 
mRNA and protein expressions levels of PADI2 were detected in each cell line using qRT-PCR 
and Western blotting, respectively. The two detection methods produced inconsistent results 
in SKOV-3 cell lines (Figure 5.5a and 5.5b). PADI2 mRNA expression was detected in PADI2 
overexpressing SKOV-3 cells; however, subsequent analysis of the transfected cells by 
Western blotting did not detect protein expression. Conversely, both the PADI2 mRNA and 
protein expression was detected in PADI2 overexpressing ID8-Luc2 cells (Figure 5.5c and 
5.5d). PADI gene family members share similar sequences and functional domains, therefore 
PADI4 recombinant was used to confirm the specificity of the PADI2 antibody. Since it was 
previously established that Ca2+ induces the activation of PADI isozymes and subsequently 
catalyse PADI2-citrullination reaction. Therefore, it is important to assess this in vitro, and 
determine whether increasing e[Ca2+] could affect the total PADI2-induced citrullination in 
PADI2 overexpressing cells. At 96 hours post transfection, PADI2 overexpressing ID8-Luc2 cells 
were incubated in 1mM CaCl2 (e[Ca2+]) for a duration of 72 hours. However, citrullination was 
not detected irrespective of Ca2+ treatment (Figure 5.5d). 
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Figure 5.5. The effect of overexpressing PADI2 on total protein citrullination in SKOV-3 and 
ID8-Luc2 cell lines treated with CaCl2. Cells were transiently transfected with PADI2 
overexpression vector (PADI2) and control empty vector (EV). (a) and (b) At 96 hours post-
transfection and enrichment, PADI2 mRNA expression levels were determined by qRT-PCR. 
Representative bar graphs of average PADI2 transcription levels normalised to 18S mRNA 
levels. Results are representative of the average fold change ± SD of triplicate independent 
experiments relative to the untreated controls. Bars are presented as mean ± SD (n = 3). 
***p ≤ 0.001; and ****p ≤ 0.0001. (c) and (d) At 96 hours post-transfection and enrichment, 
cells were incubated in the presence and absence of 1mM CaCl2 for 72 hours. Cell lysates were 
assessed for PADI2 protein and total citrullination by Western blot using antibodies specific to 
PADI2 and citrulline. Recombinant PADI2 and C2C12, murine muscle cell line, were used as 
positive controls. Representative blots for quantification of PAD2 were normalized to β-actin 
in the lower panel.  
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To better examine the effect of PADI2 overexpression in EOC, it was helpful to use more than 
one EOC cell line. Furthermore, using different cancer cell lines will help better explore the 
possible functions of PADI2 in EOC tumorigenesis. Since PADI2 protein was not detected in 
PADI2 overexpressing SKOV-3 cells (Figure 5.5b), as a result, this cell line was not used as in 
vitro model to examine PADI2 function in EOC. Therefore, the OVCAR-4 cell line was selected 
as an alternative EOC cell line model. Similarly, G418 IC50 values were initially determined for 
OVCAR-4 cell line, followed by transfection experiments, qPCR and Western blotting analysis 
of OVCAR-4 control empty vector and PADI2 overexpression transfected cells. 
 
 
5.3.2.4 Enrichment of OVCAR-4 cells transfected with PADI2 gene 
Cell viability was determined using trypan blue method. On day two of enrichment, IC50 
values were then determined by plotting the cell viability percentages on a semi-log-dose-
response graph (Figure 5.6a). 50% of the cell population died in OVCAR-4 cell line at G418 
concentration estimated to 943.6µg/ml (Figure 5.6b). 
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Figure 5.6. The percentage cell viability of OVCAR-4 cells in the presence of G418 (200-
1000µg/ml). (a) Cells were incubated for total of seven days and cell viability was measured 
every 24 hours using 1% trypan blue. Percentage viability values were represented in time-kill 
curves. (b) G418 Log-dose response curves were used to determine the IC50 value at day two; 
943.6µg/ml. Results are representative of the average percentages of ± SD of duplicate 
independent experiments relative to the untreated controls. Bars are presented as mean ± SD 
(n = 3).  
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5.3.2.5 PADI2 overexpression induced protein citrullination in OVCAR-4 
To determine whether the PADI2 expression levels affect the total citrullination in OVCAR-4, 
cells were transfected with PADI2 overexpression vector and control empty vector for 48 
hours. The transfected cells were enriched by G418 for additional 48 hours. After the 
confirmation of successful PADI2 mRNA and protein overexpression, at 96 hours post-
transfection and enrichment, PADI2 overexpressing OVCAR-4 cells were incubated in 1mM 
CaCl2 (e[Ca2+]) for 72 hours consecutive. Total citrullination was then detected in cells treated 
with 1mM CaCl2 (Figure 5.7).  
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Figure 5.7. PADI2 overexpression induced total protein citrullination in OVCAR-4 cell line 
treated with CaCl2. Cells were transiently transfected with PADI2 overexpression vector 
(PADI2) and control empty vector (EV). (a) At 96 hours post-transfection and enrichment, 
PADI2 mRNA expression levels were determined by qRT-PCR. Representative bar graphs of 
average PADI2 transcription levels normalised to 18S mRNA levels. Results are representative 
of the average fold change ± SD of triplicate independent experiments relative to the 
untreated controls. Bars are presented as mean ± SD (n = 3). ****p ≤ 0.0001. (b) At 96 hours 
post-transfection and mammalian selection, cells were incubated in the presence and absence 
of 1mM CaCl2 for 72 hours. Cell lysates were assessed for PADI2 protein and total citrulline 
protein by Western blot using antibodies specific to PADI2 and citrulline. Recombinant PADI2 
and C2C12; murine muscle cell line, were used as positive controls.  
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5.3.3 PADI2 overexpression can alter EOC cell activity in vitro 
The aim of the present study was to assess the role of PADI2 in EOC cells, to determine 
whether increasing PADI2 expression affected EOC cellular activity. Therefore, PADI2 
overexpression was assessed in EOC cell proliferation, apoptosis, autophagy, necrosis and 
cellular aggregation.  
 
5.3.3.1 The effect of PADI2 overexpression on the proliferation of EOC cells 
5.3.3.1.1 PADI2 overexpression did not affect the proliferation of OVCAR-4 or ID8-Luc2 cells 
To investigate the role of PADI2 in EOC proliferation, OVCAR-4 and ID8-Luc2 wild type were 
transiently transfected with PADI2 overexpression and vector control empty vector. At 96 
hours post-transfection, cells were seeded into 96-well plates at cell density of 1x104. Cell 
proliferation was then determined using WST-1 assay. There was no statistically significant 
difference between wild type, control empty vector and PADI2 overexpression vector 
transfected cell lines (Figure 5.8). 
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Figure 5.8. PADI2 overexpression did not affect cell proliferation in OVCAR-4 and ID8-Luc2 
cells. Cells were transiently transfected with PADI2 expression vector and control empty 
vector. At 96 hours post-transfection and enrichment, cell proliferation was measured using 
WST-1 assay for duration of 72 hours. Results are representative of the average percentages 
of ± SD of triplicate independent experiments relative to the untreated controls. Bars are 
presented as mean ± SD (n = 3).  
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5.3.3.1.2 The effect of PADI2 overexpression and increased e[Ca2+] on OVCAR-4 and ID8-Luc2 
cell proliferation  
Since Ca2+ is a known to activate PADI2 and may induce PADI2-mediated citrullination as 
observed in OVCAR-4 (section above 5.3.3.5), therefore, CaCl2 was added to the cell culture 
media of both OVCAR-4 and ID8-Luc2 cell lines. The growth medium used for cell culture 
contained pre-existing concentrations of Ca2+, which were previously indicated by the 
manufacturing company (RPMI: 1.05mM and DMEM: 0.43mM). Ca2+, as a major intracellular 
second messenger, regulates multiple physiological functions in cells, including cell survival 
and cell death.  Therefore, it is important to evaluate the Ca2+ concentrations required for 
PADI2 activity while maintaining viable cells. To examine the effect of increasing e[Ca2+] on 
PADI2 activity in EOC, the effect of the addition of CaCl2 was assessed in PADI2 overexpressing 
OVCAR-4 and ID8-Luc2 cells. At 96 hours post-transfection and enrichment, cells were 
incubated in media containing increasing concentrations of 0.05-2.5mM CaCl2 for 24, 48 and 
72 hours. Cell proliferation was then determined using WST-1 assay. Overall, PADI2 
overexpression significantly decreased cell proliferation in OVCAR-4 cells treated with CaCl2 at 
all concentrations. The lowest cell proliferation percentages were observed when PADI2 
overexpressing OVCAR-4 cells were treated with 1mM CaCl2. Conversely, the incubation of 
PADI2 overexpressing ID8-Luc2 cells in increasing CaCl2 concentrations, resulted in an 
inconsistent pattern of cell proliferation at all incubation times (Figure 5.9a). A microscopic 
view of OVCAR-4 cell proliferation at 72 hours post-treatment with increasing concentrations 
of 0.05-2.5 CaCl2mM (Figure 5.9b). 
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Figure 5.9. The effect of PADI2 overexpression on cell proliferation in OVCAR-4 and ID8-Luc2 
cells incubated with increasing concentrations of CaCl2. Cell proliferation was analysed by 
WST-1 assay. (a) OVCAR-4 and ID8-Luc2 cells were transiently transfected with PADI2 
overexpression vector and control empty vector. At 96 hours post transfection and 
enrichment, cells were incubated in increasing concentrations of 0.5-2.5mM CaCl2 for a 
duration of 72 hours. (b) Representative senescence-associated with exposing PADI2 
overexpressing OVCAR-4 cells to increasing concentration of 0.5-2m.5mM CaCl2 for 72 hours. 
Results are representative of the average percentages of ± SD of triplicate independent 
experiments relative to the untreated controls. Bars are presented as mean ± SD (n = 3). 
****p ≤ 0.0001. 
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5.3.3.1.3 OVCAR-4 cells are more susceptible to cisplatin drug treatment than ID8-Luc2 cells 
The vast majority of previous and current studies frequently evaluate the cytotoxicity and 
inhibitory effect of a potential biomarker or oncogene with commonly used chemotherapeutic 
drugs. Evaluating the utility of a novel biomarker will help identify reliable biomarkers that can 
be used in a clinical context. As previously mentioned, (introduction chapter 1.6), cisplatin is 
the most commonly used chemotherapeutic treatment for EOC patients, therefore, it was 
used as a positive control in this study to assess the utility of PADI2 as a potential biomarker 
and therapeutic target for EOC. To enable better assessment of PADI2, it was important to 
first evaluate OVCAR-4 and ID8-Luc2 sensitivity to cisplatin treatment. Therefore, cisplatin 
drug efficacy was initially determined in wild type (non-transfected) OVCAR-4 and ID8-Luc2 
cells. 
In the current study, e[Ca2+] was shown to promote PADI2 activity in EOC cells and therefore 
downstream experiments on PADI2 activity will involve the addition of e[Ca2+] (Figure 5.9). 
Since Ca2+ is also a key regulator of cisplatin-induced ROS, and was previously shown to 
alleviate oxidative stress, subsequently increasing cisplatin sensitivity in human EOC cells (Ma 
et al., 2016). Thus, it was crucial to evaluate cisplatin drug efficacy with or without the addition 
of CaCl2 treatment. This was achieved by incubating cells with increasing cisplatin 
concentrations of 1-100µg/ml in the presence of 1mM CaCl2 for a duration of 72 hours. All cell 
proliferation percentages were then plotted on a semi-log-dose-response graph to report drug 
exposure time and evaluate IC50 values. The inhibitory rate was determined by WST-1 assay. 
IC50 values were significantly decreased in OVCAR-4 and ID8-Luc2 cells treated with Cisplatin 
in the presence and absence of CaCl2, at all incubation periods (Figure 5.10). 
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Figure 5.10. The evaluation of cisplatin drug efficacy in EOC cells treated with 1mM CaCl2. 
Wild type non-transfected cells were incubated in increasing concentrations of 1-100µg/ml 
cisplatin in the presence and absence of 1mM CaCl2 for a duration of 72 hours. Cell 
proliferation was analysed by WST-1 assay. IC50 values were then determined by plotting the 
cell inhibition rate with the corresponding drug concentration on a dose-response curve. 
OVCAR-4 cells were more susceptible to cisplatin than ID8-luc2 cells. Results are 
representative of the average percentages of ± SD of triplicate independent cell proliferation 
experiments relative to cells incubated in the absence of cisplatin. Results are representative 
of the average percentages of ± SD of triplicate independent experiments relative to untreated 
and 0.05% DMSO treated controls. Bars are presented as mean ± SD (n = 3). **** p ≤ 0.0001. 
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5.3.3.1.4 Exploring the utility of PADI2 as a potential biomarker in EOC 
After assessing cisplatin drug efficacy in wild type OVCAR-4 and ID8-Luc2 cells, as explained in 
the results section above (5.3.3.1.3), cisplatin was then used as a positive control to assess the 
utility of PADI2 as a potential biomarker and therapeutic target in EOC. To do so, wild type 
OVCAR-4 and ID8-Luc2 cells were transiently transfected with PADI2 overexpression vector 
and control empty vector. At 96 hours post-transfection and enrichment, PADI2 
overexpressing OVCAR-4 and ID8-Luc2 cells were incubated in 1mM CaCl2 and increasing 
cisplatin concentrations of 1-100µg/ml for the duration of 72 hours. Cell proliferation was then 
determined using a WST-1 assay. Cisplatin treatment significantly reduced cell proliferation in 
PADI2-overexpressing OVCAR-4 and ID8-Luc2 cells (Figure 5.11 and Figure 5.12).  
However, the addition of 1mM CaCl2, significantly reduced the cisplatin drug efficacy in 
OVCAR-4 cells, only for the first 48 hours of incubation. This CaCl2-induced reduction in 
cisplatin cytotoxicity subsequently increased cell proliferation significantly in both control and 
PADI2 overexpressing cells at 24 and 48 hours. Cisplatin cytotoxicity was recovered at 72 hours 
in PADI2 overexpressing cells, and proliferation percentages were consistent with those 
treated with cisplatin without 1mM CaCl2. Thus, PADI2 overexpression significantly increased 
cisplatin cytotoxicity in a Ca2+-dependent manner in OVCAR-4 cells (incubated with 1mM 
CaCl2, Figure 5.11). Conversely, in ID8-Luc2 cells, PADI2 overexpression significantly reduced 
cisplatin cytotoxicity, independently of e[Ca2+] treatment. The addition of 1mM CaCl2 did not 
have any effect on ID8-Luc2-cisplatin sensitivity. Thus, PADI2 overexpression significantly 
reduced cisplatin cytotoxicity in ID8-Luc2 cells, independently of e[Ca2+] treatment, at all 
incubation times (Figure 5.11).  
To better illustrate the effect of PADI2 on cisplatin cytotoxicity in OVCAR-4 and ID8-Luc2 cells, 
the proliferation data obtained by measuring the impact of PADI2 overexpression on optimal 
IC50 values of cisplatin (50µg/ml) and CaCl2 (1mM) were demonstrated in a bar graph (Figure 
5.12). In OVCAR-4, PADI2 overexpression relatively decreased cell proliferation by 21% and 
22% in a Ca2+-dependent manner at 48 and 72 hours, respectively. Also, cisplatin cytotoxicity 
was significantly increased by 10% in PADI2 overexpressing OVCAR-4 cells (relative to control) 
in a Ca2+-dependent manner at 72 hours (Figure 5.12). Conversely, in ID8-Luc2, PADI2 
overexpression relatively increased cell proliferation by 20%, independently of e[Ca2+] 
treatment, at 72 hours. Also, cisplatin cytotoxicity was significantly reduced by 21% and 24% 
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in PADI2 overexpressing OVCAR-4 cells (relative to control) in a Ca2+-dependent manner at 48 
and 72 hours, respectively (Figure 5.12). 
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Figure 5.11. The effect of PADI2 overexpression on cisplatin cytotoxicity in EOC cells 
incubated with 1mM CaCl2. Cell proliferation was analysed by WST-1 assay. OVCAR-4 and ID8-
Luc2 cells were transiently transfected with a control empty vector and PADI2 overexpression 
vector. At 96 hours post transfection and enrichment, cells were treated with various 
concentrations of 1-100µg/ml cisplatin in the presence or absence of 1mM CaCl2 for total of 
72 hours. The addition of 1mM CaCl2 subsequently reduced cisplatin cytotoxicity in wild type, 
control empty vector and PADI2 overexpressing OVCAR-4 cells. Cisplatin cytotoxicity was not 
affected by the addition of 1mM CaCl2 in wild type, control empty vector and PADI2 
overexpressing ID8-Luc2 cells. Results are representative of the average percentages of ± SD 
of triplicate independent experiments relative to the untreated and 0.05% DMSO treated 
controls. Bars are presented as mean ± SD (n = 3).  
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Figure 5.12. The effect of PADI2 overexpression on the cytotoxicity of 50µg/ml cisplatin in 
EOC cells incubated with 1mM CaCl2. Cell proliferation was analysed by WST-1 assay. OVCAR-
4 and ID8-Luc2 cells were transiently transfected with control empty vector and PADI2 
overexpression vector. At 96 hours post transfection and enrichment, cells were treated with 
50µg/ml cisplatin in the presence and absence of 1mM CaCl2 for total of 72 hours. Results are 
representative of the average percentages of ± SD of triplicate independent experiments 
relative to the untreated and 0.05% DMSO treated controls. Bars are presented as mean ± SD 
(n = 3). ***p ≤ 0.001; ****p ≤ 0.0001. 
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5.3.4 The effect of PADI2 overexpression on OVCAR-4 cell apoptosis 
Since the proliferation data showed that PADI2 overexpression reduced cell proliferation and 
increased cisplatin cytotoxicity in OVCAR-4 cells in a Ca2+-dependent manner. Thereafter, the 
effect of PADI2 overexpression was furthermore explored in other cellular activities, including 
cell apoptosis. This was achieved by incubating PADI2 overexpressing OVCAR-4 cells (after 96 
hours post-transfection and enrichment) with 1mM CaCl2, 50µg/ml cisplatin, 50µg/ml cisplatin 
with 1mM CaCl2, 50µg/ml cisplatin with 2mM CaCl2 for 48 and 72 hours. Interestingly, it was 
shown that PADI2 overexpression significantly induced cell apoptosis by 20% and 34% (relative 
to control), in a Ca2+-dependent manner, at 48 and 72 hours, respectively. These results 
further validated the ones obtained from proliferation data. However, unlike the previous 
observation in proliferation data, there was no significant increase in cisplatin-induced 
apoptosis in PADI2-overexpressing cells irrespective of 1mM CaCl2 treatment, there was no 
difference relative to control (Figure 5.13). 
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Figure 5.13. The effect of PADI2 overexpression on cisplatin-induced apoptosis in OVCAR-4 
incubated with 1mM CaCl2. Cell apoptosis was measured by apoptosis detection kit. OVCAR-
4 cells were transiently transfected with a control empty vector and PADI2 overexpression 
vector. At 96 hours post transfection and enrichment, cells were incubated with 1mM CaCl2 
and cisplatin 50μg/ml in the presence and absence of CaCl2 1mM or 2mM for total of 72 hours. 
Results are representative of the average percentages of ± SD of triplicate independent cell 
proliferation experiments relative to the untreated and 0.05% DMSO treated controls. Bars 
are presented as mean ± SD (n = 3), **p ≤ 0.01; ****p ≤ 0.0001.  
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5.3.5 The effect of PADI2 overexpression on autophagy and necrosis in OVCAR-4 cells 
To further confirm previous observations from proliferation and apoptosis data, cell 
autophagy and necrosis were also investigated in OVCAR-4. OVCAR-4 wild type cells were 
transiently transfected with PADI2 overexpression vector and control empty vector. At 96 
hours post-transfection and enrichment, cells were then incubated with increasing 
concentrations of CaCl2 (1-3mM) for 48 and 72 hours. Chloroquine and Earle's balanced salt 
solution (EBSS) were used as positive control treatments in this experiment. EBSS is an 
autophagy inducer, and chloroquine is a autophagy inhibitor. Consistent with the cell 
proliferation and apoptosis data, PADI2 overexpression significantly increased cell autophagy 
by 26%, 34%, 33% (relative to control), in OVCAR-4 cells treated with 1mM, 2mM and 3mM 
CaCl2, respectively, at 48 hours. Likewise, at 72 hours, PADI2 overexpression significantly 
increased cell autophagy by 38%, 24%, 18% (relative to control), in OVCAR-4 cells treated with 
1mM, 2mM and 3mM CaCl2, respectively (Figure 5.14a). Whereas, in cell necrosis analysis, 
PADI2 overexpressing cells showed a marked increase in necrotic death upon 3mM CaCl2 
treatment relative to control (Figure 5.14b). 
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Figure 5.14. The effect of PADI2 overexpression on autophagy and necrosis in OVCAR-4 cells 
incubated with increasing concentrations of CaCl2. OVCAR-4 cells were transiently 
transfected with PADI2 overexpression vector and control empty vector. At 96 hours post-
transfection and enrichment, cells were incubated in increasing concentration of 1-3mM CaCl2 
for total a duration of 72 hours. Cells were also treated with autophagy positive controls; 
100µM chloroquine autophagy inhibitor and EBSS autophagy inducer positive control. (a) 
Represent autophagy results and (b) represent necrosis results. Results are representative of 
the average percentages of ± SD of triplicate independent cell proliferation experiments 
relative to the untreated and 0.05% DMSO treated controls. Bars are presented as mean ± SD 
(n = 3). * p ≤ 0.05, p ≤ 0.01, **** p ≤ 0.0001. EBSS, serum starved cell media. 
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5.3.6 The effect of PADI2 overexpression on OVCAR-4 cell aggregation 
It was previously shown that PADI2 modulates epithelial-mesenchymal plasticity in cancer by 
modulating intracellular interactions (Horibata et al., 2017). Since 3D cell cultures also exhibit 
intracellular junctions that are similar to the in vivo states compared to classic monolayer 
cultures. Therefore, 3D cultures did provide suitable system to explore whether PADI2 
overexpression may affect cell adhesion in EOC. Following transfection and enrichment, the 
hanging drop protocol was used to aggregate OVCAR-4 cells. Once assembled, cell aggregates 
were incubated for further 72 hours with or without 1mM CaCl2. Spheroid morphological 
differences were also observed using inverted microscope. The spheroids in wild type and 
control cells did not increase in size but progressively compacted (as observed with inverted 
microscope) in the presence 1mM CaCl2. When compared to control cells, the diameter area 
of PADI2 overexpressing OVCAR-4 spheroids significantly decreased by 94% in the presence 
of 1mM CaCl2 (Figure 5.16a). More interestingly, even when OVCAR-4 cells were not incubated 
in 1mM CaCl2, PADI2 overexpressing cells demonstrated less organised and more dispersed 
aggregate structures (Figure 5.16b). 
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Figure 5.16. PADI2 disrupts aggregate formation in OVCAR-4 treated with 1mM CaCl2. 
OVCAR-4 cells were transiently transfected with PADI2 overexpression vector and control 
empty vector. At 96 hours post-transfection and enrichment, cellular aggregates were initially 
cultured using hanging drop protocol. Once assembled, cell aggregates were further incubated 
in the presence and absence of 1mM CaCl2. (a) Spheroid structures diameter and density were 
analysed using ImageJ. (b) Spheroid morphological differences observed using inverted 
microscope. Results are representative of the average percentages of ± SD of triplicate 
independent cell proliferation experiments relative to the untreated and 0.05% DMSO treated 
controls. Bars are presented as mean ± SD (n = 3). ****p ≤ 0.0001.  
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5.4 DISCUSSION 
 
 
5.4.1 Endogenous PADI2 expression in EOC cell lines 
PADI2 deregulation was shown to be an early event in the development of cancer (Cantarino 
et al., 2016). Previous findings suggest that PADI2 can serve as a biomarker or independent 
predictor of breast cancer (Wang et al., 2016; McElwee et al., 2012). Although PADI2 was 
deregulated in many cancers, the role of PADI2 in the pathogenesis of EOC was not explored 
previously (McElwee et al., 2014; McElwee et al., 2012; Wang et al., 2017; Funayama et al., 
2017). Hence, the aim of this research was to examine whether PADI2 plays a role in EOC 
tumorigenesis. Initially, endogenous PADI2 was assessed to establish the protein expression 
levels, thereafter, the downstream investigations were planned accordingly. All the EOC cell 
lines examined in the current study showed minimal to no PADI2 mRNA expression and its 
protein was not detected in any cell line. The reason for this observation is unclear; however, 
it is important to report that most of the cell lines used in this study were pre-defined as HGS 
(except for TOV-112D and ID8-Luc2 cell lines). Well-defined EOC histological and molecular 
subtypes are characterised by a consistent pattern of expression of specific genes, such as 
biomarkers and oncogenes, that commonly correlate with subtype differentiation (Köbel et 
al., 2008). Notably, while some gene expression/mutation strongly correlate with one 
subtype, but their prevalence may not be detected in other disease subtypes. For example, 
the aberrant p53 expression induced by a TP53 mutation is one of the most frequent genetic 
alternations characterising around 90% of HGS (Na et al., 2017). This p53 aberrant expression 
was rarely detected in other EOC subtypes (Kurman and Shih, 2016). PADI2 expression may 
be detected in specific cell subtypes of EOC, such as clear cell, mucinous, LGS, and 
undifferentiated. A future validation of this work would include EOC cell lines representing 
different disease subtypes and determine whether PADI2 expression is detected in other 
subtypes. Since high PADI2 expression was shown to associate with decreased proliferation 
and increased apoptosis of EOC human OVCAR-4 cells. This finding combined with the fact 
that endogenous PADI2 was not detected in any of the EOC cell lines tested in this study, 
suggests the absence of PADI2 expression in these cell lines, could be one of the underlying 
causes of cancer development. 
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5.4.2 The effect of e[Ca2+] treatment on PADI2-mediated citrullination in EOC cells 
5.4.2.1 e[Ca2+] treatment induced PADI2-mediated citrullination in OVCAR-4 cells 
Previous studies reported that PADI2 expression levels correlates with citrullination events in 
cancer cells, indicating a possible role of PADI2-meidated citrullination in cancer (Cantarino et 
al., 2016). PADI2 is thought to exist in an “inactive” form under insufficient i[Ca2+] levels. 
Recently, Slade et al., (2015) used x-ray crystallography diffraction method and determined 
that PADI2 enzyme is activated by relatively high Ca2+ concentrations between 1-10mM. This 
regulatory method is yet to be confirmed in vitro studies. One of the aims of this chapter was 
to examine the implications of increasing e[Ca2+] on PADI2 activity and furthermore explore 
whether Ca2+-PADI2 activation affects the overall citrullination and downstream cellular 
activity in EOC cell lines. After overexpressing PADI2 in EOC cells, citrullinated proteins were 
only detected in OVCAR-4 cells cultured with 1mM CaCl2. These observations confirm previous 
findings by Slade et al., (2015); that high Ca2+ concentration (≥1mM) may be required for 
activating PADI2-mediated citrullination. In line with these findings, Vossenaar, (2004) found 
that vimentin, a known PADI2 target in RA, is specifically citrullinated after Ca2+-influx in 
macrophages, which are abundant in the inflamed RA synovium (Lewallen et al., 2014). Others 
also reported that all PADI isozymes generally require Ca2+ concentrations around 0.2-0.5mM 
for half-maximal activity and 2-2.5mM for full enzymatic activity (Kearney et al., 2005; Arita et 
al., 2004; Damgaard et al., 2014). However, the cytosolic and nucleoplasmic Ca2+ 
concentrations existing under normal physiological conditions are lower than the 
concentrations required for PADI activity. The highest noted e[Ca2+] concentration in plasma 
was estimated to be 1.1-1.3mM (Darrah et al., 2013). Moreover, the highest i[Ca2+] 
concentration achieved by primary human cells does not exceed 100μM and higher i[Ca2+] 
concentrations are observed in cells undergoing apoptosis (Vossenaar, 2004; Darrah et al., 
2013). PADI2-meditaed citrullination possibly requires a high concentration of both, i[Ca2+] 
and e[Ca2+]. However, the i[Ca2+] levels were not measured in this study. Therefore, additional 
future work might be required to determine whether the addition of e[Ca2+] and possibly 
subsequent increase in i[Ca2+] concentrations, is responsible for PADI2 activation and 
subsequent citrullination. This can be achieved by using the Ca2+ indicator dye Fura-2 AM, a 
poly-amino carboxylic acid that binds to free i[Ca2+] and is excited at 340 nm and 380 nm 
(Gahete et al., 2012).  
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5.4.2.2 Citrullination was not detected in ID8-Luc2 cells 
In contrast to OVCAR-4, Ca2+ treatment did not induce citrullination in PADI2 overexpressing 
ID8-Luc2 cells. Indeed, PADI2 overexpression was confirmed in ID8-Luc2; however, 
citrullination was not detected. The inconsistency of outcomes between both PADI2 
overexpressing OVCAR-4 and ID8-Luc2 cell lines may be as a result of several contributing 
factors. It may be indicative of subsequent outcome of cell heterogeneity. Each of the cell 
lines; OVCAR-4 and ID8-Luc2, represent different EOC disease subtype; serous EOC and 
undefined subtype, respectively. This heterogeneity complicates the understanding of the 
underlying PADI2-regulating mechanisms, but provides the ability to capture EOC 
heterogeneity based on the activity of PADI2 and its associated regulatory pathways (Huang 
et al., 2003).  
While the basics of cell culture experiments share certain similarities, cell culture conditions 
vary widely for each cell type (Yao and Asayama, 2017). Different culture conditions, including 
growth medium, FBS% and other cell growth requirement, are often cell type-specific and can 
contribute to different phenotypes being expressed (Neumann et al., 2010). For example, the 
cell lines used in this study were cultured in different growth medium; OVCAR-4 cells were 
cultured in RPMI, whereas, ID8-Luc2 cells were cultured in DMEM growth media containing 
insulin. It was previously shown that insulin protects pancreatic acinar cells from stress-
induced cytosolic Ca2+-influx or overload, thereby, avoiding mitochondrial dysfunction and 
apoptosis (Lanner et al., 2006). Similarly, the insulin present in DMEM growth media may 
inhibit or delay Ca2+ influx by hindering the function of calcium chelators, thereby, reducing 
Ca2+ entry into ID8-Luc2 cells. Due to the low i[Ca2+] levels in ID8-Luc2, PADI2 enzyme remain 
inactive and therefore no citrullination was detected.  
Other environmental factors, such as cell culture passaging, can alter the gene expression 
pattern and proliferation rate of cell lines (Neumann et al., 2010). For example, in contrast to 
rapidly proliferating ID8-Luc2 cells, OVCAR-4 are slow to moderately proliferating cell 
populations, which show a constant pheno- and/or genotype for prolonged cultivation 
periods. Extended cultivation of OVCAR-4 cells, may alter their in vivo phenotype. Therefore, 
only limited amounts of OVCAR-4 cells were collected, and low quantities of mRNA were 
obtained for molecular analysis. As a result, OVCAR-4 cells were regularly grown over several 
passages to obtain sufficient cellular material to carry out the required experiments 
(Neumann et al., 2010). In this situation, it is increasingly difficult to determine whether the 
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cell population after a prolonged cultivation period still harbours the identical gene profile 
detected in HGS EOC population shortly after isolation from the tissue (Neumann et al., 2010; 
Marques et al., 2017). Furthermore, passaging may result in a selection pressure for parts of 
the cell population in cell lines. For example, ID8-Luc2 are less adherent, therefore, a part of 
the cell population was removed from the culture flask during passaging steps prior to 
collection and that may alter the overall gene expression profile in higher passages compared 
to earlier passages. 
 
5.4.3 The effect of PADI2 overexpression and increasing e[Ca2+] on EOC cellular activity 
Previous studies on PADI2 mainly focused on its role in disease by evaluating the subsequent 
effects of increasing or decreasing its expression. These studies led to the identification of 
possible targets for PADI2, including apoptotic or cell migration-related and chromatin 
associated proteins (Sharma et al., 2019; Horibata et al., 2017; Falcão et al., 2018). However, 
the precise mechanisms regulating PADI2 activation and underlying interactions in cancer 
remain unclear. It was previously established that PADI isozyme require high Ca2+ levels to 
retain proper enzymatic activity (Zhou et al., 2018). However, this Ca2+-dependent activation 
of PADI2 was not previously explored in vitro or in EOC. Since Ca2+ is also a key regulator of 
several cellular processes, and the disruption of i[Ca2+]  homeostasis is involved in cancer 
(Giorgi et al., 2012; Sun et al., 2016). Therefore, the effect of increasing Ca2+ was initially 
evaluated and IC50 values were determined. Followed by the assessment of the subsequent 
effect of increasing Ca2+ concentration on PADI2 activity and the downstream cellular activity 
in EOC cell lines. One of the aims of this chapter was to investigate whether the increase of 
PADI2 activity possibly by Ca2+, may affect cell proliferation, aggregation, apoptosis, 
autophagy, necrosis and aggregation. 
 
5.4.3.1 The effect of PADI2 overexpression on cisplatin-induced cytotoxicity and EOC cell 
proliferation 
The vast majority of previous and current studies frequently evaluated the cytotoxicity and 
inhibitory effect of potential biomarkers or oncogenes with commonly used 
chemotherapeutic drugs (e.g. cisplatin). Evaluating the utility of a novel biomarker will help 
identify reliable biomarkers that can be used in a clinical context. As previously mentioned, 
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(introduction chapter 1.6), cisplatin is the most commonly used chemotherapeutic treatment 
for EOC patients, therefore, it was used as a positive control in this study, to assess the utility 
of PADI2 as a potential biomarker in EOC.  
 
5.4.3.1.1 PADI2 reduced proliferation and increased cisplatin cytotoxicity in OVCAR-4 cells 
The present study demonstrated that PADI2 overexpression significantly decreased OVCAR-4 
cell proliferation only when treated with ≥1mM Ca2+. The gradual decrease in cell proliferation 
was observed in a time- and dose-dependent manner. In addition, Ca2+-induced PADI2 activity 
significantly enhanced OVCAR-4-cisplatin cytotoxicity at 72 hours. Given that the proliferation 
experiments were carried out over a total incubation period of 72 hours, longer incubation 
times might be required to definitively confirm whether PADI2 activity is associated with 
increased cisplatin cytotoxicity in EOC cells. Collectively, these results suggest that PADI2 
overexpression in OVCAR-4 may reduce the proliferative activity of EOC cells only when 
accompanied with high Ca2+ levels. Interestingly, other studies reached similar conclusions; 
however, they examined the role of PADI2 in cancer without including exogenous Ca2+ 
treatment (Cantarino et al., 2016; Funayama et al., 2017). 
 
5.4.3.1.2 PADI2 decreased cisplatin cytotoxicity in ID8-Luc2 cells  
The overexpression of PADI2 in ID8-Luc2 cells incubated with increasing concentrations of 
e[Ca2+], generated discrepant conclusions. There was a general inconsistency of cellular 
behaviour in response to increasing e[Ca2+] in PADI2 expressing ID8-Luc2 cells. For example, 
the cell proliferation measured in PADI2 overexpressing ID8-Luc2 increased for the first 24 
hours of incubation, while at 72 hours, opposite results existed. This Ca2+- and PADI2 
overexpression-induced discrepancy in ID8-Luc2 cell proliferation patterns resulted in 
inconclusive results. In addition, PADI2 overexpression significantly reduced cisplatin 
cytotoxicity in ID8-Luc2 cells, independently of exogenous Ca2+ treatment or induced 
citrullination. Collectively, these results suggest that PADI2 activity may be regulated by other 
mechanisms in ID8-Luc2 cells, that do not include Ca2+ or citrullination. 
When comparing both cell lines, in OVCAR-4, increasing e[Ca2+] and possibly activating PADI2 
in a Ca2+-dependent manner, subsequently decreased the cell proliferation, possibly through 
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citrullination. However, the effect of PADI2 overexpression and activity on ID8-Luc2 is 
controversial and remains undetermined. The discrepancy between both cell lines in response 
to PADI2 overexpression suggests that there may be undiscovered factors that can modulate 
PADI2 activity in EOC. In addition, PADI2 may exert its different roles through epigenetic 
mechanisms or may be responsible for regulating other PTMs-associated downstream 
pathways in EOC. These results also show that PADI2 behaves differently in different cancer 
subtypes, suggesting a subtype-specific role. Since the human-derived OVCAR-4 and mouse-
derived ID8-Luc2 cell lines used in this study represent different histological and molecular 
EOC subtypes as well as different organisms, therefore, each cell line may exhibit different 
molecular as well as clinical parameters (Hernandez et al., 2016; Rojas et al., 2016; Lengyel et 
al., 2014; Mitra et al., 2015). OVCAR-4 represents HGS EOC and these cells were retrieved 
from platinum-refractory patients (Lengyel et al., 2014; Hernandez et al., 2016). Whereas, ID8-
Luc2 is presented in most research as EOC subtype (no specific subtypes, Mitra et al., 2015). 
Each subtype is represented by a distinct genomic, transcriptomic changes and signalling 
pathways, that reflect on the intratumor heterogeneity (Rojas et al., 2016). This heterogeneity 
may define the unique cellular environment specific for a particular cancer type, in which 
PADI2 exerts its cell-specific role in cellular activity (Wang et al., 2017). Therefore, the 
mechanisms regulating PADI2 expression and activation possibly through increasing 
e[Ca2+]/i[Ca2+], require a thorough investigation. The distinction of cell line models may also 
allow the assessment of therapeutic efficacy in a context that would include intratumor 
heterogeneity.  
Differences in tumour biology between mouse and human cancers are also evident with 
regard to the tumour type spectrums within the same cancer gene-orthologues mutations 
(Zhang et al., 2013) . Around 99% of mouse genes have a homolog in the human genome, and 
for 80% of these genes, this homology is mostly found in the conserved syntenic interval of 
the mouse gene orthologues (Guénet, 2005). For instance, human p53 mutations result 
predominantly in some sarcomas and carcinomas, whereas mutations in mouse p53 result in 
multiple lymphomas and sarcomas (Jacks et al., 1994; Zhang et al., 2013). It is commonly found 
that the mouse genome harbours genes that are orthologues to human genes but variable in 
terms of copy number (Guénet, 2005). Therefore, a genetically engineered cancer mouse 
model may recapitulate many, but not all, aspects of human cancers. Since the mouse is a 
different organism, PADI2 activation in mouse-derived cell lines may be regulated by other 
mechanisms distinct from the ones present in human cell lines.  
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5.4.3.3 PADI2 induced autophagy and apoptosis in OVCAR-4 cells in a Ca2+- and citrullination-
dependent manner  
It was suggested earlier in this research that PADI2 overexpression in OVCAR-4 resulted in the 
reduction of cell proliferation in a Ca2+- and citrullination-dependent manner. Similar to the 
proliferation data, the overexpression of PADI2 in OVCAR-4 cell, increased autophagy and 
apoptosis in a Ca2+-dependent manner. The factors modulating PADI2-induced autophagy and 
apoptosis are possibly initiated by similar mechanism as described before for proliferation and 
could be linked to increased i[Ca2+] influx/overload thereby, inducing PADI2-mediated 
increase in OVCAR-4 cells autophagy and apoptosis. It was previously established that 
targeting autophagic pathways inhibits the growth of HGS EOC cells and holds promise as a 
potential and novel therapeutic target (Zhan et al., 2016). The haploinsufficiency analysis HGS 
EOCs network implicates autophagy as a major disrupted pathway as a result of coincident 
gene deletions (Delaney et al., 2017). The activation of autophagy was also previously linked 
to PADIs co-activation during apoptosis-induced oxidative stress in gastrointestinal caners 
(Song and Yu, 2019). A more direct link between autophagy and PADI2 activity was provided 
by Liu and Lin, (2017), found that PADI2 triggers ER stress and induce autophagy in Jurkat T 
cells by downregulating the transcription of p62 and inducing the accumulation of autophagic-
related proteins, including LC3-II (microtubule-associated proteins 1A/1B light chain 3B), 
autophagy related 5 (ATG5) and autophagy related 12 (ATG12). Cell autophagy is also known 
to induce PADI2-mediated protein citrullination (e.g. vimentin) onto MHC-II cross-molecules 
and subsequent activation of CD4+ T-helper cells (Crotzer and Blum, 2009; Brentville et al., 
2016). Citrullinated proteins can drive apoptosis, promote autophagic processing, therefore, 
resulting in antigenic presentation by antigen presenting cells, subsequently inducing tumour 
inflammation. PADI-induced tumour inflammation and the subsequent antigenic presentation 
was shown to  induce CD4+/CD8+-mediated tumour clearance in melanoma and lung cancer 
models (Moaaz and Lotfy, 2017; Valesini et al., 2015). Collectively, these findings suggest that 
modulating cell apoptosis and autophagy could be another way by which PADI2 regulates 
controlled and Ca2+-dependent cell death in OVCAR-4 cells. These findings also clearly 
represent a variety of potential pathways by which PADI2 regulates its downstream effect on 
cellular activity; however, the underlying mechanisms remain elusive and may involve 
citrullination-dependent pathways.  
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5.4.3.4 PADI2 did not induce necrosis in OVCAR-4 cells 
In contrast to the proliferation, autophagy and apoptosis, PADI2 overexpression in OVCAR-4 
did induce cell necrosis only in response to e[Ca2+] concentrations higher than ≥3mM. 
Exposing cells to higher e[Ca2+] concentrations than the those observed under physiological 
conditions, led to a relatively significant increase in cell necrosis only at 48 hours.  
 
5.4.3.5 PADI2 role in cell adhesion and aggregation 
The interaction of cell-cell and cell-ECM adhesion play a significant role in cancer cell adhesion, 
aggregation and migration (Arcangeli et al., 2014; Turel and Rao, 1998; Zhong and Rescorla, 
2012). Alterations in cell-cell adhesion receptors, such as cadherins, integrins and cell surface 
proteoglycans, contribute to cancer progression and metastasis (Rosso et al., 2017). In EOC, 
the deregulation of cell adhesion molecules, including cadherin switching during EMT, loss or 
induction of adhesion molecules, mesenchymal markers (e.g. E-cadherin), ß1 integrins and 
proteoglycans (e.g. Collagen II) were found to induce aggregation of EOC cells (Liao et al., 
2014; Powan et al., 2017; Fernández, 2011; Casey et al., 2001). The current study shows that 
overexpressing PADI2 in OVCAR-4 cells impaired the formation of EOC aggregates 
independently of e[Ca2+] supplementation and resulted in more dispersed aggregated cell 
colonies. Interestingly, exposing PADI2 overexpressing OVCAR-4 cells to high e[Ca2+] (1mM 
CaCl2), disrupted the aggregate establishment entirely. Similar results were reported by 
Yuzhalin et al., (2018) and Song and Yu, (2019), who found that increased PADIs-mediated 
citrullination resulted in the downregulation of E-cadherin and concurrently disrupted cell 
aggregation and impaired metastatic growth in gastrointestinal cancers. Collectively, these 
findings provide evidence that PADI2 disrupts the formation of cancer cell aggregates, by 
modulating the expression of key cell-adhesion molecules involved in this process, possibly 
through citrullinating adhesion molecules, such as E-cadherin.  
The dissociation of cell aggregates in vivo, increases cancer cell susceptibility to cancer 
therapeutic treatments, including chemotherapy and radiotherapy (Weiswald et al., 2015). 
The PADI2-mediated dissociation of EOC aggregates in vivo can lead to successful efforts of 
sensitising EOC cells to chemotherapeutic treatment, thereby, inducing cancer cell apoptosis. 
Thus, the detection of PADI2 expression patterns can be used as a prognostic indicator or 
predictor of chemotherapeutic outcome in EOC patients. For example, the detection of high 
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PADI2 expression in an EOC patient sample, may indicate successful chemotherapeutic 
outcome. In addition, future advancement, such as gene therapy, can be utilised to produce 
patient tailored therapy, by inducing PADI2 expression in EOC patients as a priming step to 
disrupt cell aggregates, subsequently sensitising drug-resistant EOC subtypes to 
chemotherapeutic treatment.  
 
5.5 CONCLUSIONS  
 
In conclusion, the present study presents evidence, using the human-derived OVCAR-4 EOC 
cell line, that PADI2 is a crucial physiological Ca2+-dependent modulator in human EOC, and its 
overexpression contributes to lower cell proliferation and aggregation and increased 
autophagy and apoptosis, through protein citrullination. The overexpression of PADI2 
expression also increases cisplatin cytotoxicity in OVCAR-4 cells. Conversely, the PADI2 
overexpression of decreased cisplatin cytotoxicity in the mouse-derived ID8-Luc2 cells. 
Overall, the results presented in this chapter can serve as a guide to select appropriate cell 
lines representing different histological and molecular subtype of EOC for future in vitro 
patient tailored therapeutic studies in EOC. This study potentially had intrinsic methodology 
limitations. PADI2 overexpression and downstream functional studies were carried in out two 
cell line models, each representing a different organism (human and mouse). The molecular 
mechanisms regulating PADI2 and its subsequent mediated functional activity in one cell line 
may not be completely similar to the mechanisms observed in another cell line.  
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CHAPTER 6: Targeted mutagenesis of the PADI2 locus using CRISPR/Cas9 genome editing  
 
6.1 INTRODUCTION 
 
Genome-editing technology is widely used for DNA engineering to inactivate or modify specific 
genes in functional studies and therapeutic intervention techniques (Sánchez-Rivera and 
Jacks, 2015). The application of such tools has a significant impact on the understanding of the 
genetic basis behind various cancers (Kannan and Ventura, 2015). Cancer development is a 
multistep process triggered by germline and somatic mutations (Hanahan and Weinberg, 
2000). The recently developed clustered regularly interspaced short palindromic repeats 
(CRISPR)-associated proteins (CRISPR/Cas9) system provides a robust and multiplexable 
genome editing tool, that enables more precise genomic editing and facilitates the elucidation 
of target gene function in cancer biology (Chen et al., 2016). The CRISPR/Cas system is 
endogenously found in a variety of bacterial species with acquired adaptive immune systems 
and serve as a defence mechanism against invading viruses (Rath et al., 2015; Chylinski et al., 
2014). This defence mechanism relies on RNA-guided recognition and cleavage of invasive 
viral and plasmid DNA (Rath et al., 2015). The CRISPR part of the system functions as an 
“immune memory” which stores the unique viral DNA sequence in-between sections of 
regularly interspaced palindromic repeated segments. The CRISPR-associated proteins (Cas) 
part of the system catalyses site-specific cleavage of the targeted DNA sequences of invading 
viruses. Single guide RNA (sgRNA) in the CRISPR/Cas9 system, is used to guide the Cas9 
nuclease to the target genomic site containing the protospacer adjacent motif (PAM) 
sequence, NGG, located at the 5’- end of the target sequence (Dabrowska et al., 2018). 
Modified variants of this system have been used for genome editing applications in various 
organisms. Cas9-induced double-strand breaks (DSBs) at ∼3bp upstream from PAM are mainly 
repaired by error-prone non-homologous end joining (NHEJ), resulting in random indel 
mutations (e.g. insertion/deletion) and consequent premature translation termination and 
transcript degradation (Jiang and Doudna, 2017). Alternatively, the homology-directed repair 
(HDR) mechanism can repair the DSB precisely using a homologous repair template (Jiang and 
Doudna, 2017; Wang et al., 2016). Mutations generated by the CRISPR/Cas9 system can be 
characterised by sequencing amplicons comprising the complete target site. Next generation 
sequencing (NGS) and Sanger sequencing are commonly used approaches to analyse bulk 
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amplicon mixture or individual cloned fragments (Zischewski et al., 2017). Recently, 
CRISPR/Cas9 system has been modified into diverse innovative tools for targeting a large-scale 
cancer driver genes and oncogenes (Xiao et al., 2018). More recently, the CRISPR/Cas9 system 
has been utilised to engineer immune cells for cancer immunotherapy, such as chimeric 
antigen receptor T (CART) cells (Wu and Cao, 2019; Fan et al., 2018).  
In this study, the CRISPR/Cas9 tool was used to disrupt the PADI2 locus in SKOV-3 and ID8-
Luc2 cell lines. The Cas9 endonuclease was targeted to exons 1 and 7 using sgRNA sequences 
specific to the PADI2 locus. Thereafter, DNA was specifically cleaved at ∼3-bp                                                                                                                                                                                                                            
upstream of PAM to induce DSBs that will be potentially repaired by NHEJ, subsequently 
resulting in indels. The genomic cleavage assay and Sanger sequencing approaches were then 
utilised to determine whether CRISPR/Cas9 targeted mutagenesis of the PADI2 locus was 
successful. 
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6.2 AIMS AND OBJECTIVES 
 
The aim of this chapter was to knockout PADI2 in human SKOV-3 and mouse ID8-Luc2 EOC cell 
lines, using CRISPR/Cas9 system.  
 
1. Design sgRNAs that target PADI2 locus in both human and mouse genomes. 
 
2. Transfect CRISPR/Cas9-sgRNA complex constructs into the mouse ID8-Luc2 and human 
SKOV-3 cell lines to genetically delete PADI2 locus. 
 
3. Characterise the efficiency and specificity of CRISPR/Cas9-PADI2 knockout in EOC cells 
using cleavage assay and Sanger sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 143 
6.3 RESULTS 
 
6.3.1 Restriction digest analysis of CRISPR/Cas9 plasmids 
E. coli DH5-α cells were transformed with CRISPR/Cas9 sgRNA1 or CRISPR/Cas9 sgRNA 2 and 
spread onto LB ampicillin plates for selection of the transformed colonies. The growth of 
bacterial colonies was indicative of cells harbouring the plasmids. Plasmid DNA was then 
extracted and analysed using restriction enzyme digestion by SacI enzyme and resolved on 1% 
TAE Agarose (Figure 6.1). 
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Figure 6.1. Agarose gel electrophoresis analysis of the restriction enzyme digests fragments 
using SacI (a) CRISPR/Cas9 sgRNA1 and (b) CRISPR/Cas9 sgRNA2. Restriction digest product 
was resolved on 1% Agarose gel electrophoresis TAE. Bands 1 and 3 are visible at 6579bp and 
bands 2 and 4 are visible at 2598bp. Results are representative of three independent 
experiments. Lane M: DNA Hyperladder (1kb). 
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6.3.2 Flow cytometric analysis of CRISPR/Cas9 plasmids transfection efficiency in EOC cell 
lines  
CRISPR/Cas9 (pX459) sgRNA1 or sgRNA2 plasmids were co-transfected with a fluorescent GFP- 
containing plasmid (pCMV-GFP) into SKOV-3 and ID8-Luc2 cell lines. To thoroughly investigate 
the efficiency of CRISPR/Cas9 plasmid transfection and systematically optimise experimental 
parameters, plasmid DNA (sgRNA plasmid and GFP plasmid) was transfected at different ratios 
(1:1, 4:1 and 3:2,) to give a total of 5µg of plasmid DNA. After incubation for 48 hours, cells 
were then trypsinised and re-suspended in PBS/10% FCS. Transfection efficiency was then 
assessed by measuring the intracellular GFP expression using flow cytometry. The flow 
cytometric data collected was analysed using Flowing software to determine the transfection 
efficiency of plasmids in cells. In the analysis, cellular debris were excluded by gating cells on 
the forward and side scatter (FSC linear and SSC log) parameters. When analysing co-
transfected cells, the background fluorescence intensity of mock-transfected (treated with 
Lipofectamine 3000) cells were subtracted to eliminate background fluorescence (Figure 
6.2a). The histograms produced by the Flowing software indicated the transfection efficiency 
(x-axis) percentages of control empty vector and PADI2 overexpression vector in SKOV-3 and 
ID8-Luc2 cell lines. The transfection efficiency of the both sgRNA1 and sgRNA2 plasmids co-
transfected ID8-Luc2 cells at 1:1 ratio, exhibited transfection efficiencies of 39.81% and 
48.07%, respectively. While, the transfection efficiencies of sgRNA1 detected in SKOV-3 were 
41.1%, 55.1% and 48.6%, at 1:1, 3:1 and 4:1 ratios, respectively. The transfection efficiencies 
of sgRNA2 detected in SKOV-3 were; 40.7%, 57.7% and 54.9%, at 1:1, 3:1 and 4:1 ratios, 
respectively (Figure 6.2a and 6.2b). 
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Figure 6.2. Flow cytometry analysis of CRISPR/Cas9 transfection efficiency in SKOV3 and ID8-
Luc2 cell lines. A total amount of 5µg of plasmid DNA was co-transfected into cells at different 
ratios; 1:1, 4:1 and 3:2 in SKOV-3 and 1:1 in ID8-Luc2 of GFP (pCMV): CRISPR/Cas9 sgRNA1 or 
CRISPR/Cas9 sgRNA2 vectors, using Lipofectamine 3000. At 48 hours post-transfection, cells 
were re-suspended in PBS+10% FBS and analysed using flow cytometry. (a) Representative 
dot plots of side scatter and forward scatter displaying the gated events of viable cells (R-1) 
and non-viable cells (black). The flow cytometric histograms representing GFP fluorescent 
peak (H-2 marker) were used evaluate transfection efficiency percentages of Cas9 transfected 
cells relative to the control untreated cells (Lipofectamine 3000 treated). (b) Bar graph 
representation of plasmids transfection efficiency percentages in cell lines.  
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6.3.3 Enrichment of CRISPR/Cas9 transfected cell population using the mammalian selection 
antibiotic: puromycin 
To allow more accurate interpretation of the effects of CRISPR/Cas9-induced mutagenesis in 
PADI2 locus, optimal concentrations of the mammalian antibiotics, puromycin, for enrichment 
were determined. This was achieved by applying different antibiotic concentrations to non-
transfected cells for seven days. The cell viability percentage was then determined using 
trypan blue method (Figure 6.3a). On day two of enrichment, IC50 values were then 
determined by plotting the cell viability percentages on a semi-log-dose-response graph. 50% 
of the cell population died in SKOV-3 and ID8-Luc2 lines at Puromycin concentrations 
2.63µg/ml and 2.96µg/ml of in SKOV-3 and ID8-Luc2, respectively (Figure 6.3b). 
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Figure 6.3. The percentage of cell viability in SKOV3 and ID8-Luc2 cells after treatment with 
puromycin (1-5µg/ml). (a) Cells were incubated for total of seven days and cell viability was 
measured every 24 hours using 1% Trypan blue. Percentage viability values were represented 
in time-kill curves. (b) Puromycin Log-dose response curves were used to determine the IC50 
value at day two; 2.63µg/ml and 2.96µg/ml in SKOV-3 and ID8-Luc2, respectively. Results are 
representative of the average percentages of ± SD of duplicate independent experiments 
relative to the untreated controls. Bars are presented as mean ± SD (n = 3).  
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6.3.4 Gradient optimisation of sgRNA1 and sgRNA primers for PCR amplification 
CRISPR/Cas9 was used to induce mutations in exon 1 and 7 in the PADI2 locus of SKOV-3 and 
ID8-Luc2. The designed chimeric sgRNA sequences (20bp excluding PAM) containing a 
complementarity region to the PADI2 locus on the human and mouse genome were used to 
delete a segment of the genomic DNA (>100bp) up- stream of the targeted sequence. The 
targeted deletions guided by sgRNA and subsequent repair and generation of indels were then 
confirmed by PCR analysis using primers flanking the targeted regions. The sgRNA1 and 
sgRNA2 forward and reverse primer sets; A, B, C and D, were designed to generate a 400-
450bp DNA template including the sgRNA-guided deletion junction by PCR amplification 
(Figure 6.4). The designed primers optimal annealing temperatures (Ta) were determined 
using the gradient PCR program. The PCR products were then resolved by agarose gel 
electrophoresis (2%) which allowed the visualisation of specific amplicons corresponding to 
the expected band size (400-500bp). Based on these experiments, the optimal Ta selected for 
primers A, C and D was 63.8°C, and primer B Ta was selected at 55.8°C (Figure 6.5). 
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Figure 6.4 Schematic representation of sgRNA1 and sgRNA2 target sites and their 
corresponding designed primers in PADI2 locus DNA sequence including Ca2+ binding sites.  
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Figure 6.5. Agarose gel electrophoresis analysis of purified human and mouse genomic DNA 
amplified by PCR to determine the optimal annealing temperature of CRISPR/Cas9 sgRNA1 
and CRISPR/Cas9 sgRNA2 primers. This was achieved by setting gradient annealing 
temperatures between 55.8-63.8°C. Red boxes indicates the optimal annealing temperatures 
selected for further downstream analyses. The following cycling conditions were used: 
activation 95°C, 10 minutes, denaturation 95°C, 30 seconds, annealing 55.8°C -63.3°C, 30 
seconds, elongation 72°C, 30 seconds. PCR products were then resolved on 2% Agarose gel 
and the length of the expected band size was 400bp. M, Molecular weight marker (bp). 
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6.3.5 Detection of the sgRNA: CRISPR/Cas9- mediated cleavage of PADI2 locus by genomic 
cleavage assay 
After optimising PCR amplification conditions for the targeted region, sgRNA primers were 
then employed in the PCR-based GeneArt genomic cleavage detection assay to detect 
CRISPR/Cas9-mediated gene editing. At 96 hours post-transfection and enrichment, DNA 
corresponding to the edited region was amplified using previously optimised annealing 
conditions for sgRNA primer sets: A, B, C and D, along with the manufacturer’s pre-determined 
Ta for kit/control primers. This PCR amplicon was then denatured and re-annealed by heating 
and slow cooling steps. After CRISPR/Cas9 cleavage, if an aberrant NHEJ event has occurred, 
a heteroduplex will form between amplicons of different lengths (e.g., mutant and wild type 
amplicons), leading to a DNA distortion that is then recognised and cleaved by T7 
endonuclease 1 (T7E1); is a structure-selective enzyme that detects structural deformities 
(e.g. mismatched and ssDNA) in heteroduplexed DNA (Mashal et al., 1995, Figure 6.6a). The 
band patterns of the cleaved products are compared between non-transfected and 
CRISPR/Cas9 edited samples to determine the frequency of mutations. The cleaved products 
were then analysed by gel electrophoresis, the bands of full length and cleaved PCR products 
were visualized and used to evaluate editing efficiency and indel frequency (Sentmanat et al., 
2018; Wu et al., 2014). Based on the gel electrophoresis analysis, the detection enzyme 
mediated-cleavage of PCR product in CRISPR/Cas9-sgRNA1 transfected SKOV-3 cells displayed 
multiple cleaved PCR amplicons bands (each band represent an indel) indicating successful 
editing of PADI2 locus. The intensity of each band was then calculated (using Image J software 
and normalized to the non-transfected cells level) to determine the mutation or indel 
frequency in the edited population. The mutation frequency of each indel band; a, b and c, 
was measured to be 32.1%, 34.6% and 8.3%, respectively. Conversely, no indels were detected 
in SKOV-3 cells transfected with CRISPR/Cas9-sgRNA2. Cleaved PCR amplicons were not 
detected in ID8-Luc2 cells transfected with CRISPR/Cas9 sgRNA1 or CRISPR/Cas9 sgRNA2 
(Figure 6.6b). CRISPR/Cas9 sgRNA1-mediated mutagenesis in SKOV-3 PADI2 locus was further 
analysed by Sanger sequencing to confirm and quantify indel formation. 
  
  
 153 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 6.6. Agarose gel electrophoresis analysis of the extracted Genomic DNA from 
CRISPR/Cas9 sgRNA1 or sgRNA2 transfected SKOV-3 and ID8-Luc2. At 96 hours post-
transfection and enrichment, Genomic DNA was extracted from; CRISPR/Cas9 transfected 
polyclonal populations (+) and non-transfected cells (U). (a) The extracted DNA was then 
amplified by PCR using the optimised sgRNA1 and sgRNA2 primers. The PCR amplification 
conditions for kit/control primers were pre-determined by the manufacturer’s protocol (Ta: 
55oC). The previously optimised CRISPR-Cas sgRNA primer sets: A, B, C and D, were amplified 
using the optimal Ta selected. The following cycling conditions were used: activation 95°C, 10 
minutes, denaturation 95°C, 30 seconds, annealing 55.8°C or 63.3°C, 30 seconds, elongation 
72°C, 30 seconds. PCR products were then resolved on 2% Agarose gel and the expected band 
size was 400bp. (b) After re-annealing, samples were treated with and without the detection 
enzyme. Treated samples were then resolved on a 2% Agarose gel. CRISPR/Cas9 treated cell 
lines showing bands after digestion (indicated with red box) were selected and used for 
further experiments. The intensity of each band was then calculated using Image J to 
determine the indel frequency in the edited population; bands a, b and c represent a mutation 
frequency of 32.1%, 34.6% and 8.3%, respectively.; Kit control/Primers, Human and mouse 
purified genomic DNA (G), were used as control. M, Molecular weight marker (100bp or 1kb). 
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6.3.6 Sanger sequencing analysis of CRISPR/Cas9 sgRNA1-mediated mutagenesis in SKOV-3 
PADI2 locus 
Sanger sequencing was used to confirm the CRISPR/Cas9-sgRNA1-induced mutagenesis of the 
PADI2 locus and identify the indels generated by NHEJ cell repair system in polyclonal SKOV-3 
cell population. Sanger sequencing is a targeted sequencing technique that uses 
oligonucleotide primers to seek out specific DNA regions (Robin et al., 2018). Sanger 
sequencing was performed using the CRISPR/Cas9-sgRNA1 edited SKOV-3 PCR product 
generated in a similar manner as previously explained in section 6.3.4 and 6.3.5. Sanger 
sequencing products of the whole edited SKOV-3 cell population (containing non-homozygous 
edited events) were analysed using Synthego software-tracking of indels by decomposition 
(TIDE) to generate DNA trace chromatograms. TIDE decodes the mixed chromatogram signals 
from the edited polyclonal cell population to accurately determine the mutation frequency of 
each deletion and insertion size by comparing and decomposing Sanger traces (Brinkman et 
al., 2014). Sequence indels were detected by comparing the chromatogram peak heights 
between the DNA trace files of non-transfected SKOV-3 and CRISPR/Cas9-sgRNA transfected 
SKOV-3.  However, the absolute peak heights in a chromatogram is dependent on the amount 
of template DNA in the sequencing reaction, therefore, relative (rather than absolute) peak 
heights were initially determined for each trace. This normalization is performed by 
comparing the CRISPR/Cas9 edited nucleotide's peak height to that of the non-transfected 
cells. After sequence alignment, a range of deletions and insertions (represented after DNA 
DSBs) were detected in exon 1. The TIDE-coupled Sanger sequencing confirmed previous 
observations from cleavage detection assay; CRISPR/Cas9 sgRNA1 induced mutagenesis 
resulted in indel formation at DSBs site in SKOV-3 PADI2 locus. The TIDE analysis of Sanger 
sequencing-DNA chromatograms identified 29 indel events with overall few insertion events 
than deletion events within the edited PADI2 locus of which the majority was deletions 
(56.5%) with fewer insertion events (17.8%) and a ratio of 3.8 : 1; deletions to insertions, based 
on two independent experiments. The highest mutational activity for CRISPR/Cas9 sgRNA1 
was detected at -1 deletions and +1 insertion sites, each represented with the highest targeted 
indel frequency percentage of 13.3% an 10.8%, respectively (Figure 6.7b and 6.7c). 
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Figure 6.7.   Sanger sequencing analysis of CRISPR/Cas9 sgRNA1-mediated mutagenesis of 
PADI2 locus in SKOV-3. A PCR product encoding the region of interest was amplified from the 
genomic DNA of whole cell population using primers flanking the targeted site, which was 
then analysed by Sanger sequencing. (a) The DNA chromatograms of TIDE (tracking of indels 
by decomposition) algorithms compared the CRISPR/Cas9 edited and non-transfected 
sequence alignments. The black arrow indicates the expected site of cleavage. (b) Normalised 
contributions showing the inferred sequences present in the edited population and their 
relative proportions. Cut sites are represented by black vertical dotted lines. (c) Indel plot 
displays the inferred distribution of indels in the entire edited population of genomes. (d) The 
discordance plot details the level of alignment per base between the non-transfected and 
CRISPR/Cas9 edited sample in the inference window (the region around the cute site). On the 
plot, the green line and orange line should be close together before the cut site, with a typical 
CRISPR/Cas9 edit resulting in a jump in the discordance near the cut site and continuing to 
remain far apart after the cut site (representing an elevated level of sequence discordance). 
The blue box region represents the guide sequence. The vertical red doted, and black doted 
lines represent the PAM site and cleavage site of Cas9 (DSBs, double strand breaks), 
respectively.  (-) Deletions or (+) insertions were found near the PAM sequence, *; 
consensus sequence and yellow boxes represent non-frameshift indels. Results are 
representative of two independent experiments. 
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6.4 DISCUSSION 
 
6.4.1 CRISPR-mediated PADI2 knock out in EOC cell lines 
Among its many applications, CRISPR/Cas9 has shown a promising potential 
in clinical applications and has prompted the emergence of novel molecular targets for cancer 
therapy (Zhan et al., 2019; Martinez-Lage et al., 2018). CRISPR-Cas9-mediated gene therapy 
can be exploited for precise genome editing therapeutics and future preclinical target 
validation (Martinez-Lage et al., 2018). The availability of various virtual or computational 
CRISPR/Cas9 libraries and databases facilitate high-throughput screening to identify gene 
signatures involved in carcinogenesis, progression, metastasis and tolerance (Ma et al., 2017; 
Fan et al., 2018). These signatures can therefore be explored in downstream analysis in vitro, 
and in vivo animal models to reveal novel functions and their consequent effect on the biology 
of cancer (Fan et al., 2018). This knowledge enabled the evaluation of small molecules drugs 
and antibodies targeting oncogenic signalling pathways for cancer therapy. Recently, 
CRISPR/Cas9 system was used in preclinical and clinical cancer studies to validate potential 
therapeutic targets and associated druggable target proteins to better guide future drug 
discovery efforts (Fan et al., 2018). Huang et al., (2017) used CRISPR/Cas9-mediated knockout 
of maternal embryonic leucine zipper kinase (MELK), an established oncogene in basal breast 
cancer, to validate whether MELK is necessary for the survival of basal breast cancer. Other 
studies used CRISPR/Cas9-mediated p53, BRCA1, PTEN and nuclear factor 1 (NF1) and BRCA2 
knockout to investigate the biology of HGS EOC (Walton et al., 2017; Walton et al., 2016). 
Collectively, these findings provide a general framework and represent promising potential of 
CRISPR/Cas9 technology to accelerate the discovery of novel molecular targets and gene 
signatures (Nault, 2017). Previous studies provided genetic evidence that PADI2 may function 
as an oncogene by mediating the tumourigenic processes and inducing inflammation within 
the tumour microenvironment (Wang et al., 2016). Although PADI2 expression has been 
linked to some female reproductive organ cancers, the role of PADI2 in EOC oncogenesis is 
poorly understood. Herein, the main aim of this chapter was to generate genetically modified 
PADI2-knockout EOC cells, that can be utilised in future studies to enhance the understanding 
of PADI2 function in EOC. After transfection studies, the efficiency CRISPR/Cas9 system was 
validated by analysing the edited region by multiple methods. 
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6.4.2 Detection of the sgRNA: CRISPR/Cas9- mediated gene editing of the PADI2 locus in EOC 
cell lines  
Herein, the results obtained by cleavage detection assay provided the foundation for 
interpreting the diverse outcomes from CRISPR/Cas9-sgRNA complex-mediated PADI2 
knockout. Surprisingly, successful editing of PADI2 locus was only confirmed in the human-
derived SKOV-3 cell line transfected with CRISPR/Cas9 guided with sgRNA1. This result 
suggests that the selected sgRNA1 was specific to the targeted sequence in the human 
genome and not in the mouse genome. In addition, CRISPR/Cas9 guided with sgRNA2, did not 
knockout PADI2 in both human and mouse cell lines. This result shows that the CRISPR/Cas9-
sgRNA2 complex have low specificity or low Cas9 binding affinity to the targeted sequence in 
both human and mouse genomes. However, troubleshooting methods will be required to 
determine the factors that may have contributed to this unsuccessful CRISPR/Cas9-targeted 
PADI2 manipulation in ID8-Luc2 cells.  
Current studies aiming to improve target specificity determined that a CRISPR/Cas9 or 
CRISPR/Cas9-sgRNA complex efficiency is dependent on the number of alleles for each gene 
that may vary depending on the specific cell line used or organism. In line with these findings, 
a number of studies also evaluated the efficiency of one CRISPR/Cas9 complex across different 
target sites and determined that specific target sites are inherently more effective (Wang et 
al., 2014; Chari et al., 2015; Moreno-Mateos et al., 2015; Wilson et al., 2018). These findings 
led to a series of large-scale screens of CRISPR/Cas9-sgRNA complex activity across various 
target sites and organisms/cell types, aimed to identify the specific features contributing to 
on-target efficiency (Horlbeck et al., 2016; Moreno-Mateos et al., 2015; Chari et al., 2015; 
Wilson et al., 2018). One study aimed to increase the on-target efficiency by modifying the 
sgRNA structures. This was achieved by limiting the GC content, avoiding poly-T sequences 
and including a ‘G‘ directly up-stream of the PAM sequence (i.e. an GNGG motif). Building on 
this research, CRISPR-associated computational tools are regularly optimised to minimise 
potential guide specificity (off-target effects) while also maximise guide efficiency (on-target 
activity) by analysing the features of the target sites (Wilson et al., 2018). Another successful 
approach was discussed by Zheng et al., (2014), also aimed to improve CRISPR/Cas9-sgNRA 
complex by combining two sgRNA cassettes (separated by tRNA pattern) targeting the same 
gene in one single delivery system. This multiple sgRNA-mediated editing process resulted in 
a large fragment deletion of the targeted gene and subsequent high and effective genome-
wide mutation frequency. This method strictly depends on two sgRNAs binding to the DNA 
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with a defined orientation and spacing, significantly reducing the probability that a suitable 
target site will occur more than once in a genome and therefore enhancing the specificity (Tsai 
et al., 2014). However, having multiple sgRNA expression cassettes on the same construct 
limits the cloning capacity and increases off-target mutations (Chira et al., 2017; Chen et al., 
2015). Therefore, testing individual sgRNA systems is required as a primary step to 
characterise sgRNA-specific-induced gene mutation and potential off-target deletions.  
Recently, various methods have been developed to improve Cas9-sgRNA complex specificity 
by utilising natural or engineered Cas9 orthologues, engineering the Cas9 protein/sgRNA, or 
modulating the kinetics and regulation of the CRISPR components in the cell (Tycko et al., 
2016). Hence, Cas9 activity is not only determined by the specific target site, but also by the 
mode of Cas9/sgRNA delivery, gene of interest and cell type (Tycko et al., 2016). For example, 
He et al., (2018) showed that CRISPR/Cas9-targeted manipulation of the OC–related DNA 
methyltransferase 1 (DNMT1) gene was only successful when combined with lipid-mediated 
delivery system (i.e. folate receptor-targeted liposome (F-LP)) for precise genome editing. 
These methods can be used in the future to develop more efficient CRISPR/Cas9-sgRNA 
delivery system that will successfully target PADI2 in ID8-Luc2 cells. Despite the fact that 
CRISPR/Cas9 gene editing was not successful in ID8-Luc2 in this study; Walton et al., (2017)  
reported generating ID8 cells with deletions in number of tumour suppressor genes using the 
CRISPR/Cas9. 
 
6.4.3 Targeted Sanger sequencing detection of CRISPR/Cas9-sgRNA1 mediated mutagenesis 
of PADI2 locus in SKOV-3 cells 
TIDE-coupled Sanger sequencing analysis confirmed successful mutation of the PADI2 locus in 
the CRISPR/Cas9-sgRNA1 edited SKOV-3 cell population. This observation was determined by 
comparing the sequence identity of SKOV-3 edited cell pool with the wild type cells. The DNA 
trace chromatograms produced by TIDE analysis, displayed the precise site confirming that 
Cas9-induced DSBs has occurred exactly 3bp upstream of the PAM sequence. It was also 
detected by the TIDE analysis that around 14% of the CRISPR/Cas9 edited SKOV-3 population 
remain unedited. The reasons that account for the ability of these cells to escape 
chromosomal CRISPR targeting are not entirely understood. It is possible that the trans-acting 
factors, such as anti-CRISPR proteins (i.e. AcrIIC4 and AcrIIC5 ) may inhibit the expression or 
activity of Cas9 in specific cancer cell phenotypes, leading to higher tolerance of CRISPR within 
the transfected population (Lee et al., 2018). It is known that the mutational outcomes are 
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not random and are dependent on the DNA sequence at the targeted site (Allen et al., 2018). 
Therefore, the characterisation of these outcome can predict repair profiles reproducibility, 
Cas9-gRNA efficacy and reveal the biological impact on the targeted sequence (Allen et al., 
2018). Thereafter, the detailed analysis of DNA trace sequence by TIDE also provided 
invaluable information of the edited sequences. The TIDE-generated indel frequencies, were 
used to characterise the mutation/genetic outcome of CRISPR/Cas9-sgRNA1 edited SKOV-3 
population. The detected frequency of insertion events (17.8%) were less than the deletion 
events (56.5%). The high deletion frequency reflects on the spontaneous joining between the 
distant ends of two DSBs and repaired by NHEJ (Taylor et al., 2004).  
Deletions and insertions of one to three nucleotides represent around 70% of all unique 
coding indels (Lin et al., 2017; Allen et al., 2018). Indels have the propensity to generate highly 
mutagenic peptides via creation of a shifted novel open reading frame (Turajlic et al., 2017). 
CRISPR/Cas9-induced indel mutations that cause a FS (FS indels) create a novel open reading 
frame that commonly result in complete gene dysfunction by producing truncated 
polypeptides and/or nonsense-mediated mRNA decay, thereby, knocking out target gene 
(Turajlic et al., 2017). In the current study, the indel mutations that causes FS are substantially 
high (21 FS indels) representing 62% of the indels and the remaining are non-frame shift (NFS) 
indels (8 FS indels) 38%. For example, NFS coding indels included more rare variants, such as 
-21 (0.1%), whereas, FS indels, included more frequent indels, such as +1 indels found in 13.3% 
of the polyclonal edited population. Collectively, the number of FS indels was greater than 
expected, which is not surprising since FS are thought to be more deleterious, and mutants 
with FS are more likely to increase DNA damage and result in premature termination of 
translation (Taylor, Ponting and Copley, 2004). 
 
6.5 CONCLUSIONS 
 
In summary, this work provides a novel platform, using CRISPR/Cas9 technology for 
successful PADI2 knockout. The designed sgRNA1 successfully guided the Cas9 nuclease to 
the target genomic site on PADI2 locus (exon 1), thereby generating the knockout cell line. 
This CRISPR/Cas9-sgRNA1 complex can therefore be used in future studies to elucidate the 
role of PADI2 in EOC. Despite the understanding gained from analysing CRISPR/Cas9 mediated 
mutagenesis in SKOV-3 using cleavage assay and Sanger sequencing, more extensive analysis 
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may be required to further investigate sgRNA1 comprehensive specificity. The off-target effect 
of engineered nucleases is a main concern, particularly in therapeutic applications in a clinical 
context. The off-target mutations can be found at very low frequencies and below the 
detection limit of the cleavage assay or Sanger sequencing but can be revealed by NGS. Great 
advances have been made in recent years in developing methods for identifying off-target 
sites to determine the safe application of CRISPR/Cas system in a clinical context.  
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CHAPTER 7: Discussion  
 
The discovery of new EOC biomarkers contributes to improved diagnosis, prognosis, 
therapeutic response and monitoring of cancer patients (Toss and Cristofanilli, 2015; 
Yurkovetsky et al., 2010; Sidhu and Capalash, 2017). At present, there is a need for highly 
reliable and predictive prognostic biomarkers for EOC to enable the stratification of patient 
risk, facilitate treatment choice and improve patient counselling. Like many tumour markers, 
PADI2 expression was found to be frequently dysregulated in malignant tumours (Copeland 
et al., 2009; Bannister and Kouzarides, 2011). This aberrant expression, or dysregulation of 
PADI2 deregulates the expression of other proteins, including transcription factors (e.g. p53 
and p21), key signalling molecules (e.g. RhoA, Rac1 and Cdc42) and is involved in the 
dysregulation of cell cycle related genes (e.g. CXCR2, Patch et al., 2015; Guo et al., 2017; 
Horibata et al., 2017; Song and Yu, 2019). Therefore, PADI2-induced dysregulations contribute 
to its potent role in the progression of some cancers or suppression of others (Wang et al., 
2016; McElwee et al., 2012). Previous studies also provided genetic evidence that PADI2 may 
function as mediator of tumorigenesis (Wang, et al., 2016). PADI2 mRNA expression was also 
found to correlate with HER2/ERBB2 expression in HER2/ERBB2+ breast cancers and 
gastrointestinal cancers (McElwee et al., 2012; Bertucci et al., 2004; Guo and Fast, 2011; Guo 
et al., 2017; Funayama et al., 2017). Although PADI2 expression has been previously linked to 
female reproductive organ cancers, the role of PADI2 in EOC is unexplored. The detailed role 
of Ca2+ in PADI2 enzyme activation, and subsequent citrullination in cancer remains largely 
unknown. (Guo et al., 2017). One of the main aims of this study was to assess whether high 
PADI2 expression conferred a survival advantage in EOC patients by examining TCGA primary 
tumour data. The role of PADI2 as a modulator of pathogenesis and therapeutic target was 
investigated in vitro EOC cell lines by assessing the effect of its overexpression on proliferation, 
apoptosis, cellular aggregation, autophagy and necrosis. In the context of combined therapy, 
PADI2 expression was assessed to determine its impact on cisplatin drug efficacy in EOC cells. 
In addition, PADI2 correlation and putative interactions with other genes was explored to 
provide a new understanding of PADI2 regulatory pathways and novel gene targets by which 
it carries out its role in EOC. Another aim of this research was to develop a CRISPR/Cas9-sgRNA 
tool to genetically edit/disrupt the PADI2 locus by inducing NHEJ-based mutations that result 
in non-templated insertions and deletions. Finally, one of the main aims of this thesis was to 
examine the PADI2 evolutionary history and identify PADI2-functionally important residues by 
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assessing the evidence for natural selection amongst 31 orthologues sequences.  All these 
aims were achieved in this thesis work. 
 
7.1 PADI2 deregulates the expression of various genes involved in EOC tumorigenesis 
Uncontrolled cellular proliferation, cell death and increased invasion and metastasis are 
known hallmarks of cancer. Underlying these hallmarks are genome instability, which 
generates the genetic diversity in cancer cells required as a substrate to accelerate the 
acquisition of replicative immortality, and inflammation (Hanahan and Weinberg, 2000; 
Hanahan and Weinberg, 2011). While previous studies have shown that PADI2 is involved in 
proliferation, invasion and inflammation of cancer cells, the mechanisms by which PADI2 
expression and consequent citrullination may regulate these processes remain largely 
unknown. Herein, the pathway by which PADI2 is involved in cancer was explored by 
evaluating the impact of PADI2 overexpression and the consequent alteration of the 
expression of some genes involved in tumour progression and signal transduction. The 
correlating genes identified from analysing the TCGA co-expression data were validated in 
PADI2 overexpressing OVCAR-4 cells using qRT-PCR. Thus, the mRNA expression analysis 
verified decreased and increased expression of FZD5 and ARHGEF10, respectively. The 
increased expression of FZD5, was previously shown to be associated with poor patient 
outcome in EOC malignancy (Barbolina et al., 2011; Bobbs et al., 2015; Verardo et al., 2014; 
Torchiaro et al., 2016). Therefore, PADI2-mediated decrease in FZD5 expression may 
contribute improved survival outcome in EOC patient. Whereas, Rho-GTPase activating 
proteins, such as ARHGEF10L, are positively associated with good prognosis (Aleskandarany 
et al., 2019; Zhao et al., 2014). PADI2 may render the progression of EOC by upregulating the 
expression of ARHGEF10L and downregulating FZD5, subsequently reducing FZD5-mediated 
ECM adhesion in EOC (Bobbs et al., 2015), although further functional studies are required. 
The observed PADI2-mediated deregulation of these genes could be a direct or indirect 
consequence of the irreversible nature of citrullination and subsequent differential expression 
(Darrah and Andrade, 2018). 
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7.2 PADI2 expression associated with different survival outcomes in EOC patients 
In this study, the role of PADI2 in EOC was evaluated in the human-derived OVCAR-4 and 
mouse-derived ID8-Luc2 cell lines. The role of PADI2 was assessed by exploring the impact of 
its overexpression on downstream cellular activity, including cell proliferation, apoptosis, 
autophagy, necrosis and aggregation. The relationship between PADI2 expression and OS of 
EOC patients was initially established by Dr L. Machado (unpublished data), by analysing 
primary tumour TMAs collected from EOC patients, where higher PADI2 expression was found 
to positively correlate with improved patient survival (Appendix Figure S.3). Thus, the TMA 
data indicates that PADI2 mRNA expression is significantly associated with improved patient 
prognosis and higher OS with an increase in mean survival of 22 months. To confirm the TMA 
findings, the current study explored PADI2 mRNA expression association with OS of EOC 
patients by analysing primary tumour clinical data obtained from TCGA cbioPortal. Well 
characterised bioinformatics and statistical approaches were then employed to investigate 
the survival rate of EOC patients from U133 and RNA-seq cohorts in correspondence to PADI2 
mRNA expression levels. In contrast to the TMA data, the survival analysis of PADI2 mRNA 
expression data indicated that high levels of PADI2 mRNA was associated with decreased 
(rather than increased) OS in EOC patients by 11 months. It is important to note that this 
inconsistency between both the TMA and TCGA studies which led to inconclusive conclusions 
was a result of each study analysis was conducted using different patient cohorts with 
different OC subtypes. For example, the current study survival analysis of TCGA data was 
obtained from EOC patient cases with only serous subtype, whereas the TMA cohort 
contained OC patients with various OC subtypes. Thereafter, the analysis of the expression 
data collected from TCGA cBioPortal U133 and RNA-seq presented contrasting outcome to 
that observed in the TMA data; and that is PADI2 mRNA expression is associated with a lower 
survival rate of EOC patients. This is not surprising, given that the underlying assumption that 
PADI2 expression patterns were measured in different patients’ cohorts. The discrepancy of 
both outcomes resides not only in the fact that different data pools were used in each analysis, 
but in the inconsistency of the histological subtypes of EOC patient cases tested (Xue et al., 
2018). Guo et al., (2017) previously used immunohistochemistry to assess whether PADI2 was 
expressed in ovarian cancer TMAs in comparison to normal TMAs. The Guo group found that 
significant PADI2 expression was detected in 34.1% of cervical squamous cell carcinomas, 95% 
of breast-invasive ductal carcinomas, 88% of oesophageal cancers, 97.5% of colon 
adenocarcinomas, 62.8% of gastric adenocarcinomas, 55.2% of liver hepatocellular 
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carcinomas, 30% of ovarian serous papillary adenocarcinomas, 92.5% of lung cancers, 90% of 
papillary thyroid carcinoma samples and 58.5% of rectal adenocarcinomas and (Guo et al., 
2017). 
 
7.3 Endogenous PADI2 expression was not detected in any of the EOC cell lines tested 
As mentioned above (in section 7.2), Guo et al., (2017) reported that PADI2 expression was 
significantly increased in only 30% of ovarian serous adenocarcinomas tissues in comparison 
to 95% of breast cancer and 97.5% of colon cancer. Correspondingly, Protein Atlas analysis of 
EOC TMAs indicated that only 10% of EOC tissue had high endogenous PADI2 expression; 
however, the TMA cohort only included few EOC cases (28 cases). In line with Guo’s group and 
Protein Atlas’ findings, the current study shows that EOC cell lines displayed weak endogenous 
PADI2 mRNA expression and its protein was not detected. Collectively, these findings suggest 
that low endogenous PADI2 expression may contribute to lower risk of EOC, therefore, PADI2 
expression is suppressed in EOC cancer cells. However, the unpublished TMA data disagrees 
with the above findings. 
 
7.4 The overexpression of PADI2 altered EOC cellular function in vitro 
Discordant results were also observed between the two cell lines examined in the study. For 
example, PADI2 overexpression significantly reduced cisplatin cytotoxicity in ID8-luc2 cells, 
resulting in a significant increase of cell proliferation and induced cell-cisplatin resistance. This 
PADI2-mediated cisplatin resistance in ID8-Luc2 was observed in a Ca2+- and citrullination- 
independent manner. The reasons for this result are currently unclear but may indicate that 
PADI2 contributes to EOC tumorigenesis (in some context) and its overexpression leads to 
increased ID8-Luc2 cell resistance to cisplatin in the absence of citrullination, and irrespective 
of the Ca2+ concentrations in the extracellular medium. Multiple studies correspondingly 
reported that PADI2 overexpression promotes cell proliferation in tumours, such as breast and 
prostate cancers (Cherrington et al., 2012; McElwee, Mohanan et al., 2012; Wang et al., 2017). 
However, this cell line model may not recapitulate what occurs in primary tumours given this 
human protein was expressed in a mouse cell line and was defective in mediating 
citrullination. Collectively, these observations agree with the data obtained from cBioPortal 
demonstrating PADI2 expression association with poor EOC patient prognosis but disagrees 
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with prior TMA data. It is important to state that the TMA data was collected from EOC 
patients with various disease subtypes, whereas the RNA-seq and U133 data were collected 
from patient with serous disease subtype only.  
In contrast to ID8-Luc2 cells, PADI2 overexpression in the human-derived OVCAR-4 was shown 
to increase citrullination in a Ca2+ -dependent and citrullination-dependent manner. In 
addition, PADI2 overexpression significantly increased apoptosis and autophagy, decreased 
proliferation and cellular aggregation in response to high Ca2+ levels (≥1mM Ca2+). Notably, 
PADI2 overexpression also resulted in increased total protein citrullination in PADI2 
overexpressing cells incubated in 1mM Ca2+. These findings indicate that PADI2 may mediate 
OVCAR-4 cellular activity in a Ca2+- and citrullination- dependent manner. Thus, these results 
suggest that the overexpression of PADI2 suppresses cell proliferation and induces apoptosis 
and autophagy of OVCAR-4 cells through catalysis of protein citrullination, and that the 
downregulation of PADI2 expression might therefore contribute to ovarian carcinogenesis. 
These cell functional studies support the TMA unpublished data (Appendix Figure S.3) and 
disagrees with TCGA cBioPortal data (Figure 3.1). Funayama et al., (2017) correspondingly 
reported that PADI2 suppresses the proliferation in colonic epithelial cells by catalysing 
protein citrullination, but in this study the effect of Ca2+ on PADI2 was not investigated. 
Combined with the previous findings from the co-expression analysis, PADI2 may suppress 
proliferation and aggregation OVCAR4 cells via FZD5 and ARHGEF10L signalling pathways. 
Whatever the reasons for this discrepancy in PADI2 function in the different cell lines used in 
this study, a probable speculation is the epigenetic or/and genetic intratumor heterogeneity 
(Schwarz et al., 2014; Burrell et al., 2013; Assenov et al., 2018). This heterogeneity complicates 
the understanding of the underlying PADI2-regulating mechanisms, but provides the ability to 
capture EOC heterogeneity based on the activity of PADI2 and its associated regulatory 
pathways (Huang et al., 2003). Therefore, multiple signalling pathways may be involved in the 
regulation of PADI2 and these pathways may differ depending on the molecular context that 
infers the heterogeneity. This discrepant pattern was also observed amongst different studies, 
all investigating the role of PADI2 in breast cancer tumorigenesis. For example, one study 
found that PADI2 overexpression promoted the proliferation of MCF-7 cells (Cherrington et 
al., 2012). Conversely, in another study by Wang et al., (2016), PADI2 overexpression was 
found to contribute to breast cancer tumorigenesis not by inducing proliferation or apoptosis, 
but by promoting cancer cell migration and invasion. Collectively, all these reports combined 
with the findings from this study, demonstrate that PADI2 may have different functions in 
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different cells lines (and primary tumours), possibly depending on the genomic content of 
each cell lines. Interestingly, all the above studies by Wang, McElwee and Cherrington groups, 
commenced detecting PADI2 function after overexpression or inhibition studies in the 
absence of exogenous Ca2+ treatment. 
It is also important to point out, that ID8-Luc2 is a mouse-derived EOC cell line model. The 
mouse cell lines are the most widely used model in cancer research due to their ability to 
preserve temporal disease development, including stromal compartments and coevolution of 
cancer (Zhang et al., 2013; Walrath et al., 2010). Even though animal models are likely to 
reflect similar regulatory molecular mechanisms observed in human disease, they are 
probably subject to the different evolutionary pressures as conventional cancer cell lines 
during propagation (Perlman, 2016). To understand the different outcomes observed in 
human-derived OVCAR-4 and mouse-derived ID8-Luc2 cell lines, the human and mouse PADI2 
aligned sequences were compared using an EMBL-Pairwise sequence alignment tool. The 
comparison of both orthologues demonstrated that mouse PADI2 has a 11.7% difference in 
nucleotide sequence and a 2.9% amino acid difference between mouse and human PADI2 
(Appendix Figure S.1 and Figure S.2). Supporting the observations from EMBL-Pairwise 
sequence alignment, Bayesian phylogenetic analysis using DNA sequences, further supported 
good homology between human and mouse PADI2 orthologues. However, on the 
phylogenetic tree, the homologous human and mouse PADI2 were located on divergent taxa 
within subclade (Ia), indicating genomic biodiversity. This differentiation in phylogenetic taxa 
can demonstrate a different protein function/responsiveness to certain regulators: these 
theories have been previously discussed by Chu et al., (2018). Collectively, these findings can 
also provide further clarification and possible reasons for the discrepant effects of PADI2 
overexpression between OVCAR-4 and ID8-Luc2 cells. 
 
7.5 The evolutionary history of PADI2 and how is it related to structure and function? 
Phylogenetic analysis and codon-based selection tests were used to reconstruct the 
evolutionary history and ancestral reconstruction of PADI2 orthologues. This technique 
attempts to computationally dissect and study the evidence for natural selection by assessing 
the divergence points occurring amongst PADI2 orthologues sequences retrieved from 31 
organisms. Following the phylogenetic analysis, PADI2 3D/2D structures were mapped to the 
published structures of the aligned PADI2 codon selection data, thereby, allowing the 
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identification of the conserved amino acid residues that correspond to important sites on 
PADI2, such as active binding site and Ca2+ binding sites.  
 
7.5.1 PADI2 is a phylogenetically conserved gene 
The highly conserved protein sequences are thought to maintain an important function 
(Robson et al., 2002; Sadeque et al., 2010). The phylogenetic approach was previously 
employed for PADI2 by Hosakawa group, who examined a small range of different species, 
including rhesus monkey, chimpanzee, mouse, dog, chicken, rat, frog, and zebrafish 
(Hosokawa et al., 2018). That study showed that PADI2 orthologues were conserved amongst 
all tested species. Likewise, this thesis also assessed PADI2 phylogenetic history but in larger 
number (i.e. 31 species) and more diverse species, including fish, aves, mammals and 
amphibians, in addition to newly available sequences from species, such as Miniopterus 
Natalensis bat (Stoffberg et al., 2004). In the Bayesian phylogenetic analysis using PADI2 
ortholog DNA sequences, the calculated p-values for likelihood ratio tests were not significant 
between all 31 organisms; thus, indicating no evidence of PADI2 positive selection amongst 
distinct species, and suggesting that PADI2 is highly conserved throughout evolution. In line 
with these findings, Vossenaar et al., (2003) also showed that the physiological and 
pathophysiological roles of PADI isozymes are conserved throughout evolution from bacteria 
to mammals. Moreover, Hosokawa et al., (2018) phylogenetic analysis of all PADI isozymes 
also show PADI2 is the most phylogenetically conserved PADI isozyme and is predicted to be 
the ancestral homologue of the other PADI isozymes. One of the most exciting findings in this 
thesis, was the identification of conserved PADI2 sequences even in teleost fish, such as 
Catfish, Piranha, Molly, Bonytongue and Vulus, that diverged almost 400 million years ago. 
This indicates that PADI2 is of a very ancient origin and may likely be found in most, if not all, 
cartilaginous and teleost fish species. 
Moreover, in prior phylogenetic studies, evolutionarily conserved genes, such as PADI2, are a 
consequence of extensive purifying selection that eliminates deleterious mutations (Pollock, 
2002). Thus, reducing the level of a genes’ diversity within species, as well as a decreasing its 
rate of evolutionary change between species (Nei, 2007). Protein folds that tolerate mutations 
better are more likely to evolve functional innovations  (Abrusán and Marsh, 2016), therefore, 
PADI2 functional importance may reside in its sequence conservation. Further analysis using 
a Genic Intolerance tool of PADI2 residual variation Intolerance indicate that PADI2 has fewer 
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common functional mutations than expected. The residual variation intolerance score showed 
that for PADI2, 80.22% of the mutations that may occur in the sequence are intolerant and 
are likely to be disease-causing. In addition, the cBioPortal genetic alteration analysis detected 
that PADI2 was altered in only 6% of EOC primary tumours. Collectively, these findings indicate 
that PADI2 is highly conserved and possibly has low mutational robustness, i.e. the ability to 
accept mutations without change. Therefore, PADI2 is robust against accepting destabilising 
mutations and the presence of mutations in the PADI2 genome (e.g. missense) are more likely 
to cause protein dysfunction (Abrusán and Marsh, 2016). 
 
 
7.5.2 Conserved Ca2+ binding sites on PADI2 enzyme indicate its subsequent activation in a 
Ca2+-dependent manner 
Ca2+ binding sites (Ca1-6) are located in PAD and PAD_M domains containing the highest 
proportion of conserved amino acid residues (89%) and (84%), respectively. The amino acid 
residues corresponding to Ca1, 2 and 6 binding sites were more conserved than those 
observed for Ca3-5, which is indicative of regulatory importance of PADI2 enzyme activation. 
In accordance with this observation, Slade et al., (2015) showed that Ca1 and Ca6 do play a 
critical role in the activation of PADI2 enzymes by promoting the relief of active-site shielding. 
Followed by Ca3-5-induced conformational changes, thereby, promoting Ca2 binding and 
subsequently generating a catalytically competent enzyme by rearranging residues (i.e. 
arginine347) within the active site (Slade et al., 2015). The protein conformational changes 
are essential for the function or catalysis carried out by the protein, such examples can be 
observed within the PADI family: binding of Ca2+ to acidic concave surfaces of PADI4 was 
shown to stabilise the unstable domains and therefore organise the active site of the protein 
(Arita et al., 2004; Liu et al., 2017). Collectively, the 3D/2D structure and evolutionary study 
provided insights into the biochemical and molecular dependency of PADI2 activation on Ca2+ 
and catalysing Ca2+-dependent citrullination in cancer cell lines. The functional data obtained 
in this study provide evidence conferring the crucial interplay between Ca2+ and PADI2 in 
cellular activity, where PADI2 overexpression and high Ca2+ concentrations conferred survival 
disadvantage in human OVCAR-4 cells. 
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7.6 Successful CRISPR/Cas9-mediated knockout of PADI2 in EOC cell lines 
The work in this thesis provides a novel platform using CRISPR/Cas9 gene editing for 
successful PADI2 knockout. The designed sgRNA1 successfully guided the Cas9 nuclease to 
the target genomic site on PADI2 locus (exon 1), thereby generating the knockout cell line. 
This developed CRISPR/Cas9-sgRNA1 tool can therefore be used in future studies to 
elucidate the role of PADI2 in EOC. This CRISPR/Cas9-sgRNA complex can be therefore utilised 
to monitor the effect of multiple pharmacological and chemical intervention in PADI2-
knockout cells. The application of such tools has a significant impact on understanding the 
genetic basis behind various types of cancers in association with PADI2. However, this tool 
was not used in the current study due to the lack of PADI2 expression in cell lines. The reason 
for this lack of PADI2 expression in all cell lines examined compared with primary tumour 
tissue is currently unclear by may represent the inability to propagate and culture established 
PADI2 cell lines from primary clinical material. 
 
7.7 Limitations and future work 
The research detailed in this thesis has advanced the understanding of the role of PADI2 in 
EOC, whilst also revealing several possible avenues for future research. A role for PADI2 has 
been previously well established in neurodegenerative disease and its mediation of 
citrullination has been linked to various cancers. The role of PADI2 in EOC was not explored 
previously, therefore, this thesis work is novel and provides the fundamental principles of 
PADI2 activity and its potential role in EOC.  
As described in chapter 3, the TCGA cBioPortal data was obtained from primary tumour EOC 
patients with serous disease subtype. However, including different disease subtype or 
analysing other cohorts that include only non-serous subtypes, would provide a more 
comprehensive assessment of PADI2 and whether its expression and association with serous 
EOC patients is subtype-specific. In addition, some of the identified novel co-expressed genes 
that may play important roles in PADI2-mediated pathways in EOC, were not included in the 
qRT-PCR analysis and require further examination. In addition, in chapter 5, PADI2 
overexpression studies in vitro, included empty vector and wild type (non-transfected) EOC 
cells as negative controls. However, plasmids harbouring a kinase deficient PADI2 may be 
required for further elucidation of cell function and to confirm the findings obtained from 
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overexpression studies. PADI2 mediates protein citrullination in OVCAR4 cells, thus decreasing 
cell proliferation and aggregation and increasing apoptosis and autophagy.   
This work was the first to address the role of PADI2 in EOC, therefore, this thesis contains 
optimisation steps that formed a starting point of this novel work and enabled enhanced 
characterisation of the downstream effects of PADI2 overexpression in vitro EOC cellular 
activity. This study also evaluated the efficacy of cisplatin drug in OVCAR-4 and ID8-Luc2 EOC 
cell lines. In addition, cultured cell lines were used to investigate the tumourigenic 
mechanisms. The observed mechanisms may not be entirely similar to the mechanisms in 
primary tumour tissues or patient blood samples. Typical cell culture medium is replete with 
metabolites and growth factors, among others, for which cells normally must compete in vivo 
(Hecht et al., 2016). Whether cell lines can mimic tumour cell gene expression patterns and 
cellular activity by altering the culture medium conditions is a question yet to be fully 
explored.  
In a clinical context, PADI2 expression can be initially assessed in EOC patients. Next, EOC 
patients will be given a dedicated course of cisplatin (e.g. 3-6 cycles) and followed by post-
treatment assessment of patients’ response to the chemotherapy treatment. If resistant to 
cisplatin and PADI2 is high in their tumour, a combination therapy including cisplatin and Cl-
amidine, a known PADI inhibitor, might be used to improve chemotherapeutic response by 
hindering PADI2-mediated EOC cells resistance to cisplatin treatment. This can be assessed 
initially using in vivo mouse models. In contrast, if sensitive and PADI2 expression was high, 
patients can be provided with Ca2+ supplementation as part of combination therapy to 
activate PADI2-increased cisplatin efficacy and perhaps decrease the chemotherapy 
treatment time. Future studies can include investigating the role of PADI2 in cancer 
inflammation and whether it could be used as part of an immunotherapy approach using CD4+ 
T cells targeting citrullinated epitopes (i.e. targets of PADI2 in EOC).  
Additionally, this work has developed CRISPR/Cas9-sgRNA complex for editing the PADI2 locus 
in human cell lines as described in chapter 6. Whilst the CRISPR/Cas9 editing system is a highly 
specific novel approach for genome editing, the potential for off-target effects remain to be 
fully characterised. Genome-wide off-target effects were not determined in this study. By 
sequencing the whole genome by NGS, it is possible to identify not only off-target effects but 
also structural variants, such as rearrangements, inversions, major deletions and duplications 
(Zischewski et al., 2017). New research by  Kocak et al., (2019), suggested using engineered 
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hairpin secondary RNA secondary structures combined with different variants of Cas9 or 
Cas12a, to increase CRISPR systems specificity. 
 
7.8 Concluding remarks 
 
This thesis provides evidence that PADI2 expression is associated with EOC patient survival 
time and as a functionally conserved protein is also involved in vitro in EOC cellular activity. 
PADI2 acts as a novel mediator in EOC cells in a cell line-specific manner, and its 
overexpression induces differential effects on cellular activity, reflecting the complexity of 
PADI2 biological regulation.  On the one hand, PADI2 significantly reduced cisplatin 
efficacy/cytotoxicity independently of exogenous Ca2+ supplementation or induced 
citrullination in the mouse-derived EOC cell line. However, the mechanisms by which PADI2 
reduces cisplatin cytotoxicity or whether a cofactor is required for its interaction in ID8-Luc2 
cells, remains unknown. Conversely, PADI2 overexpression contributes to decreased 
proliferation/aggregation and increased apoptosis/autophagy in human-derived serous EOC 
cells in a Ca2+- and citrullination-dependent manner. PADI2 affects EOC tumorigenesis in 
human-derived cells by regulating the expression of ARHGEF10L and FZD5, which were 
previously shown to be involved in EOC. It is envisioned that the continued research and 
identification of other potential regulatory mechanisms by which PADI2 reduces aggregation 
of EOC cells will help to predict chemotherapy treatment outcome in clinical EOC patients. It 
can also be used as part of tailored patient treatment by identifying PADI2 as a potential 
biomarker in EOC, and its high expression can be accompanied with oral Ca2+ supplements, to 
increase cisplatin efficacy in EOC patients. 
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7.1 Schematic representation of the combined findings from this thesis work. The proposed 
mechanism of PADI2 function in EOC. PADI2 activation and downstream regulatory pathways 
were assessed in human-derived OVCAR-4 cells and mouse-derived ID8-Luc2 cells. (a) In 
OVCAR-4 cells, PADI2 overexpression led to a significant reduction in the proliferation and 
cellular aggregation, and increased apoptosis and autophagy in a Ca2+- and citrullination-
dependent manner. Higher PADI2 expression was also associated with the deregulation of 
FZD5 and ARHGEF10L independently of Ca2+ treatment. By reducing the expression of FZD5, 
known to increase the adhesion to ECM, and increasing GTPases ARHGEF10L expression, 
PADI2 contributes to reduced aggregation and proliferation. PADI2 overexpression also 
induced cisplatin cytotoxicity, by sensitising cells to treatment and leading to higher drug 
efficacy. (b) In ID8-Luc2 cells, PADI2 overexpression significantly decreased cisplatin 
cytotoxicity independently of e[Ca2+] or induced citrullination, leading to reduced drug efficacy 
and increased cell survival and resistance. Abbreviations: FZD, frizzled class receptor 5; 
ARHGEF10L; Rho guanine nucleotide exchange factor (GEF) 10-like, Ca2+, calcium; ECM, 
extracellular matrix. 
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APPENDIX 
 
 
EMBOSS_001         1 CGCGAGCGGACCGTGCGGCTGCAGTACGGGAGCCGCGTGGAGGCGGTGTA     50 
                     ||.||.||||||||||||||||||||.||||||||||||||||||||||| 
EMBOSS_001         1 CGGGAACGGACCGTGCGGCTGCAGTATGGGAGCCGCGTGGAGGCGGTGTA     50 
 
EMBOSS_001        51 CGCGGCCCCAGCCGGGGCCCAAACCTTCAGCCTGAAGCACTCGGAACACG    100 
                     |||.||.||.||.||||||.||||||||||||||||||||||||||...| 
EMBOSS_001        51 CGCAGCACCTGCTGGGGCCAAAACCTTCAGCCTGAAGCACTCGGAAGGTG    100 
 
EMBOSS_001       101 TGTGGGTGGAGGTGGTGCGTGATGGGGAGGCTGAGGAGGTGGCCCGCTGG    150 
                     ||..|||||||||.||.||||||||.|||||.||||||||||.||||||| 
EMBOSS_001       101 TGAAGGTGGAGGTCGTACGTGATGGAGAGGCAGAGGAGGTGGTCCGCTGG    150 
 
EMBOSS_001       151 CTTCTCTCGCCCAGCACCACCCTGCGGGTCACCATGAGCCAGGCGAGCAC    200 
                     ...||.||.|||||||.|||.||||||.|||.||||..||||||.||||| 
EMBOSS_001       151 GCCCTGTCACCCAGCAGCACACTGCGGCTCAGCATGGCCCAGGCCAGCAC    200 
 
EMBOSS_001       201 CGAGGCCAGCAGTGACAAGGTCACCGTCAACTACTATGAGGGGAGCATTC    250 
                     .|||||||||||.|||||||||||.|||||||||||||||||.|||...| 
EMBOSS_001       201 AGAGGCCAGCAGCGACAAGGTCACTGTCAACTACTATGAGGGCAGCGCCC    250 
 
EMBOSS_001       251 CCATCGACCAGGCGGGGCTCTTCCTCACAGCCATTGAGATCTCCCTGGAT    300 
                     ||||.||||||||.||||||||||||||.||||||||||||||.|||||| 
EMBOSS_001       251 CCATTGACCAGGCTGGGCTCTTCCTCACGGCCATTGAGATCTCGCTGGAT    300 
 
EMBOSS_001       301 GTGGACGCAGACCGGGATGGTGTGGTGGAGAAGAACAACCCAAAGAAGGC    350 
                     |||||||||||.||||||||.|.|||||||||||||||.||.|||||||| 
EMBOSS_001       301 GTGGACGCAGATCGGGATGGAGAGGTGGAGAAGAACAATCCTAAGAAGGC    350 
 
EMBOSS_001       351 ATCCTGGACCTGGGGCCCCGAGGGCCAGGGGGCCATCCTGCTGGTGAACT    400 
                     |||||||||||||||.||.||||||||.|||||.||||||||||||||.| 
EMBOSS_001       351 ATCCTGGACCTGGGGTCCTGAGGGCCAAGGGGCTATCCTGCTGGTGAATT    400 
 
EMBOSS_001       401 GTGACCGAGAGACACCCTGGTTGCCCAAGGAGGACTGCCGTGATGAGAAG    450 
                     ||||||||||.||||||||||||||||||||||||||..||||.||.||| 
EMBOSS_001       401 GTGACCGAGACACACCCTGGTTGCCCAAGGAGGACTGTAGTGACGAAAAG    450 
 
EMBOSS_001       451 GTCTACAGCAAGGAAGATCTCAAGGACATGTCCCAGATGATCCTGCGGAC    500 
                     ||||||||||||.||||.|||.||||||||||.||||||||||||||.|| 
EMBOSS_001       451 GTCTACAGCAAGCAAGACCTCCAGGACATGTCTCAGATGATCCTGCGCAC    500 
 
EMBOSS_001       501 CAAAGGCCCCGACCGCCTCCCCGCCGGATACGAGATAGTTCTGTACATTT    550 
                     |||||||||.||||||||.||||||||.||.||.|||||.||.|||||.| 
EMBOSS_001       501 CAAAGGCCCTGACCGCCTGCCCGCCGGGTATGAAATAGTCCTCTACATCT    550 
 
EMBOSS_001       551 CCATGTCAGACTCAGACAAAGTGGGCGTGTTCTACGTGGAGAACCAACGC    600 
                     |||||||||||||.||||||||||||||.|||||||||||||||||.||| 
EMBOSS_001       551 CCATGTCAGACTCGGACAAAGTGGGCGTCTTCTACGTGGAGAACCAGCGC    600 
 
EMBOSS_001       601 TATATCCACATCCTGGGCCGGCGGAAGCTCTACCATGTGGTCAAGTACAC    650 
                     ||||||||||||||||||||||.||||||||||||.|||||||||||||| 
EMBOSS_001       601 TATATCCACATCCTGGGCCGGCAGAAGCTCTACCACGTGGTCAAGTACAC    650 
 
EMBOSS_001       651 GGGTTCCGCGGAGCTGCTGTTCTTCGTGGAAGGCCTCTGTTTCCCCGACG    700 
                     .||.||.||||||.||||||||||.||||||||||||||||||||||||| 
EMBOSS_001       651 CGGCTCTGCGGAGTTGCTGTTCTTTGTGGAAGGCCTCTGTTTCCCCGACG    700 
 
EMBOSS_001       701 AGGGCTTCTCAGGCCTGGTCTCCATCCATGTCAGCCTGCTGGAGTACATG    750 
                     ||.|.||||||||||||||.||.|||||.|||||.|||||||||||.||| 
EMBOSS_001       701 AGAGTTTCTCAGGCCTGGTTTCTATCCACGTCAGTCTGCTGGAGTATATG    750 
 
EMBOSS_001       751 GCCCAGGACATTCCCCTGACTCCCATCTTCACGGACACCGTGATATTCCG    800 
                     |||.|||.|||.||..||||.|||||||||||.|||||.|||||.||||| 
EMBOSS_001       751 GCCGAGGGCATCCCGTTGACCCCCATCTTCACAGACACTGTGATGTTCCG    800 
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EMBOSS_001       801 GATTGCTCCGTGGATCATGACCCCCAACATCCTGCCTCCCGTGTCGGTGT    850 
                     ||||||.||.|||||.|||||||||||||||.|||||||.|||||.|||| 
EMBOSS_001       801 GATTGCACCCTGGATTATGACCCCCAACATCTTGCCTCCTGTGTCAGTGT    850 
 
EMBOSS_001       851 TTGTGTGCTGCATGAAGGATAATTACCTGTTCCTGAAAGAGGTGAAGAAC    900 
                     |.|||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       851 TCGTGTGCTGCATGAAGGATAATTACCTGTTCCTGAAAGAGGTGAAGAAC    900 
 
EMBOSS_001       901 CTTGTGGAGAAAACCAACTGTGAGCTGAAGGTCTGCTTCCAGTACCTAAA    950 
                     .|.|||||||||||||||||.||.|||||.||.||.|||||||||.|.|| 
EMBOSS_001       901 TTGGTGGAGAAAACCAACTGCGAACTGAAAGTTTGTTTCCAGTACATGAA    950 
 
EMBOSS_001       951 CCGAGGCGATCGCTGGATCCAGGATGAAATTGAGTTTGGCTACATCGAGG   1000 
                     |||.||.||.||||||||||||||||||||.||||||||||||||.|||| 
EMBOSS_001       951 CCGCGGTGACCGCTGGATCCAGGATGAAATCGAGTTTGGCTACATTGAGG   1000 
 
EMBOSS_001      1001 CCCCCCATAAAGGCTTCCCCGTGGTGCTGGACTCTCCCCGAGATGGAAAC   1050 
                     |.|||||.|||||||||||.||.|||||||||||.||.|||||||||||| 
EMBOSS_001      1001 CACCCCACAAAGGCTTCCCAGTAGTGCTGGACTCCCCTCGAGATGGAAAC   1050 
 
EMBOSS_001      1051 CTAAAGGACTTCCTCCTGGGCCCAGATTTTGGCTACGTGACCCGGGAGCC   1100 
                     ||.||||||||||||||||||||||||||.|||||.|||||||||||||| 
EMBOSS_001      1051 CTGAAGGACTTCCTCCTGGGCCCAGATTTCGGCTATGTGACCCGGGAGCC   1100 
 
EMBOSS_001      1101 CCTCTTTGAGTCTGTCACCAGCCTTGACTCATTTGGAAACCTGGAGGTCA   1150 
                     ||||||||||.|||||||||||||.|||||.||.||.||.|||||||||| 
EMBOSS_001      1101 CCTCTTTGAGACTGTCACCAGCCTCGACTCCTTCGGGAATCTGGAGGTCA   1150 
 
EMBOSS_001      1151 GTCCCCCAGTGACCGTGAACGGCAAGACATACCCGCTTGGCCGCATCCTC   1200 
                     |||||||||||||||||||.||||||...||||||||||||||.|||||| 
EMBOSS_001      1151 GTCCCCCAGTGACCGTGAATGGCAAGGAGTACCCGCTTGGCCGGATCCTC   1200 
 
EMBOSS_001      1201 ATCGGGAGCAGCTTTCCTCTGTCTGGTGGTCGGAGGATGACCAAGGTGGT   1250 
                     |||||.|||||.||.||.||||||||.||..||||||||||||||||||| 
EMBOSS_001      1201 ATCGGAAGCAGTTTCCCCCTGTCTGGAGGCAGGAGGATGACCAAGGTGGT   1250 
 
EMBOSS_001      1251 GCGTGACTTCCTGAAGGCCCAGCAGGTGCAGGCGCCCGTGGAGCTCTACT   1300 
                     .||.|||||||||.||||||||||||||||||||||||||||.||||||| 
EMBOSS_001      1251 ACGCGACTTCCTGCAGGCCCAGCAGGTGCAGGCGCCCGTGGAACTCTACT   1300 
 
EMBOSS_001      1301 CAGACTGGCTGACTGTGGGCCACGTGGATGAGTTCATGTCCTTTGTCCCC   1350 
                     |.||||||||||||||.||||||||.||||||||.|||.|.||..||||| 
EMBOSS_001      1301 CCGACTGGCTGACTGTAGGCCACGTCGATGAGTTTATGACTTTCATCCCC   1350 
 
EMBOSS_001      1351 ATCCCCGGCACAAAGAAATTCCTGCTACTCATGGCCAGCACCTCGGCCTG   1400 
                     |||||.||||.||||.||||.|.|||.|||||||||||||||||.||||| 
EMBOSS_001      1351 ATCCCAGGCAAAAAGGAATTTCGGCTGCTCATGGCCAGCACCTCCGCCTG   1400 
 
EMBOSS_001      1401 CTACAAGCTCTTCCGAGAGAAGCAGAAGGACGGCCATGGAGAGGCCATCA   1450 
                     ||||.|||||||||||||.||||||||||..|||||.||.||||||.|.| 
EMBOSS_001      1401 CTACCAGCTCTTCCGAGAAAAGCAGAAGGCAGGCCACGGGGAGGCCGTTA   1450 
 
EMBOSS_001      1451 TGTTCAAAATGAGCAGCATCACCATCAACAAGATTCTGTCCAACGAGAGC   1500 
                     |||||||.||||||||||||||||||||||||||.||||||||.|||||| 
EMBOSS_001      1451 TGTTCAAGATGAGCAGCATCACCATCAACAAGATCCTGTCCAATGAGAGC   1500 
 
EMBOSS_001      1501 CTTGTGCAGGAGAACCTGTACTTCCAGCGCTGCCTAGACTGGAACCGTGA   1550 
                     ||...|||||||||||.|||||||||||||||.||.|||||||||||.|| 
EMBOSS_001      1501 CTCACGCAGGAGAACCAGTACTTCCAGCGCTGTCTGGACTGGAACCGCGA   1550 
 
EMBOSS_001      1551 CATCCTCAAGAAGGAGCTGGGACTGACAGAGCAGGACATCATTGACCTGC   1600 
                     ||||||.||||.||||||.|..|||||.|||.|||||||.|||||||||| 
EMBOSS_001      1551 CATCCTTAAGAGGGAGCTAGCGCTGACTGAGAAGGACATTATTGACCTGC   1600 
 
EMBOSS_001      1601 CCGCTCTGTTCAAGATGGACGAGGCCAGAGCCTTCTTCCCAAACATGGTG   1650 
                     ||||.||.|||||||||||.||.|||||.||.||||||||.||||||||| 
EMBOSS_001      1601 CCGCGCTCTTCAAGATGGATGAAGCCAGGGCTTTCTTCCCTAACATGGTG   1650 
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EMBOSS_001      1651 AACATGATCGTGCTGGACAAGGACCTGGGCATCCCCAAGCCATTCGGGCC   1700 
                     ||||||||||||||.||||||||||||||||||||||||||.|||||||| 
 
EMBOSS_001      1651 AACATGATCGTGCTAGACAAGGACCTGGGCATCCCCAAGCCTTTCGGGCC   1700 
 
EMBOSS_001      1701 ACAGGTTGAGGAGGAATGCTGCCTGGAGATGCACGTGCGTGGCCTCCTGG   1750 
                     .|||||.||||||||.|||||||||||||.||||||.||.|||||.|||| 
EMBOSS_001      1701 CCAGGTGGAGGAGGAGTGCTGCCTGGAGACGCACGTTCGAGGCCTGCTGG   1750 
 
EMBOSS_001      1751 AGCCCCTGGGCCTCGAATGCACCTTCATCGACGACATTTCTGCCTACCAC   1800 
                     |||||||||||||||..|||||.||||||||.|||||.||.||||||||| 
EMBOSS_001      1751 AGCCCCTGGGCCTCGCCTGCACGTTCATCGATGACATCTCCGCCTACCAC   1800 
 
EMBOSS_001      1801 AAATTTCTGGGGGAAGTCCACTGTGGCACCAACGTCCGC   1839 
                     ||.||.|||||.||.||.||||||||||||||.|||||| 
EMBOSS_001      1801 AAGTTCCTGGGAGAGGTTCACTGTGGCACCAATGTCCGC   1839 
 
Length: 1839 
# Similarity:  1623/1839 (88.3%) 
 
 
Figure S.1. EMBL-EMBOSS Matcher output between Human and Mouse PADI2 DNA 
sequence 
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EMBOSS_001         1 RERTVRLQYGSRVEAVYAAPAGAQTFSLKHSEHVWVEVVRDGEAEEVARW     50 
                     |||||||||||||||||||||||:||||||||.|.||||||||||||.|| 
EMBOSS_001         1 RERTVRLQYGSRVEAVYAAPAGAKTFSLKHSEGVKVEVVRDGEAEEVVRW     50 
 
EMBOSS_001        51 LLSPSTTLRVTMSQASTEASSDKVTVNYYEGSIPIDQAGLFLTAIEISLD    100 
                     .||||:|||::|:|||||||||||||||||||.||||||||||||||||| 
EMBOSS_001        51 ALSPSSTLRLSMAQASTEASSDKVTVNYYEGSAPIDQAGLFLTAIEISLD    100 
 
EMBOSS_001       101 VDADRDGVVEKNNPKKASWTWGPEGQGAILLVNCDRETPWLPKEDCRDEK    150 
                     |||||||.||||||||||||||||||||||||||||:|||||||||.||| 
EMBOSS_001       101 VDADRDGEVEKNNPKKASWTWGPEGQGAILLVNCDRDTPWLPKEDCSDEK    150 
 
EMBOSS_001       151 VYSKEDLKDMSQMILRTKGPDRLPAGYEIVLYISMSDSDKVGVFYVENQR    200 
                     ||||:||:|||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       151 VYSKQDLQDMSQMILRTKGPDRLPAGYEIVLYISMSDSDKVGVFYVENQR    200 
 
EMBOSS_001       201 YIHILGRRKLYHVVKYTGSAELLFFVEGLCFPDEGFSGLVSIHVSLLEYM    250 
                     |||||||:||||||||||||||||||||||||||.||||||||||||||| 
EMBOSS_001       201 YIHILGRQKLYHVVKYTGSAELLFFVEGLCFPDESFSGLVSIHVSLLEYM    250 
 
EMBOSS_001       251 AQDIPLTPIFTDTVIFRIAPWIMTPNILPPVSVFVCCMKDNYLFLKEVKN    300 
                     |:.|||||||||||:||||||||||||||||||||||||||||||||||| 
EMBOSS_001       251 AEGIPLTPIFTDTVMFRIAPWIMTPNILPPVSVFVCCMKDNYLFLKEVKN    300 
 
EMBOSS_001       301 LVEKTNCELKVCFQYLNRGDRWIQDEIEFGYIEAPHKGFPVVLDSPRDGN    350 
                     |||||||||||||||:|||||||||||||||||||||||||||||||||| 
EMBOSS_001       301 LVEKTNCELKVCFQYMNRGDRWIQDEIEFGYIEAPHKGFPVVLDSPRDGN    350 
 
EMBOSS_001       351 LKDFLLGPDFGYVTREPLFESVTSLDSFGNLEVSPPVTVNGKTYPLGRIL    400 
                     ||||||||||||||||||||:|||||||||||||||||||||.||||||| 
EMBOSS_001       351 LKDFLLGPDFGYVTREPLFETVTSLDSFGNLEVSPPVTVNGKEYPLGRIL    400 
 
EMBOSS_001       401 IGSSFPLSGGRRMTKVVRDFLKAQQVQAPVELYSDWLTVGHVDEFMSFVP    450 
                     |||||||||||||||||||||:||||||||||||||||||||||||:|:| 
EMBOSS_001       401 IGSSFPLSGGRRMTKVVRDFLQAQQVQAPVELYSDWLTVGHVDEFMTFIP    450 
 
EMBOSS_001       451 IPGTKKFLLLMASTSACYKLFREKQKDGHGEAIMFKMSSITINKILSNES    500 
                     |||.|:|.||||||||||:|||||||.|||||:||||||||||||||||| 
EMBOSS_001       451 IPGKKEFRLLMASTSACYQLFREKQKAGHGEAVMFKMSSITINKILSNES    500 
 
EMBOSS_001       501 LVQENLYFQRCLDWNRDILKKELGLTEQDIIDLPALFKMDEARAFFPNMV    550 
                     |.|||.||||||||||||||:||.|||:|||||||||||||||||||||| 
EMBOSS_001       501 LTQENQYFQRCLDWNRDILKRELALTEKDIIDLPALFKMDEARAFFPNMV    550 
 
EMBOSS_001       551 NMIVLDKDLGIPKPFGPQVEEECCLEMHVRGLLEPLGLECTFIDDISAYH    600 
                     ||||||||||||||||||||||||||.|||||||||||.||||||||||| 
EMBOSS_001       551 NMIVLDKDLGIPKPFGPQVEEECCLETHVRGLLEPLGLACTFIDDISAYH    600 
 
EMBOSS_001       601 KFLGEVHCGTNVR    613 
                     ||||||||||||| 
EMBOSS_001       601 KFLGEVHCGTNVR    613 
 
# Length: 613 
# Similarity:   595/613 (97.1%) 
 
 
 
Figure S.2. EMBL-EMBOSS Matcher output between Human and Mouse PADI2 protein 
sequence 
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Table S.1. Species names and database IDs 
Species name Latin name Database ID 
Human Homo sapiens XM_017000148.2 
Rhesus Monkey Macaca mulatta XM_015122520.1 
Chimpanzee Pan troglodytes XM_513113.7 
Olive Baboon Papio anubis, XM_003891202.4 
Mouse Mus musculus XM_006538632.3 
Rat Rattus norvegicus XM_008764215.2 
Alpine Marmot Marmota marmota  XM_015485640.1 
Molerat  Nannospalax galili, XM_008822632.1 
Rousette Rousettus aegyptiacus  XM_016128392.1 
Flying Fox Pteropus alecto XM_006914312.1 
Opterus Natalensis Miniopterus natalensis XM_016219459.1 
Wild Camel Camelus ferus  XM_014562260.1 
Horse Equus caballus NM_001163822.2 
Ass Equus asinus, XM_014836181.1 
Dog Canis lupus familiaris XM_022414183.1 
Giant Panda Ailuropoda melanoleuca XM_019804628.1 
Canary Serinus canaria XM_009095754.2 
Ruff Calidris pugnax XM_014959888.1 
Eagle Haliaeetus leucocephalus XM_010577500.1 
Chicken Gallus gallus NM_001319019.1 
Bony Tongue Scleropages formosus XM_018725780.1 
Piranha Pygocentrus nattereri XM_017697840.1 
Catfish Ictalurus punctatus XM_017479674.1 
Molly Poecilia Formosa XM_007546957.2 
Vulus Kryptolebias marmoratus XM_017408778.2 
Rhinocerous Sinocyclocheilus rhinocerous XM_016512332.1 
Barramundi Perch Lates calcarifer XM_018683884.1 
Poecilia Mexicana Poecilia Mexicana XM_014968042.1 
Japonicus Gekko japonicus XM_015412620.1 
Frog Xenopus laevis NM_001086900.1 
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Table S.2. The correlation between PADI2 expression and other co-expressed genes in EOC. 
 
Gene 
abbreviation Gene name Gene function 
Gene 
accession 
number 
Gene fold change 
Pearson’s Spearman’s 
ARHGEF10L 
Rho guanine 
nucleotide 
exchange factor 
(GEF) 10-Like 
 
Member of Rho GEF family of 
guanine nucleotide exchange 
factors (GEFs) that activate Rho 
GTPases (Winkler et al., 2005). 
 
NC_000001.11 
NT_032977.10 
NC_018912.2 
 
0.37 
0.42 
0.36 
0.42 
BMPR1B 
(bone) 
Bone 
morphogenetic 
protein receptor, 
type IB  
 
Member of the bone 
morphogenetic protein (BMP); 
involved in endochondral bone 
formation and embryogenesis 
and produced in ovaries, 
receptor family of 
transmembrane 
serine/threonine kinases (Inman 
et al., 2002). 
 
NC_000004.12 
NT_016354.20 
NC_018915.2 
 
-0.26 
-0.28 
-0.23 
-0.20 
 
DACH1 
Dachshund family 
transcription 
factor 1 
 
 
Encodes a chromatin-associated 
protein that associates with 
other DNA-binding transcription 
factors to regulate gene 
expression and cell fate 
determination during 
development. Expression of this 
gene is lost in some forms of 
metastatic cancer, and is 
correlated with poor prognosis 
(Zhou et al., 2010). 
 
NC_000013.1
1 
NT_024524.1
5 
NC_018924.2 
 
-0.23 
-0.25 
-0.25 
-0.21 
EPB41L1 
 
Erythrocyte 
membrane 
protein band 4.1-
like1 
 
 
Multifunctional protein that 
mediates interactions between 
the erythrocyte cytoskeleton 
and the overlying plasma 
membrane. The encoded 
protein binds and stabilizes D2 
and D3 dopamine receptors at 
the neuronal plasma 
membrane. 
 
NC_000020.1
1 
NT_011362.1
1 
NC_018931.2 
0.35 
0.42 
0.37 
0.36 
 
FUS 
FUS RNA binding 
protein 
(nucleus,  
 
Member of FET family of RNA-
binding proteins which have 
been implicated in cellular 
processes that include 
regulation of gene expression, 
maintenance of genomic 
integrity and mRNA/microRNA 
processing. Functions in 
transcription dysregulation in 
cancer, nucleic acid 
NC_000016.1
0 
NT_187260.1 
NC_018927.2 
 
-0.23 
-0.3 
-0.20 
-0.25 
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binding and identical protein 
binding (Haile et al., 2011). 
 
 
 
FUT8 
Fructosyltransfera
se 8 (alpha (1,6) 
fructosyltransfera
se) 
 
 
Member of 
fructosyltransferases family. 
The product of this gene 
catalyses the transfer of fucose 
from GDP-fucose to N-linked 
type complex glycol-peptides. 
The expression of this gene may 
contribute to the malignancy of 
cancer cells and to their 
invasive and metastatic 
capabilities. Alternative splicing 
results in multiple transcript 
variants (pancreatic acinar cell 
adenocarcinoma) (Roos et al., 
2002). 
 
NC_000014.
9 
NT_026437.
13 
NC_018925.2 
 
-0.24 
-0.26 
-0.26 
-0.24 
FZD5 
Frizzled class  
receptor 5 
 
 
Encode 7-transmembrane 
domain proteins that are 
receptors for Wnt signalling 
proteins. The FZD5 protein is a 
receptor for Wnt5A ligand.  
Involved in transduction and 
intercellular transmission of 
polarity information during 
tissue morphogenesis and/or in 
differentiated tissues (Kubo et 
al., 2003). 
 
NC_000002.12 
NC_018913.2 
NT_005403.18 
 
-0.31 
-0.37 
-0.3 
-0.21      
KRT7 Keratin 7, type II  
 
Encoded by this gene is a 
member of the keratin gene 
family. Expressed in epithelia 
l ining the cavities of the internal 
organs and in the gland ducts 
and blood vessels. Blocks 
interferon-dependent 
interphase and stimulates DNA 
synthesis in cells. Diseases 
associated with include clear 
cell  basal cell carcinoma and 
renal pelvis transitional cell 
carcinoma (Lin et al., 2001). 
 
NC_000012.1
2 
NT_029419.1
3 
NC_018923.2 
0.42 
0.43 
0.41 
0.36 
LDLRAP1 
Low density 
l ipoprotein 
receptor adaptor 
protein 1 
 
 
Encoded by this gene is a 
cytosolic protein which contains 
a phosphoserine binding (PTD) 
domain. The PTD domain has 
been found to interact with the 
cytoplasmic tail of the LDL 
receptor (Michaely et al., 2004; 
Mishra et al., 2002). 
 
NC_000001.1
1 
NT_032977.1
0 
NC_018912.2 
 
0.36 
0.35 
0.36 
0.32 
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NPTXR 
Neuronal 
pentraxin 
receptor 
 
Involved in mediating uptake of 
synaptic material during 
synapse remodelling. 
 
 
 
NC_000022.1
1 
NC_018933.2 
NT_011520.1
3 
0.40 
0.33 
0.40 
0.41 
 
PFKM Phosphofructokinase, muscle 
 
Catalyses the phosphorylation 
of D-fructose 6-phosphate to 
fructose 1,6-bisphosphate by 
ATP, the first committing step 
of glycolysis (Durante et al., 
1996). 
 
 NC_000012.1
2 
NT_029419.1
3 
NC_018923.2 
 
-0.26 
-0.28 
-0.22 
-0.21 
 
RPS6KA1 
Ribosomal 
protein s6 kinase, 
90kda, 
polypeptide 1 
 
 
Ribosomal S6 protein kinases 
(RSKs) are a family of protein 
serine/threonine kinases that 
regulate diverse cellular 
processes, such as cellular 
growth, motil ity, survival and 
proliferation (Shimamura et al., 
2000). 
 
NC_000001.1
1 
NT_032977.1
0 
NC_018912.2 
0.38 
0.42 
0.42 
0.44 
SNRPE 
Small Nuclear 
Ribonucleoprotei
n Polypeptide E 
 
Plays an important role in the 
splicing of cellular pre-mRNAs 
(Fury et al., 1997). 
 -0.27 -0.35 
-0.27 
-0.22 
ZNF22 
Zinc finger 
protein 22 
 
 
Involved in transcriptional 
regulation and may play a role 
in tooth formation (Bray et al., 
1991). 
 
NC_000010.1
1 
NC_018921.2 
NT_030059.1
4 
-0.24 
-0.27 
-0.24 
-0.24 
ZSCAN12 
Zinc finger and 
scan domain 
containing 12 
 
Involved in transcriptional 
regulation, transcription factor 
activity, sequence-specific DNA 
binding. 
 
NC_000006.1
2 
NT_007592.1
6 
NC_018917.2 
 
-0.21 
-0.29 
-0.23 
-0.27 
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Figure S.3. Kaplan Meier curves showing OS in EOC patients. (a) The Nottingham cohort and 
(b) The larger Derby cohort. Unpublished TMA data collected and analysed by Dr Lee 
Machado. 
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RERTVRLQYGSRVEAVYVLGTYLWTDVYSAAPAGAQTFSLKHSEHVWVEVVRDGEAEEVATN
GKQRWLLSPSTTLRVTMSQASTEASSDKVTVNYYDEEGSIPIDQAGLFLTAIEISLDVDADR
DGVVEKNNPKKASWTWGPEGQGAILLVNCDRETPWLPKEDCRDEKVYSKEDLKDMSQMILRT
KGPDRLPAGYEIVLYISMSDSDKVGVFYVENPFFGQRYIHILGRRKLYHVVKYTGGSAELLF
FVEGLCFPDEGFSGLVSIHVSLLEYMAQDIPLTPIFTDTVIFRIFRIAMTPNILPPVSVFVC
CMKDNYLFLKEVKNLVEKTNCELKVCFQYLNRGDRWIQDEIEFGYIEAPHKGFPVVLDSPRD
GNLKDFPVKELLGPDFGYVTREPLFESVTSLDSFGNLEVSPPVTVNGKTYPLGRILIGSSFP
LSGGRRMTKVVRDFLKAQQVQAPVELYSDWLTVGHVDEFMSFVPIPGTKKFLLLMASTSACY
KLFREKQKDGHGEAIMFKGLGGMSSKRITINKILSNESLVQENLYFQRCLDWNRDILKKELG
LTEQDIIDLPALFKMDEDHRARAFFPNMVNMIVLDKDLGIPKPFGPQVEEECCLEMHVRGLL
EPLGLECTFIDDISAYHKFLGEVHCGTNVRRKPFTFKWWHMVPSRRS 
 
 
Figure S.4. The whole protein sequence of PADI2 (without sequence alignment) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S.5. PADI2 different domains 
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Table S.3. PADI2 ligands 
 
Ligands pattern names, size of the clusters, the number of atoms in the pattern, the protein fold 
classifications according to CATH, the annotated function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ligand Ligand Name Residue N/ Chain ID  
Number 
of atoms 
CATH 
Superfamily Function 
MPD 
(4S)-2-METHYL-
2,4-
PENTANEDIOL 
701A 
8 - 
Transport/binding 
protein, hydrolase, cell 
adhesion 
702A 
703A 
CA Calcium Ion 
705A 
 
706A 
1 2.60.40.1700 
Hydrolase, serine 
protease, transport/ 
metal binding protein, 
cell adhesion and 
oxidoreductase 
ACT Acetate Ion 704A 4 2.40.128.20 
Hydrolase, cell cycle, 
transcription, 
oxidoreductase   and 
transferase 
Ligand-Protein Contacts (LPC) in PADI2 derived from the LPC software and analysed by CATH and PDBeMotif tools 
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Table S.4. List of public resources and databases relevant to domain analysis 
 
 
Resource URL 
Protein domain databases 
Pfam http://www.sanger.co.uk/Pfam/  
Prosite http://www.expasy.org/prosite/  
Superfamily http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html  
Alignment software 
BLAST http://www.ncbi.nlm.nih.gov/blast/Blast.cgi  
ClustalW http://www.ebi.ac.uk/Tools/clustalw2/  
Phylogenetic analysis 
PhyML (Max. Likelihood) http://atgc.l irmm.fr/phyml/  
Visualization 
Pymol (structural) http://pymol.sourceforge.net/  
TreeView (phylogeny) http://taxonomy.zoology.gla.ac.uk/rod/treeview.html  
Sequence depositories 
Ensembl (genome projects) http://www.ensembl.org  
PDB (structures) http://www.rcsb.org/pdb/home/home.do  
NCBI http://www.ncbi.nlm.nih.gov/sites/gquery?itool=toolbar  
UniProt http://www.expasy.uniprot.org/  
 
 
 
 
 
 
 
 
 
 
 
